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ABSTRACT 
Medicinal plant use in Africa and elsewhere is on the increase partly because of 
inconsistent availability and prohibitive costs of synthetic medicines, and partly 
because they are thought to possess fewer side effects by comparison with allopathic 
medicines. Few studies, however, have evaluated their efficacy and toxicity. 
Accordingly, the present studies were designed to determine hypoglycaemic effects of 
ethanolic extracts of selected medicinal plants in STZ-induced diabetic rats. African 
potato (Hypoxis hemerocallidea, APE), avocado (Persea americana, PAE), marula 
(Sclerocarya birrea, SBE) and Ficus thonningii (FTE), are used by various 
populations in Southern Africa in the traditional management of a multitude of 
ailments including diabetes mellitus. 
Oral glucose tolerance test responses (OGTT) were evaluated in separate groups of 
non-diabetic and STZ-induced diabetic rats starved for 18 h and loaded with 0.86 g/kg 
glucose followed by graded doses of APE, SBE, FTE and PAE (60, 120 and 240 
mg/kg). Rats treated with deionised water (3 ml/kg) acted as control, while those 
treated with insulin (100 Ilg/kg), metformin (500 mg/kg) and glibenclamide (5 mg/kg) 
acted as positive control groups. Blood glucose concentrations were monitored at 15-
min intervals for the first hour, and hourly, thereafter for 3 hours. Long term 
hypoglycaemic effects of the test extracts were investigated in non-diabetic and STZ-
induced diabetic rats, chronically administered with test extracts (120 mg/kg, p.o.) 
once daily for 6 weeks. Acute effects of test extracts on fluid and electrolyte handling 
and blood pressure were assessed in anaesthetised non-diabetic and STZ-induced 
diabetic rats challenged with 0.077M NaCI (9 ml/h) in an 8 h protocol that consisted 
xxvi 
of a 3.5 h-equilibration, 1 h control, 1.5 h treatment and 1.5 h recovery period. 
Solutions of test extracts (0.06 Jlg/min) were added to the infusate during treatment 
period. Urine sampling, for volume and electrolytes, and, blood pressure 
measurements were conducted at 30 min interval over the subsequent 4h of lh 
control, 1h 30 min treatment, and 1 h 30 min post treatment. Long term effects of test 
extracts on fluid and electrolyte handling were conducted in non-diabetic and STZ-
induced diabetic rats treated with test extracts at a dose of 120 mg/kg once daily for 6 
weeks. In order to assess direct effects of test extracts on renal tubular cells, 
cytotoxicity studies were conducted by dye-reduction assay (MIT) on MDBK and 
LLCPK-1 cell lines exposed to graded doses (100 - 1000 Jlg/ml) for 24, 48 and 72 
hours. 
Acute and long term studies revealed that test extracts possess hypoglycaemic effects 
in non-diabetic and STZ-induced diabetic rats which are insulin independent. Long 
term investigations established that all test extracts increased hepatic glycogen 
concentrations in diabetic rats. The extracts demonstrated vasodepressive effects in 
non-diabetic and STZ-induced diabetic rats, probably mediated via reduction of 
peripheral vascular resistance. Short term studies revealed that all extracts except APE 
had no effects on fluid and electrolyte handling in the diabetic rat. In vitro 
cytotoxicity studies demonstrated that SBE and P AE were cytotoxic to renal tubular 
cells, whereas, in vivo observations revealed the extracts increased glomerular 
filtration rate (GFR), as assessed by creatinine clearance, suggesting renoprotective 
properties. 
XXVll 
In conclusion, results have shown that Hypoxis hemerocallidea, Persea americana, 
(Sclerocarya birrea, and Ficus thonningii possess, hypoglycaemic and 
antihypertensive effects in experimental animals. These results, in part, explain the 




1.0. INTRODUCTION AND LITERATURE REVIEW 
1.1. Diabetes mellitus 
Diabetes mellitus a metabolic disorder characterised by hyperglycaemia, that results from 
reduced cellular glucose uptake and metabolism due to impaired insulin secretion and/or 
action. An estimated 150 million people, within the age range 20-79 years, have 
diabetes at present and the prevalence is escalating (Ahmed and Goldstein, 2006; 
Gadsby, 2002), particularly in developing countries (Girach and Vignati, 2006; Kim, 
Kang, Seo, Choi, Choi and Ku, 2006). It is estimated that by 2025, three quarters of 
all diabetics will be resident in developing countries (King, Aubert, and Herman, 
1998). The steady increase in prevalence is partly attributed to obesity in childhood 
and adolescence, urbanisation and aging of populations (Brosnan, Upchurch and 
Schreiner, 2001; King, Aubert, and Herman, 1998; Wild, Roglic, Green, Sicree and 
King, 2004). Diabetes is a major health concern because it is frequently associated 
with debilitating health complications such as blindness, kidney function failure, 
cardiovascular diseases, amputations, and subsequently, death. Quality and duration 
of life is considerably reduced in diabetics due to persistent hospitalizations and 
disability. In developing countries, one in ten deaths in economically active age range 
of 35 to 64 years can be attributed to diabetes (Roglic, Unwin, Bennett, Mathers, 
Tuomilehto, Nag, Connolly and King, (2005). Furthermore, diabetic complications 
create financial burden to health care systems (Eidi, Eidi and Zamanizadeh, 2005). 
1 
Medical care in diabetes is estimated at US$132 billion annually in the United States 
of America (Girach and Vignati, 2006). 
1.1.1. Diabetes mellitus in Mrica 
There is paucity of studies that show prevalence and/or incidence of diabetes in 
Africa. Available data, however, show that generally prevalence is low in rural areas 
and high in urbanized communities. For example, prevalence of diabetes is 0.9% in 
rural Tanzania and reaches levels of 8.8 to 12.2 % in urban Tanzania (Abbas, Lutale, 
Gill and Archibald, 2001). In South Africa, urban Indians have a prevalence rate of 
nearly 20% (Forouhi and Wareham, 2006). 
In the estimations of diabetic prevalence in a number of Sub-Saharan Africa, 
Tanzania was considered a model whose prevalence was extrapolated to several 
countries including Malawi Rwanda, Somalia, Uganda, Zambia Djibouti, Kenya, 
Madagascar, Mozambique, Burundi, Comoros, and the Democratic Republic of the 
Congo. Prevalence estimates for South Africa were extrapolated to Zimbabwe, 
Namibia, Lesotho and Swaziland. The criteria used were similarities in conditions 
including social economic standards, ethnic groups and geographical proximity (Wild, 
et at., 2004). The seemingly low rates could be a true reflection of diabetes prevalence 
in sub-Saharan Africa or could merely imply poor prognosis (Beran, Yudkin, de 
Courten, 2006). Otherwise, prevalence in many developing countries point to an 
escalation (Abdelgadir, Elbagir, Eltom and Berne, 2006). 
Due to generally low socio-economic conditions, the problem of diabetes mellitus in 
Africa is more acute (Ducorps, Ndong, Jupkwo, Belmejdoub, Poirier, Mayaudon and 
2 
Bauduceau, 1997). Risk factors for development of diabetes mellitus in Africa include 
excessive alcohol intake, smoking, obesity consumption of large food quantities that 
have toxic compounds to the kidney (Lasky, Becerra, Boto, Otim and Ntambi, 2002). 
1.2. Glucose homeostasis 
Glucose is the main fuel for most tissues. Oxidative metabolism of glucose allows 
production of adenosine triphosphate (ATP) , which is an energy source for many 
chemical reactions in the body (Wolfe, 1998). Plasma glucose concentration is a 
reflection of the balance between glucose uptake in the gut, endogenous production, 
utilization and storage in the body (Woerle, Meyer, Dostou, Gosmanov, Islam, Popa, 
Wittlin, Welle and Gerich, 2003). Endogenous production of glucose is through 
gluconeogenesis and glycogenolysis, while tissue utilization is mainly mediated via 
glycolysis and, to a lesser extent, the pentose phosphate pathway. Excess glucose is 
converted in the body into glycogen and fat (Guyton and Hall, 2000). 
Following ingestion of a meal, a third of glucose is taken up by the brain tissue where 
it undergoes complete aerobic breakdown to water and carbon dioxide, 2 to 3 hours 
later; another third is used by the muscle where it is converted to glycogen or 
catabolised to lactate or water and carbon dioxide; and the rest is taken up by the liver 
where it is mainly converted to glycogen and stored (Morifuji, Sakai and Sugiura, 
2005). The liver, therefore, plays an essential role in the maintenance of blood 
glucose. It maintains blood glucose levels by maintaining a balance between glucose 
uptake and its conversion to glycogen and the release of glucose into circulation via 
glycogenolysis and gluconeogenesis (Saadat, Pournourmoharnmadi, Donyavi, 
3 
Khorasani, Amin, Salehnia and Abdollahi, 2004). The role of other tissues such as the 
kidney in endogenous glucose production is minimal. Nevertheless, the contribution 
of the kidney is significant during prolonged fasting (Tappy, Jequier and Schneiter, 
2000). 
1.2.1. Glucose transport into cells 
The lipid nature of cell membranes offers a barrier against free glucose entry into 
cells. There are 2 major types of glucose transporters that overcome this membrane 
barrier. Sodium-glucose co-transporters are mainly located in the kidney and 
intestines. These actively transport glucose into cells against concentration gradient 
by cotransporting sodium. GLUT transporters are a family of glucose transporters that 
transport glucose into cells passively, down a concentration gradient. They include 
GLUT-l transporters which are located in the brain, erythrocytes and endothelial cell; 
GLUT-2, located in the kidney, small intestines, liver and pancreatic tissues; GLUT-
3, expressed in the neurones and placenta; GLUT-4, expressed in the skeletal, cardiac 
and adipose tissue. Transport of glucose via GLUT -4 into muscle and adipose tissue is 
the rate-controlling step in insulin-mediated glucose disposal, and this disposal is 
compromised in conditions of insulin-resistance (Herman and Kahn, 2006). GLUT-5 
transporters are located in the small intestine, sperm, brain, kidney and muscle 
(Shepherd and Kahn, 1999). 
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1.2.2. Insulin secretion 
Insulin, produced by the beta (~)-cells of the pancreas is the principal hormone 
regulating glucose metabolism. Its presence enhances glucose uptake and metabolism 
by various tissue cells including skeletal muscle, white adipose tissue and the liver 
(Barros, Machado and Gustafsson, 2006). During non-pathological states, glucose is 
the stimulus for insulin secretion in pancreatic beta cells. Glucose entry into the 
pancreatic ~-cells is through GLUT-2 transporters (Herman and Kahn, 2006). 
Oxidation of glucose and the subsequent increase in ATP/ADP ratio in the ~-cells 
triggers closure of ATP-sensitive potassium channels (Doyle and Egan, 2003). 
Inhibition of potassium efflux results in cell depolarization leading to influx of 
voltage dependent calcium ions that stimulate extrusion of insulin. Physiological 
insulin secretion consists of a basal and bolus component. During fasting, basal 
insulin secretion maintains glucose levels between 70 and 120 mg/dl, and bolus 
secretion keeps glycaemic levels below 180 mg/dl after a meal (Fonseca, 2006). 
1.2.3. The metabolic effects of insulin 
The mechanism by which insulin influences glucose uptake in target tissues is that the 
binding of insulin to a-subunit part of their receptors, on the cell surface, 
autophosphorylates the ~-subunit on tyrosine residues, intracellulary. This activates 
tyrosine kinase which further phosphporylates insulin receptor substrates (IRS) 
leading to a series of pathways that result into insulin signal transduction. Depending 
on the target tissue cell, the outcome of the signal transduction might be movement of 
GLUT 4, for instance, from intracellular pools towards the cell surface of skeletal 
5 
muscle and white adipose tissues, or reducing expression of gluconeogenesis genes in 
the liver (LeRoith and Gavrilova, 2006), or indeed, increasing levels and activities of 
glycogen synthase and glycogen phosphorylase in the liver (Barros et al., 2006). 
1.2.4. Insulin regulatory and counteregulatory hormones 
~-cells are located in the islets of Langerhans in the pancreas. Other cell types present 
in islets include a, 8 and pancreatic polypeptide (PP) cells. Glucagon, secreted by the 
pancreatic a-cells, is a major counter-regulatory hormone involved in regulation of 
glucose homeostasis (Hussain, Daniel and Habener, 2000). Glucagon increases 
glycaemia by mediating hepatic glycogenolysis (Robertson and Harmon, 2006). 
Studies have shown that diabetics have basal or increased plasma glucagon 
concentrations. Furthermore, suppression of this hormone is associated with reduction 
of plasma glucose concentration (Cherrington, Lacy and Chiasson, 1976). 8-cells also 
secrete somatostatin which plays an inhibitory role in the secretion of several 
hormones, including insulin (Robertson and Harmon, 2006). 
Counteregulatory effects of epinephrine are due to its direct effects on target tissues 
and its effects on other participating hormones. For example, adrenaline stimulates 
increased glucagon secretion by activating ~-adrenergic receptors on a-cells of 
pancreatic islets (Guy, Sandoval, Richardson, Tate and Davis, 2005). Due to its 
effects on muscle, epinephrine also decreases insulin mediated glucose uptake as a 
result of glucose-6-phosphate-dependent inhibition of hexokinase (Raz, Katz and 
Spencer, 1991). In addition adrenaline compromises insulin-induced glycogen 
synthesis attributed to its inhibition of glycogen synthase (Raz et al., 1991). 
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Glycogenolysis and inhibition of glycogen synthesis, by both epinephrine and 
glucagon, are mediated via increased generation of cAMP which activates protein 
kinase A. Protein kinase A inactivates glycogen synthase and activates phosphorylase 
(Hodis, Kutinova-Canova, Potmesil, Kamenikova, Kmonickova, Zidek, Farghali, 
2007). 
Glucocorticoids antagonise effects of insulin. Excessive levels of glucocorticoids may 
cause insulin resistance and central obesity (Liu, Nakagawa, Wang, Sakurai, Tripathi, 
Lutfy and Friedman, 2005). In addition, glucocorticoids enhance hepatic 
gluconeogenesis and impair effects of insulin to reduce glucose production in type II 
diabetes (Delaunay, Khan, Cintra, Davani, Ling, Andersson, Ostenson, Gustafsson, 
Efendic and Okret, 1997; Liu et ai., 2005). In states of intensive glycaemic control 
resulting in hypo glycaemia, hormones antagonistic to insulin action are released to 
restore normoglycaemia (Ross, Warren, Kelnar and Frier, 2005). Hence, 
counteregulatory hormones may offer benefits in specific conditions. 
Adiponectin is an adipocyte derived peptide which improves insulin sensitivity via 
several mechanisms. It modulates fatty acid oxidation, inhibits fatty acid synthesis 
and uptake in the liver and enhances glucose and fatty acid oxidation in the muscle 
(Mlinar, Marc, Janez and Pfeifer, 2007). These effects are mediated through 
stimulation of perixosome proliferator gamma receptors (PP AR-y) nuclear receptors 
and activation of AMP kinase (Mlinar et ai. , 2007). 
Like adiponectin, leptin is an adipocyte derived-hormone that circulates in plasma in 
free and bound form. Acting through its receptors located in the hypothalamus, 
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hippocampus, cortex, cerebellum, thalamus and choroids plexus, leptin decreases 
levels of circulating neuropepide Y resulting in reduced appetite (Mantzoros, 1999). 
Leptin also modulates glucose homeostasis (Levy and Stevens, 2001). In insulin-
deficient rats, administration of leptin restores normal glucose levels, enhances 
glucose metabolism in the post absorptive stages and improves hepatic insulin 
sensitivity during glucose clamp (Chinookoswong, Wang, and Shi, 1999). Leptin, 
therefore, acts agonistically to effects of insulin. Moreover, leptin modulates release 
of thyroid hormones which playa homeostatic role in glucose metabolism (Wang, 
Chinookoswong, Yin and Shi, 2000). 
Thyroid hormones secreted by the thyroid glands also exert glucose homeostatic 
functions in synergy as well as antagonistic to insulin action. Thyroid hormones may 
increase glucose production via hepatic gluconeogenesis, to meet increased energy 
requirements by the body (Lenzen and Bailey, 1984). Thyroid hormones, however, 
enhance transcription of insulin sensitive glucose transporter-4 (GLUT-4) (Chidakel, 
Mentuccia and Celi, 2005). This allows increased uptake of glucose by tissue cells 
thereby offsetting initial increase in blood glucose (Lenzen and Bailey, 1984). 
1.2.5. Insulin resistance 
Insulin resistance largely caused by central obesity is a key component in the 
pathogenesis of type II diabetes mellitus. It is defined as the inability of insulin to 
curtail hepatic glucose production and promote glucose disposal in the peripheral 
tissues (McGarry, 2002). Insulin resistance constitutes defective insulin receptor 
function, insulin receptor signal transduction, glucose transport and phosphorylation, 
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glucose uptake and glycogen synthesis in adipose, skeletal and hepatic tissues 
(DeFronzo, 1999; Kahn and Flier, 2000; Panunti, Jawa and Fonseca, 2004). 
Adipose tissue secretes large quantities of tumour necrosis factor (TNF)-a. According 
to Mlinar et al. , (2007), TNF -a is the main factor that stimulates increased levels of 
circulating free fatty acids into circulation. Increased intraportal free fatty acids impair 
insulin clearance. The mechanisms by which this is mediated are still unclear (Kahn 
and Flier, 2000). It is, however, suggested that accumulation of intramyocellular 
lipids in striated muscles suppresses glucose uptake, glycogen synthesis and glucose 
oxidation (Flordellis, Ilias and Papavassiliou, 2005). Moreover, TNF-a inhibits 
expression of PPAR-y, tyrosine phosphorylation on the insulin receptor and 
intermediates of insulin post-receptor signalling (Bailey, 2000). 
In addition to TNF -a, adipose tissue also secretes resistin, which has been established 
as one of the possible links between excessive adiposity and insulin resistance (Liu, 
Fan, Qiu, Wang, Zhang, Gu, Zhang, Fei, Pan, Guo, Chen and Guo, 2008). This link, 
however, has been disputed by other investigators (De Courten, Degawa-Yamauchi, 
Considine and Tataranni, 2004). 
Insulin resistance may manifest at the level of glucose entry into cells (Shepherd and 
Kahn, 1999). Indeed, in obesity insulin resistance is characterised by downregulation 
of glucose transporters (GLUT)-4 in skeletal muscles (Kahn and Flier, 2000). Insulin 
resistance is the main target of antihyperglycaemic agents because, if left unchecked, 
it results in the pathogenesis of a wide allay of disorders including hypertension, 
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dyslipidaemia, atherosclerosis, or the metabolic syndrome (Chakrabarti, Damarla, 
Mullangi, Sharma, Vikramadithyan and Rajagopalan, 2006). 
1.3. The metabolic syndrome 
The metabolic syndrome is the association of metabolic disorders including insulin 
resistance, hypertension, central obesity and dyslipidaemia (Boney, Verma, Tucker 
and Vohr, 2005). Dyslipidaemia is characterized by increased levels of plasma 
triglycerides, low density lipoproteins, very low density lipoproteins and reduced 
levels of high density lipoproteins. Moreover increased plasma levels of plasminogen 
activator inhibitor-I (PAl-I) and fibrinogen levels mediate hypercoagulability which 
is a major problem in the metabolic syndrome (Flordellis, et ai., 2005). Prevalence of 
metabolic syndrome is on the increase due to increasing levels of obesity and ageing. 
Metabolic syndrome poses an enormous health challenge as it predisposes victims to 
cardiovascular diseases and diabetes mellitus. This syndrome can be managed by use 
of hypolipidaemic agents e.g. fibrates, antihyperglycaemic agents e.g. metformin and 
thiazolidinediones, and physical exercise to improve insulin resistance (Chew, Gan 
and Watts, 2006). 
1.4. Types of diabetes mellitus 
The major types of diabetes mellitus are type 1 and type 2, the former arising from 
inadequate production of insulin due to pancreatic p-cell dysfunction, and the latter 
arising from reduced sensitivity of insulin in target tissues and / or inadequate insulin 
secretion. 
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1.4.1. Type 1 diabetes 
There are two fonns of type I diabetes, namely, Immune-mediated and Idiopathic 
diabetes 
1.4.1.1. Immune-mediated diabetes 
Immune-mediated type 1 diabetes mellitus, previously known as insulin dependent 
diabetes mellitus (IDDM), constitutes 5 to 10% of all diabetic cases (American 
Diabetes association, 2004). The cause of inadequate insulin production is T-cell 
mediated autoimmune destruction of pancreatic beta cells. The pathogenesis of 
autoimmune p-cell destruction is initiated months or years before overt diabetes 
(Kukreja and Maclaren, 1999). The initiating factors(s) for autoimmune destruction is 
(are) still unclear. It is, however, suggested that, among others, it probably begins 
with p-cell infiltration of the pancreatic islets by macrophages which present antigens 
to T -helper cell (Lernmark, Barmeier, Dube, Hagopian, Karlsen, Markholst, Wilson 
and Wassmuth, 1990). Major genetic factors responsible for autoimmune destruction 
in type I diabetes are linked to histocompatibility leucocyte antigen (HLA), located on 
chromosome 6. Interaction of these and other environmental factors precipitate 
autoimmune activities resulting in p-cell destruction (Kukreja and Maclaren, 1999). 
Risk factors for pathogenesis of type 1 diabetes include genotype, diet and viral 
infections e.g. rubella, coxsackie, mumps (Wei, Li, Chang, Sung, Li, Lin, Chiang and 
Chuang, 2006). Coxsackie viral infections are a type of environmental factors that do 
not initiate, but enhance development of type I diabetes in genetically prone victims 
(Serreze, Ottendorfer, Ellis, Gauntt and Atkinson, 2000). It is proposed that coxsackie 
11 
viral infections probably provide a molecular mimic during replication that triggers a 
cross-reactive CD4+ T-cell response against the candidate ~-cell autoantigen (Serreze 
et al., 2000). Ultimately ~-cell death occurs by apoptosis (Kurrer, Pakala, Hanson and 
Katz, 1997). 
In addition, low birth weight is considered a risk factor for type I diabetes. Low birth 
weight is indicative of exposure of foetus to maternal viral infection and the 
interaction of immune cross-reactivity between virus and autoantigens which may 
lead to destruction of pancreatic ~-cells (Wei et al. , 2006). Furthermore, low birth 
weight is commonly associated with a reduced beta cell mass which is a vital factor in 
the pathogenesis of diabetes. Worldwide, an estimated 4.9 million people have type 1 
diabetes (Gadsby, 2002) and, approximately 35100 children have type 1 diabetes in 
Africa (Beran, et al., 2006). 
1.4.1.2. Idiopathic diabetes 
Unlike immune-mediated diabetes, idiopathic diabetes does not have established 
aetiology. It accounts for a minority of diabetic cases, most of whom are Africans and 
Asians. Idiopathic diabetes mellitus has a strong genetic component (American 
Diabetes Association, 2004). 
1.4.2. Type II diabetes mellitus 
Type II diabetes mellitus, formerly known as non insulin dependent diabetes 
(NIDDM) is the most common type of diabetes mellitus accounting for 90 to 95% of 
12 
all diagnosed cases of diabetes (American Diabetes Association, 2004). Type II 
diabetes is a polygenic disease caused by diminished response of target cells to insulin 
action, and/or insufficient production of insulin. Inadequate insulin production often 
characterizes later stages of type II diabetes and is attributed to reduced ~-cell mass or 
beta cell dysfunction (Nattrass and Bailey, 1999). Hepatic gluconeogenesis and renal 
gluconeogenesis significantly contribute to postprandial hyperglycaemia in type II 
diabetes (Meyer, Stumvoll, Nadkarni, Dostou, Mitrakou and Gerich, 1998). In recent 
times, interest has been generated into the possibility of involvement of the 
hypothalamus - pituitary - adrenal axis in the pathogenesis of type II diabetes. 
(Koshiyama, Hamamoto, Honjo, Wada, Ikeda, 2006). 
Risk factors for type 2 diabetes include genotype, age, previous history of gestational 
diabetes, behavioral factors including poor diet, and sedentary lifestyle. Genetic 
predisposition interacts with the environmental factors to influence disease prevalence 
(Noonan and Banks, 2000). In industrialized nations the increase in prevalence and 
incidences of diabetes are due in part to the increase in the age of the populations 
(Sowers and Epstein, 1995). Obesity is present in 50% and 70% of type II diabetic 
men and women, respectively (Oku, Veta, Arakawa, Ishihara, Nawano, Kuronuma, 
Matsumoto, Saito, Tsujihara, Anai, Asano, Kanai and Endou, 1999). It leads to 
increased lipolysis which results in increased levels of circulating free fatty acids and 
triglycerides and their subsequent deposition in muscle bed (McGarry, 2001). 
1.4.3. Gestational diabetes mellitus 
Gestational diabetes, which occurs during pregnancy, is the third commonest type of 
diabetes. It is derangement in carbohydrate metabolism resulting in hyperglycaemia 
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with onset or first detection during pregnancy (Xiong, Buekens, Vastardis and 
Pridjian, 2006). Causative factors for gestational diabetes mellitus are unknown but 
autoimmune activities in the pancreatic p-cells of pregnant mothers are suggested 
(McEvoy, Franklin and Ginsberg, 2004). 
It has high prevalence in developed countries at 3-19%, and is low in Africa, at 0 to 
1 % (Seyoum, Kiros, Haileselase and Leole, 1999). The significance of gestational 
diabetes mellitus is that it poses 16 to 63 % risk factor to the mother for future 
development of type II diabetes within 5 to 16 years (Hyer and Shehata, 2005). 
Gestational hyperglycaemia also exposes the foetus to risk of future diabetes, 
hypertension, and obesity (Boloker, Gertz and Simmons, 2002; Maresh, 2005). In 
addition to the perinatal morbidity, immediate dangers of gestational diabetes include 
pre-term birth, macrosomia, pre-eclampsia and caesarean section (Fan, Yang, Gao, 
Lintu and Sun, 2006). 
Excessive foetal exposure to glucose as a result of maternal hyperglycaemia results in 
permanent reduction in levels of GLUT-l and GLUT-4 transporters in the newborn 
and adult offspring of a gestational diabetic mother (Boloker et ai., 2002). 
Downregulation of these transporters may be an adaptive mechanism by which the 
foetus protects itself against the adverse effects of hyperglycaemia. The foetus adapts 
to a changed environment in the uterus that may enhance its chance of short-term 
survival but at the expense of a long-term capacity for normal growth and 
development, resulting in the development of diabetes (Boloker et ai., 2002). 
Foetal exposure to excessive levels of glucocorticoids in diabetic pregnancy is one of 
several factors that subject them to growth retardation, hypertension and diabetes 
mellitus later in life (Fujisawa et ai., 2004). Phillips, Barker, Fall, Seckl, Whorwood, 
Wood and Walker, (1998) also demonstrated that increased plasma cortisol levels 
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were strongly associated with hypertension, hyperglycaemia, fasting 
hypertriglyceridaemia and insulin resistance in adults. The authors asserted that 
intrauterine exposure to transient stressful conditions such as low protein diet, alcohol 
and maternal infections, permanently alters the hypothalamic-pituitary-adrenal axis, 
as a result of excessive foetal exposure to glucocorticoids. Later in adult life, victims 
express increased cortisol activities accounting for diabetes mellitus, hypertension and 
other complications. 
It has been shown that diabetic pregnancy suppresses expreSSIOn of 11 beta-
hydroxysteroid dehydrogenase (llh-HSD) type 2 in the placenta and foetal kidney 
(Fujisawa, Nakagawa, Ren-shan and Ohzeki, 2004). llh-HSD is a high affinity 
NAD+ -dependent enzyme that inactivates glucocorticoids. The role of glucocorticoids 
in insulin resistance is well established. Glucocorticoids mediate lipolysis resulting in 
increased availability of free fatty acids which culminates in reduced glucose 
oxidation and uptake in peripheral tissues. Moreover, the presence of glucocorticoids 
also compromises translocation of GLUT -4 transporters to the cell membranes 
(Mlinar et al., 2007). These substances promote blood vessel vasoconstriction, 
gluconeogenesis, glucose release and discourage glucose uptake in the peripheral 
tissues (Mlinar et al. , 2007). 
There are opposing views about influence of birth weight on future occurrence of 
chronic diseases including diabetes mellitus. One view asserts that gestational 
diabetes leads to low birth weight which is a risk factor for typel diabetes (Boney et 
al., 2005). An alternative view, however, holds that gestational diabetes mellitus 
results in overweight children who will subsequently develop diabetes mellitus 
(Ozumba, Obi and ali, 2004). Either way, use of weights as predictive risk factor for 
future diabetic incidence is insignificant as diabetes mellitus occurs in both obese and 
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lean individuals (Nattrass and Bailey, 1999). Indeed, Curhan, Willett, Rimm, 
Spiegelman, Ascherio and Stampfer, (1996), reported that low birth weight is 
associated with future occurrence of hypertension and diabetes, while high birth 
weight is associated with future incidence of obesity. 
1.4.4. Other types of diabetes mellitus 
Other specific types of diabetes are: Diabetes due to genetic defect of beta cells, also 
known as Maturity onset diabetes of the young, (MODy), diabetes due to genetic 
defects in insulin action, diabetes due to diseases of the exocrine pancreas, diabetes 
due to endocrinopathies, and, drug or chemical-induced diabetes (American Diabetes 
Association, 2004). 
1.5. Diabetic complications 
Complications arising from hyperglycaemia are both microvascular and 
macro vascular in nature. Microvascular complications, affecting the smaller blood 
vessels frequently result from type 1 diabetes while macrovascular complications 
affecting large blood vessels, originate from type II (Bate and Jerums, 2003; 
Gonzalez-Correa, Arrebola, Guerrero, Cafiada, Munoz Marin, Sanchez De la Cuesta, 
De la Cruz, 2006; Girach and V ignati , 2006). The two are the leading cause of 
morbidity and death in people with diabetes (Brites, Fema'ndez, Verona, Malusardi, 
Ischoff, Beresan, Elbert and Wikinski, 2007). 
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1.5.1. Microvascular complications 
Microvascular complications include (a) neuropathy, (b) retinopathy, and, (c) 
nephropathy. 
1.5.1.1. Diabetic neuropathy 
Diabetic neuropathy is a term that describes many pathological conditions each 
characterized by peripheral nerve dysfunction in the presence of diabetes (Apfel, 
2006). Aetiology of diabetic neuropathy is multifactorial with hyperglycaemia, and! 
or lack of insulin, playing a major role. 
Chronic hyperglycaemia induces glycation of myelin. Glycated myelin is prone to 
phagocytosis by macrophages (Ahmed, 2005). Furthermore, glycated myelin 
stimulates macrophages to secrete proteases which may cause demyelination. Such 
nerve degeneration may lead to hyperalgesia or loss of pain or temperature sensation 
(Berti-Mattera, Gariepy, Burke and Hall, 2006). 
Endothelins are a family of peptides that, among others, mediate pain perception. 
Reduced expression oftype-B endothelin receptors in peripheral nerves may be one of 
the factors responsible for pathogenesis and exacerbation of hyperalgesia and tactile 
allodynia in diabetes (Berti-Mattera, et ai. , 2006). Severe cases of peripheral 
neuropathy result in foot ulcers and amputations (Viberti, 2005). 
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1.5.1.2. Diabetic nephropathy 
Diabetic nephropathy is the most important cause of renal failure in developed 
countries (Amador-Licona, Juan-Manuel, Guizar-Mendoza, Vargas, Sanchez-
Camargo and Zamora-Mata, 2000). Patients with early renal damage manifest with 
microalbuminuria which progresses into proteinuria (Leiter, 2005). In renal tissue, 
advanced glycation end products can induce activities of transforming growth factor-~ 
and raise expressions of various extracellular matrix mRNAs. These mediate 
hypertrophy of the glomeruli, thickening of basal membrane, and expansion of the 
mesangial extracellular matrix. 
Such structural changes are associated with albuminuria and proteinuria (Stitt, 2003). 
Blocking activities of advanced glycation end products by a phenyl hydrazine 
compound, aminoguanidine, slows down mesangial expansion and proteinuria 
(Kedziora-Komatowska, Luciak, Blaszczyk, and Pawlak, 1998; Amador-licona et al., 
2000; Adler, 2003). In addition, hypertension associated with diabetes is one of the 
most important factors in the pathogenesis and progression of diabetic nephropathy 
(Bretzel, 1997). In turn, diabetic nephropathy is critical in the development of 
hypertension in diabetics (Sowers and Epstein, 1995). As pointed out by Lewis, 
Hunsicker, Bain, and Rohde, (1993), diabetic nephropathy results in progressive 
deterioration of glomerular function. The decline in renal function, however, can be 
attenuated by management of hypertension. 
Hyperglycaemia causes a redox imbalance. This is as a result of excessive reactive 
oxygen species generation as well as glycation of enzymes responsible for scavenging 
reactive oxygen species (Ha and Kim, 1999; Agardh, Stenram, Torffvit and Agardh, 
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2002). Enzymes involved in cellular defence against exceSSIve reactive oxygen 
species build up include catalase, glutathione peroxidase and superoxide dismutase. 
Glutathione and vitamin E are non-enzymatic antioxidants. Studies have shown that 
superoxides directly mediate vasoconstriction m renal microvasculature 
(Schnackenberg, 2002). This is either by stimulating synthesis of a vasoconstrictor, 
adenosine, or by blocking effects or secretion of a vasodilator, prostaglandin2 (PGh). 
These processes, occurring on a subcellular level, ultimately compromise the overall 
renal function. Renal function failure is itself major risk factor for pathogenesis and/or 
exacerbation of hypertension (Diepeveen, Verhoeven, Palen, Dikkeschei, Tits, 
Kolsters, Offerman, Bilo and Stalenhoef, 2005). Increased incidences of 
cardiovascular complications and renal function deterioration are partly attributed to 
reduced excretion of electrolytes such as sodium (Roland, O'Hare, Walters and 
Corrall, 1986; Dahar and Gutkowska, 2000). The UKPDS demonstrated the 
insufficiency of controlling blood glucose alone in the prevention of macrovascular 
complications (Bate and Jerums, 2003). This was supported by other trials that 
showed that reduction of hypertension in addition to managing glycaemia to 
acceptable levels did reduce incidences of macrovascular complications (Bate and 
Jerums, 2003). 
1.5.1.3. Diabetic retinopathy 
Diabetic retinopathy is the commonest cause of blindness in people afflicted with 
diabetes aged between 20 and 74 years (Girach and Vignati, 2006). Accumulation of 
advanced glycation end products in the retinal cells and vasculature is critical for 
pathogenesis and progression of diabetic retinopathy (Stitt, 2003). These cause 
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reduced cell viability of the retinal cells. Hyperglycaemia-induced secretion of 
vasoconstrictors such as angiotensin II and endothelin-l are thought to compromise 
retinal perfusion (Leiter, 2005). Studies have revealed that diabetic retinopathy is 
itself a risk factor for nephropathy in addition to all other established risks (EI-Asrar, 
AI-Rubeaan, Al-Amor, Moharram and Kangave, 2002). In these studies, patients with 
diabetic retinopathy were 13.39, and 3.51 times more likely to have nephropathy than 
patients with type 1 and type II diabetes, respectively. Furthennore, hyperglycaemia 
compromises nitric oxide secretion of the retinal microvasculature thereby 
contributing to disturbed retinal perfusion (EI-Asrar et ai., 2002). 
1.5.2. Macrovascular complications 
Macrovascular complications are largely responsible for mortality in diabetes, with 
cardiovascular diseases accounting for up to 80% morbidity (Akula, Kota, Gopisetty, 
Chitrapu, Kalagara, Kalagara, Veeravalli and Gomedhikam, 2003). Macrovascular 
complications include (a) atherosclerosis, (b) reproductive problems, (c) stroke, and 
(d) coronary artery diseases. 
1.5.2.1 Atherosclerosis 
Due to hyperglycaemia, fonnation of advanced glycation end products in arterial 
collagen results in trapping of low density lipoproteins. This process speeds up the 
rate of atheroma fonnation in blood vessels (Ahmed, 2005). In addition advanced 
glycation end products promote smooth muscle cell proliferation in blood vessels 
(Basta, Schmidt and, De Caterina, 2004). In coronary artery disease, advanced 
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glycation end products cause increased deposition of lipids in the cardiac cells, and 
compromise ventricular compliance (Sobel and Schneider, 2005). 
1.5.2.2. Reproductive problems 
Hyperglycaemia due to diabetes is a significant underlying cause of a number of 
sexual disorders associated with diabetes mellitus. About 90 % of diabetics manifest 
sexual problems characterised by impotence, infertility and low sexual drive (Amaral, 
Moreno, Santos, Seic and Ramalho-Santos, 2006). These are attributed to 
hyperglycaemia-induced reactive oxygen species generation. Erectile dysfunction in 
diabetes is caused by lack of smooth muscle relaxation mediated by nitric oxide due 
to endothelial dysfunction and autonomic neuropathy (Price, 2006). Moreover, 
interaction of reactive oxygen species generated as a consequence of diabetes 
mellitus, with DNA of spermatozoa, results in reduced motility and fertility of human 
sperm (Amaral, et al., 2006). 
1.5.3. Pathogenesis of diabetic complications 
Development and progression of diabetic complications are mediated by 4 major 
pathways including increased sorbitol (polyol) pathway flux, increased formation of 
advanced glycosylation end products, increased activities of protein kinase C, and 
increased hexosamine pathway flux (Ceriello, 2003; Lapolla, Fedele and Traldi, 
2005). 
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Generation of reactive oxygen species have been implicated as the main pathogenic 
factor as well as the result, in these processes. In endothelial cells, glucose enters into 
cells via plasma membrane transported by insulin-independent GLUT -1 transporters. 
Its subsequent accumulation in the cells causes generation of superoxide which is 
considered a key component in the initiation of all other pathways (Ceriello, 2003). 
Excessive formation of reactive oxygen species results in damage, oxidatively, to 
DNA, proteins and lipids (Dandona, Thusu, Cook, Snyder, Makowski, Armstrong and 
Nicotera, 1996). The most affected organs appear to be those whose glucose uptake is 
independent of insulin influence including the nervous system, kidney, heart and 
small blood vessels (Ahmed, 2005). 
1.5.3.1. The polyol (sorbitol) pathway 
In the polyol (sorbitol) pathway, aldose reductase is a key enzyme that has been 
reported to catalyze the reduction of glucose to sorbitol in non-insulin dependent 
tissues. Sorbitol does not readily diffuse across cell membranes, and its intracellular 
accumulation is implicated in the chronic complications of diabetes such as peripheral 
neuropathy, retinopathy and cataracts (Matsuda, Morikawa and Yoshikawa, 2002). 
Osmotic changes as a result of increased concentration of sorbitol disrupts normal 
cellular function, leading to cataract formation (Gugliucci, 2000). Sorbitol is 
metabolised by sorbitol dehydrogenase to fructose and nicotinamide adenine 
dinucleotide (NADH). Increased levels of NADH are sensed by many tissues as 
hypoxia (Gugliucci, 2000). 
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In this pathway, aldose reductase uses nicotinamide adenine dinucleotide phosphate 
(NADPH) as a cofactor (Gugliucci, 2000). This denies other important pathways 
access to adequate levels of NADPH. For instance, glutathione, an antioxidant 
depends on NADPH for its recycling. Inadequate NADPH, therefore, can cause redox 
imbalance due to insufficient glutathione levels (Gugliucci, 2000). Other reactions 
that use NADPH as a coenzyme include nitric oxide formation. Compromised nitric 
acid synthesis as a result of inadequate NADPH can cause vasoconstriction resulting 
in peripheral vascular resistance and ultimately, hypertension. Thus, use of NADPH 
in the polyol pathway is one way by which hyperglycaemia causes diabetic 
complications. Oxidative stress generated via the polyol pathway is considered to be a 
major contributing factor in the pathogenesis of diabetic neuropathy (Chung, Ho, Lam 
and, Chung, 2003). 
1.5.3.2. Advanced glycation products 
Figure 1 illustrates a modified process of protein glycation. Chronic hyperglycaemia 
promotes nonenzymatic glycation of proteins. This occurs by covalent binding of 
aldehyde groups of reducing sugars to free amino acid groups of proteins resulting in 
formation of the relatively unstable Schiff's base (Ahmed, 2005). Rearrangement of 
Schiff's base results in formation of Amadoli's products and, subsequently, advanced 
glycation end products (AGEs) (Basta et al., 2004). Advanced glycation end products 
mediate their adverse effects by interacting with advanced glycation end product 
receptors (RAGE) found on endothelial cells, monocytes and macrophages (Kedziora-
Komatowska, et al., 1998). Such interaction results in intracellular oxidative stress 
and activation of NF -lCB through activation of mitogen-activated protein kinase 
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signalling pathway (peyroux and Sternberg, 2006). NF -lCB stimulates transcription of 
genes for various factors including endothelin-l, vascular endothelial growth factor 
(VEGF), transforming growth factor-p (TGF- P), inteleukin-6 and tumour necrosis 
factor-a (TNF -a) (Peyroux and Sternberg, 2006). These mediate vasoconstriction, 
inflammation and coagulation (Ahmed, 2005). Advanced glycation end products 
crosslink with collagen resulting in arterial stiffening thereby creating hypertensive 
complications. Indeed, crosslinking of advanced glycation end products and collagen 
trap plasma proteins including albumin, low density lipoproteins, and 
immunoglobulins. Accumulation of these proteins in the subendothelium causes 
luminal narrowing (Gugliucci, 2000), which may lead to development or exacerbation 
of hypertension. 
Interaction of advanced glycation end products with DNA, proteins and amino acids 
alters their structure and function. Formation of advanced glycation end products on 




The intennediate end products react to fonn glycation end products (AGEs). 
Figure 1. Glycation of protein by glucose and the fonnation of AGEs. 
(Modified from: Basta G, Schmidt A, De Caterina R. Advanced glycation end 
products and vascular inflammation: implications for accelerated atherosclerosis in 
diabetes. Cardiovascular Research, 63:582- 592,2004. 
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1.5.3.3. Protein kinase C (PKC) 
Hyperglycaemia is also associated with increased levels of circulating diacylglycerols 
which leads to synthesis of protein kinase C (PKC) (Inoguchi, Xia, Kunisaki, Higashi, 
Feener and King, 1994). Diacylglycerol generation resulting from hyperglycaemia is 
possible by several pathways. Diacylglycerols may be a product of phosphodiesteratic 
cleavage of phosphatidylinositol 4,5-biphosphate or a product of metabolism of 
phosphatidylcholine, or maybe produced via the glycolytic pathway (Inoguchi, et aZ., 
1994). Induction of PKC production is stimulated by both transient as well as 
prolonged hyperglycaemia. PKC activates NADPH oxidase, probably the most 
important enzyme in the generation of reactive oxygen species in blood vessels of the 
heart, kidney, aorta, and retina (Inoguchi et aZ., 2003). PKC catalyses phosphorylation 
of a number of chemical substances including the insulin receptor, thereby reducing 
activities of its protein-tyrosine kinase (Bollag, Roth, Beaudoin, Mochly-rosen and 
Koshland, 1986). Moreover, PKC plays a modulatory role in oxidative stress-induced 
glomerular insult (Ha and Kim, 1999). PKC also elevates levels of vasoconstricting 
prostaglandins, endothelia and several vascular growth factors that influence 
vasomotor activities and vascular growth (Sowers and Epstein, 1995). Furthermore, 
PKC is associated with an increase in the exchange activities of Na+/K+ in the renal 
cells and inhibition of activities of N a +, K+ -ATPase in proximal tubules (Bertorello, 
1992). Thus, the protein kinase C pathway may explain the association between 
diabetes mellitus and renal function failure. 
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1.5.3.4. Hexosamine pathway 
Under normal physiological conditions, 1-3% of glucose is converted into the 
hexosamine pathway leading to conversion of fructose 6-phosphate to glucosamine 6-
phosphate catalysed by the rate-limiting enzyme, glutamine:fructose-6-phosphate 
amidotransferase (James, Tang, Ingram, Ly, Thai, Cai and Scholey, 2002). During 
hyperglycaemic states, excess glucose is shunted into the hexosamine pathway 
resulting in the formation of UDP-N-acetylglucosamine, which is a substrate for 
glycation of essential intracellular factors including transcription factors. These 
reactions influence expressions of various genes such as plasminogen activator 
inhibitor-l (PAl-I) gene promoter, culminating in the pathogenesis of microvascular 
complications (Goldberg, Whiteside and Fantus, 2002). Hyperglycaemia activates the 
hexosamine pathway leading to further deterioration of pancreatic p-cell function in 
diabetes (Kaneto, Xu, Song, Suzuma, Bonner-Weir, Sharma and Weir, 2001). 
Acute exposure to hyperglycaemia has as much adverse effects as long term exposure. 
Short term hyperglycaemia causes increases in blood pressure that may be caused by 
suppression of nitric oxide (NO) synthesis (Giugliano, Marfella, Coppola, Verrazzo, 
Acampora, Giunta, Nappo, Lucarelli and D'Onofrio, 1997; Marfella, Nappo, De 
Angelis, Paolisso, Tagliamonte and Giugliano, 2000). Similar observations were 
made by Bohlen and Lash (1993), who reported that acute exposure of intestinal 
tissues to hyperglycaemia, for periods as brief as 15 minutes, has adverse effects 
affecting vasodilatory effects of endothelium - derived relaxing factor (EDRF). This 
period is sufficient to allow onset of reactive oxygen species generation. It is 
suggested that the low nitric oxide levels are a result of hyperglycaemia-induced 
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reactive oxygen species generation that preys on nitric oxide (Giugliano et al. , 1997; 
Bohlen and Nase, 2001). Oxygen radicals, e.g. superoxide, 02-, react with nitric oxide 
to produce peroxynitrite, ONOO-, thereby compromising bioavailability and effects of 
nitric oxide (Beltowski, W6jcicka, Marciniak and Jamroz, 2004). Moreover, 
peroxynitrite undergoes chemical reactions with nucleic acids, lipids and certain 
proteins. Reduced nitric oxide levels can lead to a host of adverse effects including 
platelet adhesion and aggregation, proliferation of smooth muscles, and increased 
blood viscosity (Giugliano et al., 1997; Brodsky, Morrishow, Dharia, Gross and 
Goligorsky, 2001). 
1.6. Therapy for diabetes mellitus 
As reported in the preceding sections, diabetes mellitus is an important risk factor for 
development of cardiovascular and renal complications. Appropriate therapeutic 
intervention to prevent hyperglycaemia can prevent the development and progression 
of diabetic complications (The Diabetes Control and Complications Trial Research 
Group, 2006). Control of blood glucose achieving less than 7% glycosylated 
haemoglobin is considered adequate to minimise complications of diabetes (Sim6 and 
Hernandez, 2002). In addition to achieving glycosylated haemoglobin below 7% via 
glucose control, control of hypertension to attain blood pressure levels S 130/80 
mmHg must be pursued to prevent the occurrence of microvascular complications 
(Bate and Jerums, 2003). 
A multi-pronged approach involving lifestyle changes and oral hypoglycaemic drugs 
and! or insulin therapy to control glucose metabolism is usually employed. Hence 
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various drugs are used to achieve these goals. Below is description of some of the 
major groups of antidiabetic agents used to control blood glucose. 
1.6.1. Pharmacological intervention 
1.6.1.1. Insulin 
Insulin is one of the major hypoglycaemic agents presently used in diabetes mellitus 
management. It was discovered in 1921 and is the mainstay antidiabetic agent for the 
management of type 1 diabetes and is also used in late-stage type II diabetes (Emilien, 
Maloteaux and Ponchon, 1999). There are several types of insulin classified based on 
their duration of action. These are rapid (ultra short) - acting (e.g. lispro, aspart), short 
-acting (e.g regular insulin), intermediate - acting (e.g. lente) and long-acting (e.g. 
glargine, detemir) (Bethel and Feinglos, 2005). Short acting insulin types which 
control postprandial glycaemia are designed to mimic bolus insulin secretion, while 
intermediate or long acting insulin are designed to mimic basal glycaemic control 
(Fonseca, 2006). Insulin is currently administered subcutaneously using multiple daily 
injections or external pump for continuous delivery (Hirsch, Bode, Garg, Lane, 
Sussman, Hu, Santiago and Kolaczynski, 2005). Other delivery routes include oral, 
inhaled, nasal, rectal, ocular, intravaginal and transdermal (Grover, Vats and Rathi, 
2000; Takei and Kasatani, 2004). Intensive insulin therapy to maintain optimal 
glucose levels in type 1 diabetes can reduce incidences and exacerbation of 
microvascular complications by 50 to 70% (DCCT Research group, 1993). 
Shortfalls of insulin therapy include ineffectiveness on oral application due to first 
pass hepatic metabolism, short shelf life, and severe hypo glycaemia on overdosage, 
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non-compliance to painful injections and weight gain (DeFronzo, 1999; Takei and 
Kasatani, 2004). Several observations, however, suggest that non-compliance due to 
painful daily injections can be overcome by using the oral route (Meyerovitch, Farfel, 
Sack and Shechter, 1987; Musabayane, Munjeri, Bwititi and Osim, 2000). Since 
insulin undergoes digestion in the gut, Musabayane et al. (2000) demonstrated in the 
rat that coating insulin in amidated pectin hydrogel beads evades digestion. 
1.6.1.2. Oral blood glucose lowering agents 
There are 5 classes of antidiabetic agents presently in use, including biguanides, 
sulphonylureas, thiazolidinediones, benzoic acid derivatives and a-glucosidase 
inhibitors. Highlighted below are some of their modes of actions, advantages and 
limitations. 
1.6.1.2.1 Biguanides 
Biguanides were introduced for use between 1957 and 1960 (Sim6 and Hernandez, 
2002). Biguanides (e.g. metformin) mediate antihyperglycaemic effects by sensitizing 
target tissues cells to insulin action and blocking hepatic gluconeogenesis (pari and 
Satheesh, 2006). Metformin (Dianben~ is the principal drug in this class. The drug 
has been proved effective when used either in monotherapy or in combination with 
other groups of drugs such as sulphonylureas or insulin (Chadwick, Roux, van de 
Venter, Louw and Oelofsen, 2007). Its mechanisms of actions are still unclear. 
Current studies, however, show that on a subcellular level, metformin mediates 
hypoglycaemic effects by stimulating AMP-activated protein kinase (AMPK). 
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Stimulation of AMPK results in fatty acid catabolism and enhanced muscle glucose 
uptake (Zhou, Myers, Li, Chen, Shen, Melody, Wu, Ventre, Doebber, Fujii, Musi, 
Hirshman, Goodyear and Moller, 2001). Metformin also increases expression or 
activities of GLUT -4 transporters which also enhances glucose uptake by muscles 
(Sim6 and Hernandez, 2002). Moreover, biguanides inhibit advanced glycation end 
product formation. The amino groups on biguanides react with carbonyl groups of 
dicarbonyl compounds thereby inhibiting advanced glycation end product formation. 
Therefore, usage of metformin prevents the occurrence of diabetic complications in 
addition to controlling glucose levels (Kiho, Kato, Usui and Hirano, 2005). Other 
examples of drugs in this class include fenformin and buformin. Lactic acidosis is the 
major adverse effect of metformin treatment. This results from accumulation of 
lactate in blood because metformin inhibits the liver from using lactate to synthesise 
glucose (Stumvoll, Nurjhan, Perriello, Dailey and Gerich, 1995). Other side effects 
are diarrhoea, nausea abdominal bloating and flatulence (Zonneveld, 2005). 
1.6.1.2.2. Sulphonylureas 
Sulphonylureas act by stimulating insulin secretion. They bind to beta cell receptors 
that are linked to ATP-dependent potassium gated channels. Interaction with these 
receptors inhibits opening of potassium channels. Potassium build up in the cell 
causes cellular depolarization evoking opening of calcium channels, and 
subsequently, influx of calcium ions which mediate exocytosis of secretory granules 
containing insulin (Sim6 and Hernandez, 2002). Sulphonylureas also minimize 
hepatic degradation of insulin thereby increasing levels in blood (Harrigan, Nathan 
and Beattie, 2001). Sulphonylureas usage is restricted to type II diabetes mellitus 
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because it requires a functioning pancreatic beta cell mass. Examples of agents 
presently in use include glibenclamide, glipizide, tolbutamide and gliclazide. 
Hypoglycaemia is the main side effect of sulphonylureas (porksen, 2006). Factors that 
enhance episodes of hypoglycaemia include poor nutrition, advanced age, alcohol 
consumption and renal and hepatic diseases (Harrigan et al., 2001). Other dangers of 
sulphonylurea class of antidiabetic agents is that they stimulate insulin release by the 
pancreatic beta cells independent of glucose loading thereby subjecting the beta cells 
to exhaustion. Furthermore, they cause allergy and weight gain as a result of increased 
blood levels of insulin. 
1.6.1.2.3. Thiazolidinediones 
Thiazolidinediones (TZDs) mediate their hypoglycaemic effects by enhancing insulin 
sensitivity, and reducing gluconeogenesis by the liver (Emilien et al., 1999). This 
group of drugs targets the perixosome proliferator gamma receptors (pPAR-y) which 
are nuclear and expressed mainly in the adipose tissues. Other tissues expressing 
PP AR-y include liver, skeletal muscle, kidney, heart, large and small intestine and 
colon (Bailey, 2000; Song, Knepper, Hu, Verbalis and Ecelbarger, 2004). Interaction 
TZDs with the receptors leads to modification of expression of major genes 
responsible for glucose metabolism (Hevener, Reichart, Janez and Olefsky, 2001). 
Stimulation ofPPAR-y activates adipocytes to secrete adiponectin which induces fatty 
acid oxidation and inhibits hepatic gluconeogenesis (Mlinar et al., 2006). Activation 
of these receptors results in improved uptake of glucose and triglycerides by cells, and 
subsequently, improved insulin sensitivity (Tamsma, Jazet, Beishuizen, Fogteloo, 
Meinders and Huisman, 2005). When administered at high doses TZDs suppress 
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hepatic gluconeogenesis (Fiordelllis et al., 2005). TZDs are particularly effective in 
combination therapy with insulin and safeguards against high insulin dose (Bailey, 
2000). In addition, TZDs possess anti-inflammatory properties, inhibit reactive 
oxygen species generation and improve beta cell function (Dandona et al. , 2003 ; 
Viberti, 2005). 
Troglitazone, roziglitazone, and pioglitazone are some of examples of drugs in this 
class. A major shortfall of thiazolidinediones is that they lead to increased plasma 
levels of cholesterol (Bailey, 2000). Other side effects of TZDs include fluid retention 
and oedema, hepatotoxicity, cardiomegaly and haemotoxicity (Song et al. , 2004; 
Chakrabarti et al., 2006). Fluid retention is due to a reduction in glomerular filtration 
rate and an increase in expressions of renal tubular transporters including (I-I subunit 
of Na-K-ATPase, the bumetanide-sensitive Na-K-2CI cotransporter (NKCC2), the 
sodium hydrogen exchanger and aquaporins 2 and 3, which result in sodium retention 
(Song et aI. , 2004). 
1.6.1.2.4. Benzoic acid derivatives 
Benzoic acid derivatives mediate hypoglycaemic effects by stimulating insulin 
secretion. Benzoic acid derivatives, bind to ATP sensitive potassium channels on p-
cells at receptor different from that bound by sulfonylureas. Interaction of benzoic 
acid derivatives with their receptors results in reduced levels of insulin release 
compared with sulphonylureas (Harrigan et al. , 2001). Hypoglycaemia may occur on 
overdose. An example of drugs in this class include repaglinide. 
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1.6.1.2.5. a-glucosidase inhibitors 
Alpha-glucosidase inhibitors mediate their hypoglycaemic effects by lowering 
glucose absorption into blood by suppressing digestion of polysaccharides and 
disaccharides into monosaccharides, thus decreasing postprandial blood glucose 
(Fujisawa, et al., 2005). This is primarily mediated by competitively and reversibly 
inhibiting the actions of a-glucosidase, a small intestine epithelial membrane bound 
enzyme which catalyses break down of polysaccharides into monosaccharides. 
Examples of a-glucosidase are acarbose and voglibose. Side effects include diarrhoea, 
flatulence abdominal bloating. These adverse effects are primarily due to 
malabsorption of glucose (Bressler and Johnson, 1992). 
1.6.1.3. Adjunct treatment 
In specific cases depending on need, non-traditional hypoglycaemic therapy maybe 
utilized. For example, statins (HMG-CoA [3-hydroxy-3-methylglutaryl coenzyme A] 
reductase inhibitors) and fibrates are used to control hypercholesterolaemia, 
hypertriglyceridaemia and increased blood levels of low density lipoproteins (LDL) 
(Bate and Jerums, 2003). Angiotensin converting enzyme inhibitors and angiotensin II 
receptor antagonist are 'first choice' drugs used to control hypertension in diabetes 
because of their effectiveness in treating diabetic nephropathy (Bate and Jerums, 
2002). Such renoprotective effects of ACE inhibitors have been confirmed by several 
investigators including Lewis, Hunsicker, Bain and Rohd, (1994). In addition, 
angiotensin II has probable adverse mediatory effects on insulin signaling due to its 
influence in generation of reactive oxygen species (Sowers and Stump, 2004). 
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Low dose aspirin is also indicated in diabetes to prevent the occurrence of myocardial 
infarction (Adler, 2003). Furthermore, diabetics on high aspirin doses have reduced 
prevalence of cataracts. These beneficial effects of aspirin have been confirmed by in 
in vitro and in vivo experiments that have shown that aspirin reduces glycation or 
glycoxidation and formation of advanced glycation end products crosslinks (Ahmed, 
2005). 
1.6.2. Non-pharmacological intervention 
Weight loss as a nonpharmacological intervention for diabetes is significant in that 
reduced adipose tissue results in lesser production of proinflammatory products 
cytokine tumour necrosis factor -a (TNF -a) which is thought among others to mediate 
insulin resistance (Mlinar et al., 2007). Consumption of food with low glycaemic 
index is beneficial in that it requires less insulin secretion and improves target tissues 
to insulin effects. Foods with low glycaemic index allow slow absorption of glucose 
in the gut. 
Regular exercise reduces levels of circulating cholesterol. Furthermore, exercise is 
known to stimulate glucose uptake by the muscles and liver and its conversion to 
glycogen (Murakami, Shimomura, Fujitsuka, Sokabe, Okamura and Sakamoto, 1997). 
Studies by Coskun, Ocakci, Bayraktaroglu and Kanter, (2004), have shown that 
exercise has therapeutic effects by decreasing oxidative stress and maintaining 
functional capacity of the pancreatic ~-cells. Moreover, in diabetic rats exercise 
improves cardiac output and raises levels of sarcolemmal GLUT-4 protein (De 
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Angelis, Oliveira, Dall'Ago, Peixoto, Gadonski, Lacchini, Fernandes, and Irigoyen, 
2000). 
As demonstrated above, pharmacological interventions with synthetic medicines are 
not without adverse limitations and secondary failures (Park, Ko and Chung, 2005). 
The failure for monotherapy in most cases to adequately control hyperglycaemia 
implies that combination therapy be used. This leads to an increase in the cost of 
maintaining normoglycaemia. Management of diabetes is, therefore, a major 
challenge. As a result diabetic patients and healthcare professionals are beginning to 
consider alternative and complementary therapy in the management of diabetes 
mellitus. 
1.7. Novel antidiabetic therapy research 
Despite the intensive use of current antidiabetic agents, many type II diabetic patients 
still exhibit poor glycaemic control and some develop serious complications. This 
suggests that individual oral agents act on only part of the pathogenic process and 
only to a partial extent. They do not reinstate normal insulin sensitivity or normal 
pancreatic ~-cell function. In addition, these agents do not prevent gradual loss of 
pancreatic ~-cells, and their efficacy depends upon availability of functional ~-cells 
(Bailey, 2000; Gadsby, 2002). Implications are that higher drug doses will be needed 
to control the increasingly worsening hyperglycaemia. Moreover, more drug classes 
will be needed to be used as an increasing number of diabetics will require 
combination therapy to control their glycaemia (Gadsby, 2002). Research of diverse 
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nature continues to be undertaken to identify antidiabetic therapies that are effective 
and affordable, but with fewer side effects. 
The incretin hormone glucagon-like peptide-l (GLP-l) is released by the L-cells of 
gut after a meal and contributes to maintaining normoglycaemia by regulating insulin 
and glucagon release, gastric emptying and body weight (Combettes, 2006). 
Furthermore, GLP-l is known to mediate ~-cell differentiation and proliferation 
(Bregenholt, M0ldrup, Blume, Karlsen, Friedrichsen, Tornhave, Knudsen, Petersen, 
2005). Based on the beneficial glucose lowering effects of GLP-l, the antidiabetic 
drug exenatide has recently been approved. Furthermore, liraglutide, a long-acting 
GLP-l analogue, has been shown, in laboratory studies to inhibit STZ-mediated 
pancreatic ~-cell damage (Bregenholt, et al., 2005). 
Oestradiol, a reproductive hormone in females is known to playa modulatory role in 
glucose homeostasis. Oestrogen therapy inhibits hepatic gluconeogenesis and reduces 
incidences of diabetes in postmenopausal women (Kanaya, Herrington, Vittinghoff, 
Lin, Grady, Bittner, Cauley and Barrett-Connor, 2003). Other studies have reported 
that these effects are probably mediated by its influence on expression of GLUT-4 
transporters (Barros et al., 2006). These findings have created the need to search for 
antidiabetic therapy that exploits oestradiol and! or its receptors. 
Long term exposure to a cold environment activates the sympathetic system resulting 
in increased energy expenditure for warmth, glucose tolerance and insulin sensitivity 
(Liu et al., 1998; Hori, Ishigaki, Kaya, Tsujita, Terada, Oku and Hori, 2006). ~3-
adrenergic receptors which are expressed in most tissues including brown and white 
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adipose tissues are thought to play a major role in these effects. Liu, et al., (1998) 
reported that long term stimulation of the ~3- receptors in adipose tissues with a 
selective agonist evoked positive glycaemic effects similar to chronic cold exposure. 
These receptors offer a potential therapeutic target worth investigating. The use of 
genetic therapy to manage diabetes mellitus is being investigated. Type I diabetes can 
be prevented in victims expressing adverse MHC alleles via genetic engineering of 
haematopoietic stem cells to restore protective MHC class II expression (Tian, 
Bagley, Cretin, Seth, Wucherpfennig and Iacomini, 2004). 
1.7.1. Experimental animal models of diabetes 
Animal models of diabetes have allowed studies and provided understanding of 
pathogenesis and progression of diabetes mellitus in humans. Furthermore, animal 
models have allowed the evaluation of various therapeutic interventions which may 
be potentially used in man. Uses of animal models have made possible studies of 
disease characteristics in humans by providing genetic and immunological 
modifications that are not possible in humans (Bach, 1994). 
1.7.1.1. Animal models of type I diabetes mellitus 
1.7.1.1.1. Streptozotocin (STZ)-induced diabetes in the rat 
The streptozotocin-induced diabetic model is an extensively used animal model in 
studies of human diabetes mellitus. It is a well-described model and the toxicity of 
STZ is relatively low compared with other diabetogenic agents (Piotrowski, 2003). 
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Streptozotocin (N-[methylnitrocarbamoyl]-D-glucosamine), STZ, is an antibiotic 
synthesised by Streptomycetes achromogenes and is commonly used in induction of 
experimental diabetes. STZ selectively destroys p-cells by alkylation of DNA through 
its nitrosourea moiety (Szkudelski, 2001 ; Vessal, Hemmati and Vasei, 2003). Other 
mechanisms of beta cell damage occur via reactive oxygen species and nitric oxide 
production. Pancreatic beta cells take up STZ via GLUT -2 transporters (Szkudelski, 
2001). Intracellular metabolism of STZ leads to liberation of nitric oxide which 
mediates in DNA damage leading to cell death (Szkudelski, 2001). In addition, STZ 
mediates mitochondrial production of superoxide ion. 
Pancreatic beta cells are vulnerable to reactive oxygen speCIes induced damage 
because of their particularly low quantities of antioxidant enzymes (Robertson and 
Harmon, 2005; Valko, Leibfritz, Moncol, Cronin, Mazur and Telser, 2007). The STZ-
diabetic model has been used by many investigators as a research tool in studies 
involving antidiabetic drug discovery or diabetic complications (Musabayane, 
Ndhlovu and Balment, 1995; Marwaha, Banday and Lokhandwala, 2004; 
Musabayane, Mahlalela, Shode and Ojewole, 2005). Although considered as a type I 
model, administration of low doses of STZ may induce type II diabetes resulting in 
hyperglycaemia due to insulin resistance as opposed to impaired secretion 
(piotrowski, 2003). 
1.7.1.1.2. Alloxan-induced diabetes 
Alloxan, 2,4,5,6[IH,3H]-pyrimidinetetrone, is probably the longest known and most 
potent diabetogenic agent (Piotrowski, 2003). Uptake of alloxan by the pancreatic p-
cells is via GLUT -2 transporters, due to similarity in molecular shape to glucose 
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(Elsner, Gurgul-Convey and Lenzen, 2006). Alloxan then undergoes reduction 
intracellulary in the presence of tripeptide thiol, glutathione, to yield dialuric acid 
whose re-oxidation, regenerates alloxan. Hence a cyclic reaction (redox cycle) is 
created that ultimately results in reactive oxygen species generation (Szkudelski, 
2001; Elsner et ai. , 2006). The reactive oxygen species so generated interact with 
pancreatic ~-cellular DNA leading to their fragmentation and cell death (Szkudelski, 
2001). Thus, like STZ, it is through reactive oxygen species generation that alloxan 
induces diabetes in experimental animals (Elsner et ai., 2006). Alloxan toxicity, 
however, affects other organs including the liver, kidney, gonads and lungs. Alloxan 
causes mortality in 37% of animals within a few days (Piotrowski, 2003). 
1.7.1.1.3. The Non-Obese diabetic (NOD) mouse 
The non-obese mouse model is a genetically homogenous animal mode of insulin 
dependent diabetes mellitus (Ikegami, Fujisawa and Ogihara, 2004). Development of 
diabetes in the NOD mouse model is remarkably similar to humans (Kurrer et ai., 
1997). Like in the BB rat, ~-cell cell destruction in the NOD mouse is spontaneous 
and is initiated by IFN-y + T cells (Kukreja, Cost, Marker, Zhang, Sun, Lin-Su, Ten, 
Sanz, Exley, Wilson, Porcelli and Maclaren, 2002). The limitations to usage of 
models that develop diabetes mellitus spontaneously are high costs of the animal 
models and low availability of genetically impaired animals (Piotrowski, 2003). 
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1.7.1.1.4. The BioBreeding (BB) rat 
This is an animal model type I diabetes that spontaneously develops autoimmune 
insulin-dependent diabetes whose characteristics are lymphocyte infiltration into the 
pancreatic islets, and T cell-mediated ~-cell destruction (Hessner, Wang, Meyer, 
Geoffrey, Jia, Fuller, Lernmark and Ghosh, 2004). Development of diabetes is often 
associated with thyroiditis in the BB rat (Bach, 1994). 
1.7.1.2. Animal models of type II diabetes mellitus 
The Zucker -ZDF is an animal experimental model that mimics type II diabetes 
mellitus. It manifests insulin resistance, obesity, hyperglycaemia, 
hypertriglyceridaemia, hypertension and hypercholesterolaemia (Liu, Perusse and 
Bukowiecki, 1998). Leptin is ineffective in suppressing food intake in the Zucker rat. 
This is because of a mutation of the leptin receptor encoding gene (Carlson, Shelton, 
White, and Wyss, 2000. 
1.7.1.3. Other animal models of experimental diabetes 
Other experimental models of diabetes include the transgenic mIce and, 
immunomanipulated models by performing thymectomy (Bach, 1994). Induction of 
type II diabetes in the rat is also possible by a subjecting the animal to a combination 
of a high fat diet and low dose STZ injection (Reed, Meszaros, Entes, Claypool, 
Pinkett, Gadbois and Reaven, 2000; Srinivasan, Viswanad, Asrat, Kaul and Ramarao, 
2005). The Goto-Kakizaki is a non-obese type II diabetes rat model that develops 
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diabetes spontaneously (Tourrel, Bailbe, Lacorne, Meile, Kergoat and Portha, 2002). 
Experimental animal models are commonly used as tools in order to establish the 
antidiabetic effects of medicinal plants and other alternative therapy. 
1.8. Background to medicinal plant research 
Medicinal plant usage by the Neanderthal man, as far back as 60000 years has been 
recorded (Hart, 2005). In animals, wild chimpanzees have been reported to swallow 
plant leaves 3$ prophylactics against gastrointestinal nematode infection when 
commonest, during the rainy season (Hart, 2005). Wood rats, Neotoma Juscips use 
leaf sprigs of California bay, Umbellularia californica, in the fumigation of their nests 
(Hart, 2005). Therefore, this shows that the usage of plants as medicines has not been 
exclusive to man. 
In the developing world, plant medicines are widely available and affordable to the 
majority of the people, and a large proportion of the populations in such countries rely 
on medicinal plants (Okine, Nyarko, Kwabena, Oppong, Barnes and Ofosuhene, 
2005). Currently, up to 80% of Africans continue to use traditional medicine in the 
management and treatment of various diseases (Ojewole, 2005). Usage of such forms 
of therapy has been practiced over generations. Consequently, there is cultural 
significance attached to such medicines (Light, Sparg, Staff old and Staden, 2005). An 
increase in the usage of medicinal plants in Africa is partly due to non-availability and 
high costs of synthetic medicines. For example, insulin availability in government 
hospitals in Sub-Saharan Africa is often irregular, and the approximate cost for 
diabetes treatment for an East African type! diabetic is US$229, annually (Beran et 
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ai. , 2006). In Sudan, about half of diabetics abandon or reduce insulin treatment 
because of inconsistent availability or prohibitive costs (Abdelgadir, Elbagir, Eltom 
and Berne, 2006). Although most of these herbal treatments are effective, they have 
received little or no scientific scrutiny to establish efficacies and toxicities. Globally, 
the usage of alternative medicines including herbal medicines is on the rise, because 
they are thought to possess fewer side effects and have multiple therapeutic effects 
compared with the synthetic medicines (lung, Lee, Jeong and Choi, 2004: Hou, Zhang 
and Wu, 2005). About a quarter of best selling drugs worldwide in 2001 and 2002 
were either natural products or traced their origins from natural products (Balunas ang 
Kinghorn, 2005). Studies have also shown that there is general acceptance of 
medicinal plant usage if their claimed therapeutic effects are substantiated with 
scientific evidence (Gilani and Rahman, 2005). This may also have contributed to 
increased use of medicinal plants. 
In general, health research in noncommunicable diseases in Sub-Saharan Africa has 
not been prioritised and mortality from these diseases is higher in the region than in 
Western countries (Unwin, Setel, Rashid, Mugusi, Mbanya, Kitange, Hayes, Edwards, 
Aspray and Albert, 2001). The World Health Organization (WHO) has 
acknowledged that three quarters of the world' s population continue to rely on herbal 
therapy. According to WHO more than 150 medicinal plants are currently used for 
management of diabetes (Eddouks, Maghrani, Zeggwagh and Michel, 2005). 
Furthermore, WHO has encouraged the scientific community to conduct further 
investigations into the therapeutic potential of natural products with antidiabetic 
properties. 
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Research into medicinal potential of plants has already yielded fruits. For example 
drugs including morphine, aspirin, atropine, artimesinin, colchicine, digoxin, 
ephedrine, morphine, physostigmine, pilocarpine, and quinine trace their origins from 
plants (Gilani and Rahman, 2005). Moreover, metformin a major antihyperglycaemic 
agent originates from a guanidine that was isolated from a plant GaZega officinalis L. 
(French lilac) (Vuksan and Sievenpiper, 2005; Martineau, Couture, Spoor, 
Benhaddou-Andaloussi, Harris, Meddah, Leduc, Burt, Vuong, Le, Prentki, Bennett, 
Amason and Haddad, 2006). Furthermore, new antidiabetic drugs including 
troglitazone and exendin-4 have originated from medicinal plants (Choi, Ko, Park, 
Jang and Park, 2005). 
Medicinal plant research is essential because it provides new drugs, new leads to new 
drugs and discovery of new chemical compounds (Butler, 2004). A fifth of all new 
chemical compounds resulted after studies of natural products between 1981 and 2002 
(Newman, Cragg and Snader, 2003). Over 200 pure phytochemicals with potent 
antidiabetic effects have been isolated from plants. For example, pinitol was isolated 
from soy beans (Bates, Jones and Bailey, 2000). This compound has demonstrated 
effectiveness at enhancing glucose transport in L6 rat muscle cells and hypoglycaemic 
effects in STZ-induced diabetic animals (Bates et aZ., 2000). Other compounds with 
antidiabetic properties include masoprocol from creosote bush, (Luo, Chuang, 
Cheung, Quan, Tsai, Sullivan, Hector, Ree, Meszaros, King, Carlson and Reaven, 
1998), diphenylamine from onions, arecoline from betel nut (Karawya, Abdel, EI-
Olemy and Farrag, 1984; Chempakam, 1993), ginsenoside Rb from ginseng (Gong, 
Jiang, Li, Zhu and Zhang, 1991), and, epigallocatechin gallate from green tea 
(Waltner-Law, Wang, Law, Hall, Nawano and Granner, 2002). It is, therefore, vital 
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for the scientific community to investigate the therapeutic efficacy and safety of these 
natural products in the management of diabetes mellitus. 
1.8.1. Some reported medicinal plants with hypoglycaemic effects 
The antidiabetic potential of a number of medicinal plants has been investigated and 
established in various laboratory settings. Presented below are some of the reported 
medicinal plants with antihyperglycaemic properties in literature. Also presented are 
other biological effects associated with the reported medicinal plants, besides 
antidiabetic effects. 
Mangifera indica L. (Anacardiceae) 
Mango, Mangifera indica, of family Anacardiaceae, is widely consumed as fruit in 
many parts of the world. Aqueous extracts of mango leaves have demonstrated 
antidiabetic effects in glucose-induced hyperglycaemic rats and mice (Muruganandan, 
Srinivasan, Gupta, Gupta and Lal, 2005). Mangiferin, catechin and epicatechin are the 
three main polyphenolic compounds present in the stem bark extracts (Hernandez, 
Rodriguez, Delgado and Walczak, 2006). Assessment of mangiferin by 
Muruganandan et ai., (2005), indicated hypoglycaemic, antilipidaemic and 
antioxidant effects. Antihyperglycaemic effects are mediated partly by delayed 
gastrointestinal absorption of glucose, as a result of inhibiting a-glucosidase actions 
(Prashanth, Amit, Samiulla Asha and Padmaja, 2001; Muruganandn, et ai., 2005). In 
addition, the hypoglycaemic effects are thought to be mediated by possible extra 
pancreatic mechanisms. 
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Cytotoxicity of M indica extracts on T -cells demonstrated protection against T-cell 
apoptosis, attributed to its antioxidant properties (Hernandez et al., 2007). Other 
established biological properties of M indica extractives include antiiflammatory 
(Garrido, Gonzalez, Lemus, Garc'la, Lodeiro, Quintero, Delporte, NUfiez-Selles and 
Delgado, 2004; Beltran, Alvarez, Xavier, Hemanz, Rodriguez, NUfiez, Alonso and 
Salaices, 2004), anti-diarrhoeal (Sairam, Hemalatha, Kumar, Srinivasan, Ganesh, 
Shankar and Venkataraman, 2003), and antioxidant effects (Anila and Vijayalakshmi, 
2003). 
May tenus senegalensis (Lam.) Excell (Celastraceae), Annona senegalensis Pers. 
(Annonaceae), Kigelia Africana (Lam.) Benth. (Bignoniaceae), and Lannea 
welwitschii (Hiein) Eng!. (Anacardiaceae) 
ADD-199 is a medicinal preparation used in Ghana, made from several plant species 
such as May tenus senegalensis, Annona senegalensis, Kigelia africana and Lannea 
welwitschii (Okine et al. , 2005). Phytochemical studies of ADD-199 have shown that 
it possesses anthocyanins, terpenoids, quinones and alkaloids. These have been shown 
by other investigators to have blood glucose lowering properties (Okine et al. , 2005). 
Toxicity studies in rats by Nyarko, Okine, Wedzi, Addo and Ofosuhene, (2005), 
revealed that ADD-199 had no effects on urinary, haematological and plasma 
biochemical parameters. Subchronic administration of ADD-199 had no effect on 
blood platelet count and would, therefore, not cause thrombocytosis (Nyarko et al., 
2005). Moreover, administration of ADD-199 did not increase levels of urea, 
creatinine, albumin and bilirubin suggesting that it was neither toxic to the liver or the 
kidney. In addition the investigators found that ADD-199 did not cause drug 
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interactions VIa the hepatic CYP-dependent monooxygenases. The liver CYP 
monooxygenases are a family of enzymes that are involved in the metabolism of some 
endogenous substances and xenobiotics (Guengerich, Dannan, Wright, Martin and 
Kamensky, 1982). 
Gongronema latifolium Benth. (Asclepiadaceae) 
The aqueous extracts of Gongronema latifolium of botanical family Asclepiadaceae is 
used in the traditional management of diabetes mellitus in the tropics (U gochukwu 
and Cobourne, 2003). Ugochukwu and Babady, (2003) demonstrated that leaves of 
Gongronema latifolium of family Asclepiadaceae, possess antihyperglycaemic effects. 
The major groups of active compounds in G. latifolium are saponins. The 
antihyperglycaemic effects of G. latifolium were mediated by increasing activities of 
glucokinase, hepatic glucose-6-phosphate dehydrogenase and hepatic glucose-6-
phosphatase (Ugochukwu and Babady, 2003). Evaluation of ethanolic extracts of G. 
latifolium in nonnal and STZ-induced diabetic Wistar rats demonstrated up regulation 
of antioxidant activities (Ugochukwu and Cobourne, 2003). Ugochukwu and Babady 
also demonstrated potent antioxidant activities of ethanolic and aqueous extracts of G. 
latifolium in type II model of diabetic rats (Ugochukwu and Babady, 2002). 
Inula viscosa L. (IV) [Asteraceae] 
Inula viscosa L. (IV) belongs to the botanical family Asteraceae. Decoctions of 1 
viscosa have been used in folkloric practice in the Mediterranean region because of its 
antiiflammatory, antipyretic and antidiabetic properties (AI-Dissi, Salhab and AI-Hajj, 
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2001). Its hypoglycaemic effects were reported by Zeggwagh, Ouahidi, Lemhadri and 
Eddouks, (2006). These effects were attributed to inhibition of hepatic 
gluconeogenesis. Administration of I viscosa in pregnant rats resulted in abortions 
(AI-Dissi, et al. , 2001). Extracts of I viscosa were demonstrated to have inhibitory 
effects on chitin synthesis in dermatophytes and Candida albicans. These findings 
prove that Inula viscosa has antifungal effects (Maoz and Neeman, 2000). 
Baccharis trimera (Less) DC (Asteraceae) 
Baccharis trimera (Less.) D.C. of botanical family Asteraceae is used in Brazil in 
folkloric treatment of diabetes mellitus, liver diseases, rheumatism, renal and 
digestive disorders (Januario, Santos, Marcussi, Mazzi, Pietro, Sato, Ellena, Sampaio, 
Franca and Soares, 2004; Oliveira, Endringer, Amorim, Brand and Coelho, 2005). 
Phytochemical evaluation by Oliveira et al. , (2005) showed the presence of 
flavonoids and chlorogenic acids. The authors also reported that laboratory studies in 
diabetic mice confIrmed the antihyperglycaemic effects. Other investigations 
demonstrated that extractives of B. trimera possess anti-proteolytic and anti-
hemorrhagic effects against Bothrops snake venoms. These effects were attributed to 
the active compound, a diterpene, 7a-hydroxy-3,13-clerodadiene-16,15:18,19-diolide, 
isolated from B. trimera (Januario et al. , 2004). Vasorelaxing properties of B. trimera, 
in smooth muscle of corpus cavernosum, isolated from guinea pigs were reported by 
Hnatyszyn, Moscatelli, Garcia, Rondina, Costa, Arranz, Balaszczuk, Ferraro and 
Coussio, (2003). In a related study Torres, Gamberini, Roque, Lima-Landman, 
Souccar and Lapa, (2000), isolated a dilactonic clerodane diterpene from the aerial 
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parts of B. trimera whose vasorelaxant properties on isolated rat portal vein were 
established. 
Helichrysum plicatum DC. subsp. plicatum (Asteraceae) 
Helichrysum plicatum ssp. plicatum capitulums is used in folkloric treatment of 
diabetes in Turkey (AsIan, Orhan, Orhan, Sezik and Yesilada, 2007). Moreover, 
laboratory studies supported this traditional usage by demonstrating antidiabetic and 
antioxidant effects in STZ-induced diabetic rats. Phytochemical evaluation revealed 
that flavonoids are the main groups of chemical compounds in H plicatum ssp. 
plicatum (AsIan et ai., 2007). Further antioxidant effects of H plicatum have been 
confirmed with reports by Tepe, Sokmen, Akpulat and Sokmen, (2005). 
Lepidium sativum L. (Brassicaceae) 
Lepidium sativum L. is reported by Eddouks et ai., (2005) to possess hypoglycaemic 
effects in both normal and diabetic animals. These hypoglycaemic effects have been 
attributed to the presence of imidazole alkaloids. L. sativaum also possesses 
therapeutic potential in management of hypertension. The aqueous extracts of L. 
sativum seeds demonstrated antihypertensive effects in spontaneously hypertensive 
rats (SHR). In addition the aqueous extracts demonstrated diuretic, natriuretic, 
kaliuretic and chloride excretion and effects in SHR and normotensive WKY rats 
(Maghrani, Zeggwagh, Michel and Eddouks, 2005). 
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Terminalia superba Engl. and Diels (Combretaceae) and Canarium schweinfurthii 
Engl. (Burseraceae) 
Antidiabetic effects of Terminalia superba and Canarium schweinfurthii were 
reported by Kamtchouing, Kahpui, Dzeufiet, T' edong, Asongalem and Dimo, (2006). 
The powder of stem bark of T. superba of family Combretaceae is used in folkloric 
management of diabetes mellitus in Senegal. In the Congo and Central African 
Republic, C. schweinfurthii is used for the management of fever, post-partum pain 
and rheumatism (Koudou, Abena, Ngaissona and Bessie're, 2005). Alkaloids are the 
principal groups of chemical compounds available between the 2 species. 
Kamtchouing et ai., (2006), suggested that the antihyperglycaemic effect of the plant 
extracts were mediated by mimicking insulin actions of promoting glucose uptake and 
subsequent breakdown and blocking liver glucose synthesis. Koudou et ai., (2005) 
isolated essential oil from resins of C. schweinfurthii, characterized octylacetate and 
nerolidol as the main principles in the essential oil, and, reported on analgesic effects 
of C. schweinfurthii essential oil. 
Opuntia megacantha Salm-Dyck (Cactaceae) 
Bwititi, Musabayane and Nhachi (2000) demonstrated that Opuntia megacantha, 
despite exhibiting favourable glycaemic effects in both normal and diabetic rats is 
renotoxic. The high phenolic content in 0. megacantha, responsible for many 
biological effects has been confirmed (Ndhlala, Kasiyamhuru, Mupure, Chitindingu, 
Benhura and Muchuweti, 2006). 
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Caesalpinia bonducella (L.) Flemming (Caesalpiniaceae) 
Caesalpinia bonducella Roxb. belongs to family Caesalpiniaceae. Studies have 
established that C. bonducella has anti-inflammatory and antimalarial effects. The 
plant decoctions are used in ayurveda as antipyretic, antirheumatic, antispasmodic, 
antiperiodic and in the management of asthma and diabetes (Saeed and Sabir, 2001; 
Kannur, Hukkeri and Akki, 2006). Phytochemical studies have revealed the presence 
of phytosterinin, a-sitosterol, flavonoids, bonducellin, aspartic acid, arginine, 
citrulline, a-carotene and triterpenoids. Kannur et al. , (2006) and Chakrabarti, Biswas, 
Seal, Rokeya, Ali, Khan, Nahar, Mosihuzzaman and Mukherjee, (2005) have 
validated the ayurvedic antidiabetic use of C. bonducella with laboratory studies. 
These hypoglycaemic effects were attributed to insulin secreting properties of C. 
bonducella and capacity to induce glycogen synthesis (Chakrabarti, Biswas, Rokeya, 
Ali, Mosihuzzaman, Nahar, Khan and Mukherjee, 2003; Chakrabarti et al. , 2005). 
Antibacterial activities of C. bonducella were reported by Saeed and Sabir, (2001). 
Euonymus alatus (Thunb.) Siebold., (Celastraceae) 
Euonymus alatus is used in folkloric management of pain relief, blood circulation 
ailments, blood clotting and dysmenorrhea in some Asian countries (Park et al., 
2005). E. alatus has hypoglycaemic and hypolipidaemic effects mediated by 
decreasing food intake, and through its influence on expression of PP ARy genes and 
hepatic lipogenesis related genes (Park et al., 2005). In addition to 
antihyperglycaemic effects, E. alatus has demonstrated potential for the management 
of cancer. From the methanolic extract of E. alatus stem, a phenolic principle with 
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anticancer potential, 5-caffeoylquinic acid has been isolated (Jin, Lee, Kang, Kim, 
Park, Kim, Moon and Kim, 2005). These authors showed that 5-caffeoylquinic acid 
suppressed effects of matrix metalloproteinase (MMP)-9, activities, an enzyme that 
mediates tumour cell invasion and metastasis. In addition, E. alatus induces nitric 
oxide production in mouse peritoneal macrophages (Chung, Jeong, Kim, Jeong, Kim, 
Kim, Kang, Ahn, Baek and Kim, 2002). According to Chung et al., (2002), this 
suggests that E. alatus, mediated via nitric oxide production can perform various 
therapeutic activities including antitumour, antimicrobial and antiviral effects. 
Management of circulatory problems by E. alatus may be mediated through nitric 
oxide production. 
Eucommia ulmoides Olivo (Eucommiaceae) 
The bark of Eucommia ulmoides is used in the management of blood pressure, prevent 
miscarriages and improve the tonicity of the kidney and liver in many places 
including Japan, China and Korea (Lee, Kim, Cho, Park, Park, Jung, Park and Choi, 
2005). The hypoglycaemic effects of leaves of E. ulmoides of family Eucommiaceae 
have been established in scientific investigations (Lee, et al., 2005; Park, Choi, Kim, 
Jung, Kim, Park, Noh, Park, Park, Lee and Lee, 2006). The major constituents in the 
plant are flavonoids, triterpenes and polyphenols. Studies by Hung, Fu, Shih, Lee and 
Yen (2006) have also demonstrated that E. ulmoides has dose-related protective 
effects on carbon tetrachloride (CCI4)-induced chronic hepatotoxity in Wistar rats. 
These effects were mediated through suppressing oxidative damage and increasing the 
antioxidant status. Moreover, aqueous and ethyl acetate extracts of E. ulmoides 
demonstrated ability to protect against copper-induced modification of low density 
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lipoprotein (LDL) oxidation (Yen and Hsieh, 2002). In an earlier study, Hsieh and 
Yen, (2000) showed that E. ulmoides has antioxidant effects against oxidative damage 
to biomolecules such as deoxyribonucleic acid (DNA) and 2'-deoxyguanosine (2'-
dG). 
Pterospartum tridentatum L. Willk. (Fabaceae) 
The folkloric usage of Pterospartum tridentatum flowers in the management of 
diabetes mellitus has been verified by laboratory studies. Vitor, Mota-Filipe, Teixeira, 
Borges, Rodrigues, Teixeira and Paulo, (2004) reported that flavonoids are the major 
groups of active compounds in P. tridentatum and their antihyperglycaemic effects 
may be mediated by their capacity to attenuate oxidative damage. 
Sutherlandiafrutescens (L.) R. Br (Fabaceae) 
Sutherlandia frutescens is endemic to Southern Africa. Decoctions of the plants 
leaves have been used by certain tribes in the management of a plethora of diseases 
including diabetes mellitus, influenza, abdominal pain, chicken pox and rheumatism 
(Chadwick et al., 2007). Laboratory investigations confirmed the antidiabetic effects 
of the S. frutescens extracts in a type II diabetic animal model. Chadwick et al., 
(2007) suggested that the hypoglycaemic effects were mediated by enhancing insulin 
sensitivity of the target cells or by stimulating insulin release. S. frutescens has 
antioxidant properties which account for some of its reported anti-inflammatory 
effects. These effects were reported by Fernandes, Duncan Cromarty and Albrecht, 
Rensburg (2005) who showed that hot aqueous extract of S. frutescens exhibited 
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superoxide and hydrogen peroxide scavenging activities. S. frutescens possesses anti-
cancer properties. Tai, Cheung, Chan, Hasman, (2004) showed that ethanolic extract 
induced cell death on a number of human tumour cell lines. These assertions were 
supported by reports by other investigators who reported that S. frutescens has 
enormous anticancer potential in (Chinkwo, 2005). 
Other investigations have revealed Anti HIV (human immunodeficiency virus) effects 
of S. frutescens were evaluated by Harnett, Oosthuizen, van de Venter, (2005). The 
authors reported that S. frutescens possessed inhibitory properties against HIV target 
enzymes. 
Trigonellafoenumgraecum Linn. (cv ghouka) [Leguminosae] 
Vats, Yadav and Grover, (2003) have demonstrated that Trigonella foenumgraecum 
has hypoglycaemic effects. These effects are mediated by enhancing hepatic and renal 
glycogen synthesis. In patients with coronary artery diseases and type II diabetes 
mellitus, administration of T. foenumgraecum reduced blood levels of cholesterol and 
triglycerides but had no effects on HDL-cholesterol (Bordia, Verma and Srivastava, 
1999). 
Hibiscus rosa sinensis L. (Malvaceae) 
Hibiscus rosa sinensis belongs to botanical family Malvaceae. In ayuverdic practice, 
petal decoction is used to manage fever and in bronchial catarrh. Studies by Sachdewa 
and Khemani (2003), have revealed that ethanolic extractives of Hibiscus rosa 
sinensis (Linn.) possess hypoglycaemic and antilipidaemic effects attributed to 
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mediatory roles that are extra-pancreatic. In these studies, phytochemical 
investigations revealed the presence of flavonoids. 
Eugenia jambolana Lam., (Myrtaceae) 
Extracts of Eugenia jambolana kernels have potent hypolipidaemic effects 
demonstrated in laboratory studies (Ravi, Rajasekaran and Subramanian, 2005). These 
effects were attributed to the presence of flavonoids, saponins, triterpenoids and 
glycosides. The administration of E. jambolana extract mediated more regulated 
mobilization of plasma triglycerides, and improved insulin secretion levels and 
actions. The authors asserted that their findings provided scientific basis for the 
present usage of E. jambolana in the management of diabetes mellitus. Compounds 
isolated from E. jambolana include quercetin, myricetin, myricitrin and myricetin 3-
O-(4-acetyl)-a-L-rhamnopyranoside (Timbola, 2002). In a related study, chronic 
treatment of E. jambolana to diabetic rabbits was shown to induce reduced plasma 
levels of cholesterol, and triglycerides while increasing high density lipoprotein 
(HDL) levels (Sharma, Nasir, Prabhu, Murthy and Dev, 2003). 
Another study showed that E. jambolana extracts have antioxidant effects which were 
attributed to its hypoglycaemic effects (Ravi, Ramachandran and Subramanian, 2004). 
Recently, the aqueous and ethanolic extracts of E. jambolana fruit were further 
demonstrated to have hypoglycaemic effects in alloxan induced diabetic rats. In these 
studies the aqueous extract was more potent than the ethanolic extract (Sharma, Nasir, 
Prabhu and Murthy, 2006). Phytochemical investigations, however, revealed the 
presence of both antihyperglycaemic and hyperglycaemic principles. Hyperglycaemic 
principles were present in the initial fractions after E. jambolana fruit extract was 
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subjected to purification via column chromatography usmg diethyl ammo ethyl 
cellulose. Other investigations suggested that the antihyperglycaemic effects of E. 
jambolana are mediated by mechanisms similar to both insulin secretagogues and 
biguanides (Grover, Vats and Rathi, 2000). 
Myrtus communis L. (Myrtaceae) 
Myrtle oil obtained from leaves of Myrtus communis L. of botanical family Myrtaceae 
is used in Turkey in the traditional management of type II diabetes. M communis is 
also used in folklore, as an antiseptic, antibacterial, analgesic and antihyperglycaemic 
remedy (Sepici-Dincel, AyIkgoz, Cevik, Sengelen and Yesilada, 2006). Laboratory 
studies have confirmed the antihyperglycaemic effects of the oil (Sepici, Gfubiiz, 
<;evik and Yesilada, 2004). Furthermore, a-glucosidase inhibitory activities of the oil 
have been established as the mechanism of action. Sepici-Dincel et al., (2006), 
demonstrated that long term administration of M communis extracts to alloxan-
induced diabetic rabbits increased their antioxidant status. M communis also 
demonstrated antioxidant (Montoro, Tuberoso, Piacente, Perrone, De Feo, Cabras and 
Pizza, 2006) and antigenotoxic effects (Hayder, Abdelwahed, Kilani, 
Ammar,Mahmoud, Ghedira and Chekir-Ghedira, 2004). 
Syzygium cordatum (Hochst.) [Myrtaceae] 
On the other hand, acute administration of S. cordatum extract to diabetic rats 
demonstrated hypoglycaemic effects. Long term administration of S. cordatum extract 
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to diabetic animals improved glycogen synthesis compared to untreated diabetic 
animals (Musabayane, et aI, 2005). 
Rhizoma coptidis (Huang Lian) [Ranunculaceae] 
Rhizoma coptidis has been used in the management of diabetes mellitus in China for 
thousands of years. Recent in vitro and in vivo laboratory studies suggest that 
berberine, a major constituent in R. coptidis, is responsible for the antihyperglycaemic 
effects mediated by stimulating insulin release (Leng, Lu and Xu, 2004). The 
hypocholesterolaemic effects of R. coptidis were demonstrated in laboratory studies 
by Yokozawa, Ishida, Cho and Nakagawa, (2003). The authors showed that oral 
administration of R. coptidis to Wistar rats fed a hypercholesterolaemic diet lowered 
their serum cholesterol levels. 
Iizuka, Miyamoto, Hazama, Y oshino, Yoshimura, Okita, Fukumoto, Yamamoto, 
Tangoku and Oka, (2000) demonstrated that oral administration of R. coptidis extract 
to tumour bearing mice significantly lowered serum interleukin (IL )-6 levels. 
Berberine, an active compound isolated from R. coptidis demonstrated potent effects 
against IL-6 both in vivo and in vitro studies. 
Solanum xanthocarpum Schrad. & Wendl. (Solanaceae) 
Fruits of Solanum xanthocarpum are used in the traditional management of a number 
of ailments for its anthelmintic, antiinflammatory, laxative, diuretic and 
antiasthamatic effects. Leaves of S. xanthocaprpum are also used for management of 
cough, catarrhal fever and chest pains (Rahman, Ahmed, Alimuzzaman and Shilpi, 
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2003; Kar, Maharana, Pattnaik and Dash, 2006). Phytochemical studies have revealed 
the presence of steroidal alkaloids. The authors reported that the antidiabetic effects of 
S. xanthocaprpum are mediated by insulin-like activities. Maruo, Bernardi and 
Spinosa, (2003), investigated the toxic effects of long term consumption of S. 
xanthocaprpum dried fruits to male and female Wistar rats. Results showed that while 
the extracts had no toxic effects in male rats, it reduced liver and uterus weights in 
female rats. Evaluation of antinociceptive effects of S. xanthocaprpum revealed that it 
reduced the frequency of acetic acid-induced abdominal constrictions in rats (Rahman 
et al., 2003). 
Solanum lycocarpum St. Hil. (Solanaceae) 
In Brazil, Solanum lycocarpum St. Hill is used as a hypoglycaemic agent (Perez, 
Franca, Daldegan and Duarte, 2006). The major constituents of S. lycocarpum are 
steroidal alkaloids. Investigations of the extracts of the plants fruit on haematological 
parameters in diabetic rats demonstrated that it has potent effects in reducing levels of 
reactive oxygen species. 
Vitis vinifera L. (Vitaceae) 
Vilis vinifera is used world wide as food and in traditional management of a number 
of human maladies including pain, inflammation and blood pressure (Orhan, AsIan, 
Orhan, Ergun and Y e~ilada, 2006). Phytochemical evaluation revealed that the main 
groups of chemical constituents in V. vinifera leaves are flavonoids, tannins and 
procyanidins. The antihyperglycaemic effects of ethyl acetate extract of V. vinifera 
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were mediated by stimulating insulin release and delaying gastrointestinal absorption 
of glucose. These effects were attributed to the presence of tannins and flavonoids 
(Orhan et al., 2006). In addition to antihyperglycaemic effects, V. vinifera has 
antimicrobial properties. These were demonstrated by Karapinar and Sengun, (2007), 
on Salmonella typhimurium present in salad vegetables. 
Cissus sicyoides C. Linnaeus (Vitaceae) 
Cissus sicyoides is used in the traditional management of a broad spectrum of diseases 
including gonorhoea, inflammation and respiratory infections in Dominican Republic 
(Garcia, Saenz, Puerta, Quilez and Fernandez, 1999). Phytochemical studies of C. 
sicyoides have shown that the major compounds in the plant include steroidal-
triterpenes, flavonoids, tannins and saponins. The plant was shown to possess 
hypoglycaemic effects (Viana, Medeiros, Lacerda, Leal, Vale and Matos, 2004). 
These effects were mediated in a manner similar to biguanides (Viana et al., 2004). 
Garcia et al., (1999), demonstrated that C. sic yo ides was effective against both gram-
positive and gram negative microbes. Furthermore, C. cisyoides demonstrated anti-
inflammatory effects that were attributed to its large contents of steroids (Garcia, 
Quilez, Saenz, Martinez-Dominguez, and de la Puerta, 1999). Other studies have 
shown that the aqueous extracts of C. sicyoides have vasoconstrictor effects on 
isolated guinea pig aortic rings thought to be mediated by inducing increase in 
intracellular calcium influx (Garcia, Cartas-Heredia, Lorenzana-lfmenez and Gijon, 
1997). Therefore, while administration of C. sicyoides may confer benefits in blood 
glucose control, it may exacerbate other complications of diabetes mellitus such as 
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hypertension. Hence studies by Garcia et at., (1997), will help users of C. sicyoides to 
be cautious. 
The consensus of a large number of studies that have characterized active principles 
from medicinal plants show that, generally, major groups of biological compounds 
with potent antihyperglycaemic effects include flavonoids, vitamins, carotenoids, 
anthocyanins (Argolo, Sant' Ana, PIetsch and Coelho, 2004; lung, Lee, Park, Kang 
and Choi, 2006). These products have multiple beneficial biological effects to humans 
and experimental animals. For example, flavonoids possess free-radical scavaenging 
capacity, affect a wide range of body enzymes, have capacity to chelate certain metal 
cations and provide protection against LDL oxidation (Asgary, Naderi, Sarrafzadegan, 
Ghassemi, Boshtam, Rafie and Arefian, 1999). 
Indeed, as highlighted above, most medicinal plants with hypoglycaemic therapeutic 
potential also exhibited antihypertensive, renoprotective, antioxidant, 
antihyperlipidaemic and anticancer properties. This demonstrates that medicinal 
plants have potential to offer multiple therapeutic benefits. 
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1.8.2. Plants used in the present study 
The plant species used in the present study were selected for study after an extensive 
ethnobotanical survey that involved interviewing traditional healers and literature 
survey. 
1.8.2.1. Ficus thonningii (Blume) [Morarceae] 
F. thonningii belongs to botanical family Moraceae. This is shown in Figure 2. The 
presence of flavonoids in F. thonningii were confinned in studies by Greenham, 
Grayer, Harborne and Reynolds, (2007). However, there is a paucity of literature on 
the biological effects of Ficus thonningii. The only available literature is on related 
species of genus Ficus. Members of same genus or family frequently have similar 
chemical composition and hence biological properties. For example, Gongronema 
latifolium belongs to botanical family Asclepiadaceae. In this family are two other 
species, G. sylvestre and G. inodorum. All the three species above possess 
antihyperglycaemic effects (Ugochukwu and Bababdy, 2003). Hence, reported below 
are some of the studies done on other species of genus Ficus. 
In India, F. hipida is used in the folkloric treatment of a number of diseases including 
diabetes, ulcers, biliousness, psoriasis, anaemia, piles, jaundice, hemorrhage of the 
nose and mouth, and diseases of the blood (Ghosh, Sharatchandra, Rita and 
Thokchom, 2004). Laboratory studies by Ghosh et al., 2004, showed that F. hipida 
bark extracts possess hypoglycaemic effects ill normal and alloxan induced Wistar 
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albino rats. These effects were attributed to enhanced glycogen synthesis in muscle 
and liver and enhanced uptake of glucose by the muscle. 
In Taiwan, F. microcarpa L. is used as an ornamental plant. Therapeutically, the 
plant extracts are known to have anti-platelet effects. Phytochemical studies of the 
bark revealed that F. microcarpa posses phenoids, a monoterpenoid, lignans, while 
the leaves and aerial roots revealed the presence of triterpenoids cycloartanoid, 
lupanoid, oleanoid, ursanoid (Chiang, Chang, Kuo, Chang and Kuo, 2005). A 
decoction of F. carica L. fruit is used as an antitussive and in the management of 
respiratory disorders in Italy, while the latex of unripe figs, fruit peduncles or twigs is 
used to treat warts (Guarrera, 2005). 
Leaf decoctions of F. thonningii are used in the treatment of rheumatism in Ivory 
Coast. Also in Ivory Coast, the stem bark of a related species, F. vallis-choudae Del. 
is used in the management of heart problems. Studies by Kone, Atindehou, Terreaux, 
Hostettmann, Traore and Dosso, (2004), demonstrated that leaf extracts of F. 
thonningii has antibacterial properties confirming the traditional usage of the plant 
decoctions against bacterial diseases. 
Ficus bengalensis is used in India in the ayuverdic management of a number of 
diseases. The leaf decoctions are used to treat ulcers, while aerial parts of the roots are 
used to treat gonorrhea. A number of investigators have demonstrated that aqueous 
bark extracts possess hypoglycaemic, hypolipidaemic and hypocholesterolaemic 
effects in laboratory studies (Shukla, Gupta, Gambhir, Prabhu and Murthy, 2004). The 





Figure 2. F thonningii branches (A), leaves (B) and, roots (C). 
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1.8.2.2. Persea americana Mill (Lauraceae) 
Persea Americana Mill, (Figure 3), known in English as avocado, belongs to 
botanical family Lauraceae. It is native to Mexico but is grown widely throughout the 
tropics (Abe, Nagafuji, Okawa, Kinjo, Akahane, Ogura, Alfaro and Chilpa, 2005; 
Adeboye, Fajonyomi, Makinde and Taiwo, 1999). Like F. thonningii, there is scarcity 
of published works on the biological effects of P. americana. Hence, the following 
section contains reported studies on the biological effects of P. americana and other 
related species. Illustrated in Figure 3 are P. americana fruit and flowers. Avocado 
fruit is used as food in most parts of the world. In Nigeria decoction of avocado leaves 
are used to treat various diseases including hypertension (Adeboye et al., 1999). 
Elsewhere, in Africa, West Indies, and in South and Central America the bark, fruit 
and leaves of P. americana have been used in traditional medicine in the treatment of 
hypertension, menorrhagia, stomach ache, bronchitis, diarrhoea and diabetes 
(Adeyemi, Okpo and Ogunti, 2002). Phytochemical screening of aqueous and 
methanolic leaf extracts revealed the presence of several bioactive groups of 
compounds including alkaloids, triterpene glycosides and coumarins saponins, 
flavonoids and tannins (Adeboye et al., 1999; Adeyemi et ai., 2002). As reported by 
Ramos, Jerz, Villanueva, Dellamary, Waibel and Winterhalter, (2004), and Lu, 
Arteaga, Zhang, Huerta, Go and Heber, (2005), extractives of avocado possess 
phytosterols, triterpenes, fatty acids, oligomeric proanthocyanidins and dimmers of 
flavonols. Ramos, et ai., (2004), further reported the presence of 2 glucosylated 
abscisic derivatives in avocado seeds. 
The fruit is also rich in fats, containing between 25% to 33% oil by composition 
(Ortiz, Dorantes, Gallndez and Cardenas, 2004; Lu et aI., 2005), monounsaturated 
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fatty acids being dominant. Ortiz et al., 2004, pointed out that the nutritional value of 
avocado fruit oils is equivalent to that of olive oil. Unlu, Bohn, Clinton and Schwartz, 
(2005), reported that dietary intake of avocado fruit with salad enhances carotenoid 
absorption from salads and salsa. These effects were attributed to the oil available in 
fruit. These observations were supported by findings ofLu et al., (2005), who pointed 
out that carotenoid absorption into the blood stream is enhanced by the high fat 
content of avocado. Mycotic and parasitic infections have been treated with 
decoctions of P. americana by the Aztec culture (Ramos et al., 2004). Extracts of P. 
americana possess hypotensive properties in anaesthetized normotensive rats 
(Adeboye et al., 1999). Hypotensive effects of P. americana were further supported 
by findings of Owolabi, Jaja and Coker, (2005), who reported that P. americana 
extracts exhibited vasorelaxing properties attributed to stimulation of release of 
endothelium derived relaxing factors (EDRF). However, administration of avocado 
oil rich diet exacerbated angiotensin II induced vasopressor effects in Wistar rats. 
This suggested that the vasodepressive properties of the avocado extracts might be 
due to compounds other than avocado fats (Salazar, Hafidi, Pastelin, Ortega and 
Mendoza, 2005). The authors also reported that avocado oil mediates the composition 
of fatty acids in cardiac and renal membranes. 
P. americana also possesses anti Chagas' disease and anticancerous properties. 
Methanolic extracts of P. americana were effective against epimastigotes of 
Trypanosome cruzi, a causative agent for Chagas' disease (Abe et al., 2005). 
Antiancerous effects of P. americana were reported by Lu et al., (2005). Working on 
LNCaP and PC3, human prostrate cancer cell lines, the authors demonstrated that the 
acetone extracts of P. americana fruit inhibited proliferation of the cell lines. These 
65 
effects were due to lutein, a principal carotenoid and other vitamin compounds 
present in the extracts. 
Assane, Diop, Niang-Sylla, Lopez-Sall, Gueye and Charlevna, (2001) have 
demonstrated that extracts of a related species of avocado almonds, Persea gratissima 
Gaertner (Lauraceae), possess antiicteric and hepatoprotective properties. The authors 
reported that lyophilisat of avocado almonds mediated the conjugation and excretion 
by the liver of bilirubin. Furthermore, the lyophilisat mediated the normalization of 




Figure 3. P. americana fruit (A), and flowers (B). 
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1.8.2.3. ScleTocarya biTTea (A. Rich) Hochst (Anacardiaceae) 
S. birrea (A. Rich) Hochst. subspecies caffra (Sond.) Kokwaro known in English as 
Marula belongs to botanical family Anacardiceae (Figure 4). It is indigenous to 
Western and Southern Africa. It has been reported to be used medicinally in the 
treatment of malaria, diarrhoea headache, diabetes mellitus and inflammatory diseases 
(Ojewole, 2000; Ojewole, 2003). The fruit and its nut are edible. Decoctions of bark 
are used to manage dysentery and diarrhoea by the Zulu people of South Africa 
(Eloff, 2001). In Niger, S. birrea fruit is used as food (Glew, VanderJagt, Huang, 
Chuang, Bosse and Glew, 2004). The pulp of the fruit is also used to make an 
alcoholic drink (Aganga and Mosase, 2001). In Burkina Faso, S. birrea decoctions are 
used to treat a host of human ailments. In addition to food and medicinal usage of S. 
birrea extracts, the wood is used as fIrewood and for carvings (Emanuel, Shackleton 
and Baxter, 2005). 
Evaluation of the physicochemical composition of S. birrea seed by Ogbobe, 1992, 
suggests that it contains 11.0% crude oil, 17.2% carbohydrate, 36.70% crude protein 
3.4% fIbre and 0.9% crude saponins. Assessment of the same in seed oil revealed nine 
different fatty acids with palmitic, stearic and arachidonic acids being the most 
predominant. Braca, Politi, Sanogo, Sanou, Morelli, Pizza and De Tommasi, (2003) 
isolated quercetin 3-0-alpha-I-(5' '-galloyl)-arabinofuranoside (1), a flavonol 
glycoside from the methanolic extract of S. birrea leaves and eight other well known 
phenols from the same extract. From the leaf methanolic extract of cultivated S. 
birrea the group isolated two epicatechin derivatives. 
In edible pits of S. birrea, Glew et al., 2005, reported the presence of linoleic acid 
which is a component of membrane phospholipids and a precursor for arachidonic 
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acid. Also present in edible pits is oleic acid which is an important fatty acid with 
known cardioprotective effects and other fatty acids which are vital sources of energy 
when consumed, in communities that face starvation due to lack of food. Aganga and 
Mosase, (2001) asserted that the presence of tannins in food blocks its digestibility 
and, therefore, minimizes its absorption in the gut. Tannins are widely prevalent in the 
bark, leaves and fruits of most species in the Anacardiceae family. In their 
phytochemical assessment of S. birrea bark extracts, Aganga and Mosase reported 
presence of tannins in the species. Other studies reported that the S. birrea bark yields 
3.5 to 20.5% tannin (Eloff, 2001). 
The folkloric usage of S. birrea decoctions in the treatment of dysentery have been 
confinned in in vitro studies by Eloff, (2001), who demonstrated that leaves and bark 
extracts had potent antibacterial effects against Staphylococcus aureus, Enterococcus 
faecalis, Pseudomonas aeruginosa and P. aeruginosa. Studies by Belemtougri, 
Constantin, Cognard, Raymond and Sawadogo, (2001) have shown that S. birrea 
antagonize calcium release from the sarcoplasm, induced by caffeine. Furthennore, 
Ojewole, 2000 substantiated the medicinal usage of S. birrea in the management of 
arthritis and an inflammatory disorder by showing that it possesses anti-inflammatory 
effects in Wistar rats. In a separate study, Ojewole, (2003), demonstrated that aqueous 




Figure 4. S. birrea fruits and leaves (A), and, bark (B). 
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1.8.2.4. Hypoxis hemerocallidea Fisch. & C.A. Mey. (Hypoxidaceae) 
Hypoxis hemerocallidea, formerly known as H roo peri, belongs to botanical family 
Hypoxidaceae (Figure 5). In English, it is known as African potato but is in fact a 
corm (Ojewole, 2006). It grows in meanders, valleys, grasslands and mountainous 
regions of South America, Southern Africa, Australia and coastal regions of Asia 
(Laporta, Pe'rez-Fons, Mallavia, Caturla and Michol, 2007). It has been used by the 
Zulus and other tribes of Southern Africa in the management of a variety of maladies 
including hypertension, diabetes, urinary tract infections, arthritis, and HIV -AIDS 
infections (Hutchings, 1989). Other studies have established that it possesses anti-
inflammatory (Ojewole 2005), antibacterial (Gaidamashvilli and van staden, 2002) 
and anticancer properties (Albrecht, 1996). The major compound in most of the 
species of family hypoxidaceae is the relatively inert hypoxoside (E)-1 ,5-bis-(3' ,4'~­
D-glucopyranosyloxy-3' -hydroxyphenyl)-pent-4-en-1-yne which can be converted to 
the more biologically active aglycone form, called rooperol, (E) 1 ,5-bis- 4' -
dihydroxyphenyl)-pent-4-en-1-yne), by ~-glucosidase (Drewes, Hall, Learmonth and 
Upfold, 1984; Albrecht, 1996). Laporta et at., 2007 reported that two compounds, 
hypoxoside and rooperol, isolated from H hemerocallidea extract have more potent 
antioxidant activities against lipid peroxidation activities than products from other 
plants such as olive leaf and herbal tea. Other compounds present in H 
hemerocallidea include ~-sitosterol, stigmasterol, ~-sitosterol glycoside and sitostanol 
(Mills, Cooper, Seely and Kanfer 2005). 
Despite the numerous positive therapeutic uses of H hemerocallidea, extracts of the 
plant might be toxic to the myocardium (Ker, 2005). The author reported on a case 
study where a hypertensive patient with a history of ischaemic heart disease and 
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diabetes, developed ventricular tachycardia after taking an H hemerocallidea root 
extract in tea. Although hypoglycaemic effects of H hemerocallidea, F. thonningii, S. 
birrea extracts have already been established in laboratory based studies, water was 
used as the medium of extraction of plant products. Furthermore, little attempt was 




Figure 5 H hemerocallidea flower (A ), H hemerocallidea leaves (B), H 
hemerocallidea corm and roots (C), and, H hemerocallidea corms (D). 
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1.9. Basis of the present study 
As aforementioned diabetes is a chronic ailment with debilitating consequences, 
reducing quality and life expectancy. The need to look into alternative therapy is 
supported by emerging evidence that show allopathic medicines do not alleviate 
diabetes, but only manage hyperglycaemia. Moreover, most of these have one or more 
serious adverse effects. Herbal medicines have been used as alternative therapy in the 
amelioration of various diseases, including diabetes in Africa and beyond. Of late, a 
lot of interest has been generated in medicinal plants as alternative therapy because 
they are thought to be effective and safe (Jung, et aZ., 2004; Hou, et aZ., 20055). 
Despite wide consumption of medicinal plants, fewer studies have investigated their 
effectiveness or possible toxic effects. Even the World Health Organisation (WHO), 
has acknowledged the antidiabetic potential of medicinal plants and has urged 
increased research into the area (Eddouks, et aZ., 2005). Since it is relatively less 
expensive in terms of monetary costs and time, to develop phytomedicines compared 
to western synthetic medicines, it is hoped that findings of this study will lead to 
discovery of drugs that are cheaper to the majority of poor patients in the region who 
cannot access the more expensive synthetic medications. 
In the present study the effects of APE, SBE, FTE were investigated in normal and 
STZ-induced diabetic animals for their antihyperglycaemic effects using short term 
and long term study designs. Although hypoglycaemic effects of some of the plants 
have already been established, previous studies did not elucidate their mechanisms of 
actions. Moreover, these studies did not evaluate whether the plant products had any 
effects on parameters often considered diabetic complications such as hypertension 
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and renal function failure. Therapeutic effects of the test extracts were compared with 
those of standard drugs. Since cardiovascular and renal complications are closely 
associated with diabetes, the effects of the test extracts on hypertension and renal 
function were also assessed. Furthermore, effects of the test extracts on the viability 
of kidney cell lines of proximal and distal origins were also assessed to establish 
whether the test extracts altered tubular epithelial cells' viability to influences tubular 
reabsorption and secretion. The present study, therefore, was undertaken with the 
hope that findings of the study would be used in the development of herbal based drug 
that is effective, safe and affordable to the majority of poor African diabetics. 
1.9.1. General objectives 
The mam purpose of the present study was to investigate the hypoglycaemic, 
cardiovascular and renal effects of extracts of Hypoxis hemerocallidea, Sclerocarya 
birrea, Ficus thonningii and Persea americana, in streptozotocin (STZ) - induced 
diabetic rats. 
1.9.2. Specific objectives 
The study aimed to investigate effects Hypoxis hemerocallidea, Sclerocarya birrea, 
Ficus thonningii and Persea americana extracts on blood pressure, and renal fluid and 
electrolyte handling in STZ-induced diabetic animals. The study also investigated in 




2.0. MATERIALS AND METHODS 
2.1. Chemical reagents and drugs 
All chemical reagents were used in the present study were of analytical grade. 
Reagents and standard drugs were sourced as indicated: potassium hydroxide (Baird 
and Tatlock S.A. (Pty) Ltd, Johannesburg, RSA), anthrone reagent, metformin, 
glibenclamide, oyster type II glycogen powder, streptozotocin, dimethly sulphoxide 
(DMXO), potassium hydroxide, DPX mountant for histology (Sigma St Louis, MO, 
USA), ethanol, D-glucose, citric acid, sodium chloride, hydrochloric acid (HCI), 
sulphuric acid (H2S04), isopropanol, paraffin (Merck, Waderville, RSA), porcine 
insulin (Intervet SA (PTy) Ltd, Isando, South Africa), heparin Novo (Novo Nordisk 
(Pty) Ltd, Johannesburg, RSA), halothane (Fluothane®, AstraZeneca Pharmaceuticals, 
Johannesburg, RSA), trapanal (sodium 5-ethyl-59-(1-methyl-butyl)-2-thio-barbiturate; 
Byk Gulden, Konstanz, Germany), penstrep-fungizone [complete culture medium 
(CCM)] (Delta Bioproducts, Kempton Park, South Africa), and MIT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Calbiochem, Darmstadt, 
Germany). 
2.2. Plant materials and extract preparation 
The plant species used in the present study were selected for study after an extensive 
ethnobotanical survey that involved interviewing traditional healers and literature 
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survey. The plants were identified and authenticated by Professor H. Baignath of the 
Botany Department, University of KwaZulu-Natal. Voucher specimens of the plant 
species are deposited at UKZN Botany Department. All the material was harvested in 
and around Durban, South Africa, between February and May, 2004. This was to 
eliminate variations in the quantities of chemical constituents that are known to 
change with seasons. All bark and leafy plant materials were air dried at room 
temperature (±24°C) before processing, except H hemerocallidea corms. 
2.2.1. Hypoxis hemerocallidea 
Fresh corms of H hemerocallidea were cleaned and pulverized while wet in a Waring 
commercial blender. The ground material (2 kg) was soaked in 8 I of 95% ethanol at 
room temperature for 24 hours (with occasional stirring). The material was then 
filtered and the filtrate was concentrated under reduced pressure (Buchi Lotavapor, 
BUCHI Labortechnik, GmbH, Essen, Germany). The material was freeze dried to 
yield a brown powdery material. The ethanolic crude material so obtained was 
denoted APE. 
2.2.2. Ficus thonningii and Sclerocarya birrea 
The bark materials of Ficus thonningii and Sclerocarya birrea were air-dried at room 
temperature and separately extracted as descried for APE. Dried bark material were 
ground into powder using a Thomas-Wiley Laboratory mill model 4 (Arthur H 
Thomas Company, Philadelphia, PA., USA). The dried and powdered bark material of 
F thonningii (5 kg), and S. birrea (5 kg) were then soaked in 15 1, respectively, of 
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95% ethanol at room temperature for 24 hours (with occasional stirring). The 
decoction was then filtered and concentrated under reduced pressure at 40°C. The 
concentrate was further air-dried at room temperature to yield a brown powdery 
material. The crude extract was denoted FTE and PAE, respectively. 
2.2.3. Persea americana 
Leaves of Persea americana were air-dried in a room. Dried leaves were ground into 
powder in a Waring commercial blender. The ground material (5 kg) was soaked in 
201 of 95% ethanol and left to stand for 24 hours (with occasional stirring). The 
material was then filtered and the filtrate concentrated in vacuo at 40°C. Extraction 
resulted in crude material that was denoted P AE. 
The final crude products for all the plants were kept in the freezer until required. 
Stock solutions of APE, SBE, FTE and P AE crude extract were prepared by 
dissolving known quantities of extracts in deionised water and administered to 
animals. Volumes administered varied between 0.25 mI and 0.6 mI, depending on the 
dosage and size of the animal. Extract solutions were prepared fresh on the day of 
each experiment. 
2.3. Ethical clearance 
The experiments were conducted according to the University'S guiding principles for 
the research involving animals. Ethical clearance number HSS/05012A was provided 
by the University KwaZulu-Natal (UKZN) Ethical committee (See Appendix 1). 
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2.4. Animals 
Male Wistar rats weighing 200-300g were procured from UKZN Biomedical 
Research Unit. The animals were maintained on a 12-h lightl12-h dark regime, with 
an ambient temperature of 23°C and relative humidity within the range of 30-40%. 
Animals had ad libitum access to standard rat pellets (Epol, Pietermaritzburg, South 
Africa) and tap water. 
Biological effects of test extracts were assessed in healthy non-diabetic and STZ-
induced diabetic rats. 
2.4.1. Induction of diabetes mellitus 
Animals were made diabetic by a single intraperitoneal (ip) administration of STZ, at 
a dose of 60 mg/kg body weight, after fasting overnight. Streptozotocin was dissolved 
in freshly made citrate buffer solution, pH 6.3. Control animals were injected with 
citrate buffer solution. Animals that exhibited glucosuria after 24 h, tested by urine 
test strips (Rapidmed Diagnostics, Sandton, South Africa), were considered diabetic. 
After 7 days blood was drawn from rat tails to confirm stable diabetes. Animals with 
blood glucose concentration above 20 mmolll were considered to have achieved stable 
diabetic state and were selected for the study. 
2.5. Experimental design 
The project was divided into 3 phases. These were (i) acute, (ii) chronic and (iii) 
cytotoxicity studies. Assessment of the hypoglycaemic, renal and cardiovascular 
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effects of test extracts was conducted in acute and chronic studies. Effects of test 
extracts on cell viability were investigated on MDBK and LLCPK-l cell lines. 
Outlined below were details of the experimental protocols. 
2.5.1. Acute studies 
2.5.1.1. Oral glucose tolerance test (OGTT) 
Effects of test extracts on oral glucose tolerance test (OGTT) were assessed on 
separate groups of control and treated non-diabetic and STZ-induced diabetic rats, 
each with 6 animals. OGrr was conducted as previously described by Musabayane, 
et al., (2005), with slight modifications. Prior to the experiments, animals were 
starved overnight for 18 hours, according to the methods of Muruganandan et al. J 
(2005; Musabayane et al., 2007). On the day of the experiment, animals in all groups 
were administered D-glucose monohydrate (0.86 g/kg body weight, p.o.) by means of 
a bulbed steel tube. This was followed by administration vehicle (deionised water at 3 
ml/kg) in control groups, and test extract (SBE, FTE, APE and P AE) or standard 
drugs (metformin, glibenclamide and insulin) in treated groups. In those animal 
groups in which the effects of test extracts were to be examined, three doses of each 
extract (60, 120 and 240 mg/kg body weight) were evaluated in separate groups (6 
animals per group). The minimum dose of 60 mg/kg had been selected for the present 
study after preliminary in vivo studies with various plant extracts demonstrated that it 
was the highest dose to elicit marginal effects in glucose tolerance. 
The effects of test extracts were compared with those of standard drugs. In groups 
where standard drugs were administered, a single dose was used ie metforrnin (500 
80 
mg/kg, p.o.), glibenclamide (5 mg/kg, p.o.) and insulin (100 ~g/kg, s.c.). The present 
dose of insulin was used in previous studies (Musabayane et al., 2000). The following 
is a summary of experimental groups: 
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Table 1 
OGrr groups of non-diabetic and STZ-induced diabetic rats. 
Group (n = 6) Treatment 
(i) Untreated/Vehicle Animals in this group were treated with deionised 
treated control 
group water orally, p.o., by gavage at a dose of 3 ml/kg. 
(ii) Insulin treated Animals were treated with a subcutaneous injection 
group 
of, porcine insulin, 100 Ilg/kg 
(iii) Metformin treated Animals were treated with metformin 500. mg/kg, 
group 
p.o. 
(iv) Glibenclamide Animals were treated with glibenclamide 5 mg/kg, 
treated 
p.o. 
(v) SBE treated groups Animals were treated with SBE at doses of 60, 120 
and 240 mg/kg, p.o. 
(vi) FTE treated group Animals were treated with FTE 60, 120 and 240 
mg/kg, p.o. 
(vii) APE treated group Animals were treated with APE 60, 120 and 240 
mg/kg, p.o. 
(viii) P AE treated group Animals were treated with PAE 60, 120 and 240 
mg/kg, p.o. 
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Blood glucose was monitored at 15 minute interval during the first hour and then 
hourly during the subsequent 4 hours. A commercial glucometer (Bayer's Glucometer 
Elite4i\ (Elite (Pty) Ltd Health care Division, Newbury, Berkshire, South Africa), was 
used in the analysis of blood glucose. A drop of blood sample was obtained from a 
prick at the tips of rat tails, under aseptic conditions. Evaluation of the test extracts for 
glucose tolerance was conducted in an identical manner in both non-diabetic and 
STZ-induced diabetic animals. 
2.5.1.2. Insulin measurements 
In order to determine whether test extracts affect insulin release, insulin levels were 
monitored. Separate groups of animals were prepared as for OGTT (see section 
2.5.1.1.). These were treated with test extracts, at the maximal dose of 240 mg/kg, and 
standard drugs, after an oral glucose challenge (0.86 g/kg). Blood was collected by 
cardiac puncture into heparinised pre-chilled tubes 45 minutes after treatment, 
following light halothane anaesthesia The blood was then promptly centrifuged 
(Eppendorf centrifuge 5403, Germany) at 4°C, 4000 rpm for 15 minutes to obtain 
plasma. Separated plasma was stored at -70°C in a Bio Ultra freezer (Mallkinckrodt, 
Ohio, USA) until required for insulin assay. Blood glucose, at 60 minutes, of animals 
challenged with an oral glucose load and treated with test extracts at a dose of 240 
mg/kg, and standard drugs were used to monitor effects of insulin. 
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2.5.1.3. Renal function studies 
Effects of test extracts on renal function were assessed in anaesthetized non-diabetic 
and STZ-induced diabetic animals using a modified procedure that has been 
previously described (Musabayane, Cooper, Osim, and Balment, 2000). Animals were 
divided into 2 major groups of non-diabetic and STZ-induced diabetic rats. Under 
each major group, animals were further divided into separate groups each with 6 
animals. The groups were vehicle control and separate groups of animals treated with 
plant extracts (APE, SBE, FTE and P AE). 
The animals were anaesthetized by intraperitoneal injection of trapanal (sodium 5-
ethyl-59-(1-methyl-butyl)-2-thio-barbiturate) at 11 0 mglkg body weight. The left 
jugular vein was cannulated with polyethylene tubing (internal diameter, Ld., 0.86 
mm; external diameter, o.d., 1.27 mm; Portex, Hythe, Kent, UK) to allow intravenous 
infusion of 0.077 M NaCl. The bladders were exposed after an abdominal incision and 
cannulated with polyethylene tubing of the same size to facilitate collection timed 
urine samples. Tracheostomy was conducted on each animal to allow free breathing. 
The body temperature was maintained at 37 ± 1°C with a heated table. After surgical 
procedures, animals were challenged with 0.077M NaCl sustainably administered via 
the jugular vein, at a rate of 9 mllh using Harvard Apparatus Syringe Infusion Pump 
22 (Instech Solomon, Plymouth Meeting, PA, USA). Following an initial 3.5h 
equilibration period, eight consecutive urine collections were made into pre-weighed 
plastic vials at 30-min over the subsequent 4 h for measurements of urine flow, Na + 
and K+ excretion rates. The control group was designed to check the stability of renal 
function. 
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2.5.1.3.1. Treated groups 
Renal effects of test extracts were assessed in separate groups of rats following a 3.5h 
equilibration period. Solutions of test extracts were prepared fresh before use in each 
case (See Section 2.2.3) Urine samples were collected at 30 minute interval for 1 h 
(control period), 1 h 30 min treatment, and 1 h 30 min post treatment periods for 
measurements of urine flow, sodium and potassium excretion rates. The effects of test 
extracts were assessed in separate groups in which the extract solutions were infused 
at 0.06 Ilg/min during the lh 30 min treatment period. The animals were switched 
back to the infusate alone for the final 1 h 30 min recovery period. 
2.5.1.4. Acute blood pressure studies 
Similar groups of animals were prepared as for acute renal studies for assessment of 
hypotensive effects of test extracts, except that the right carotid artery was also 
surgically prepared and cannulated with heparinized portex tubing (Hythe, Kent, UK) 
and then attached to a Stratham MLT 0380 blood pressure transducer compatible with 
the PowerLab System ML4101W, (ADInstruments Inc., Bella Vista, NSW, Australia) 
for measurements of MAP. After a 3.5h-equilibration as in acute renal function, blood 
pressure measurements were conducted at 30 minutes interval over the subsequent 4 h 
of 1 h control, 1 h 30 min treatment, and 1 h 30 min post treatment. 
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2.5.2. Chronic studies 
Long term hypotensive effects of test extracts were assessed in unanaesthetised non-
diabetic and STZ induced-diabetic animals for a period of 6 weeks. Animals were 
divided into separate groups of control and treated groups (n=8 in each group). 
Control groups were administered with vehicle (deionised water), 3 ml/kg, p.o), while 
treated groups were administered with metformin (500 mg/kg, p.o.), glibenclamide (5 
mg/kg, p.o.), SBE (120 mg/kg, p.o.), FTE (120 mg/kg, p.o.), (vi) APE (120 mg/kg, 
p.o.) and PAE (120 mg/kg, p.o). Insulin as a standard drug was not used in long term 
studies because preliminary fmdings of acute hypoglycaemic studies revealed that 
none of test extracts had insulin releasing properties. Animals were placed in clean 
individual Makrolon polycarbonate metabolic cages (Techniplast, Labotec, RSA), 
through the duration of the study to allow for the monitoring of parameters under 
investigation i.e. food intake, water intake, weight changes, urine flow and electrolyte 
excretion rates. Metabolic cages were cleaned daily. 
Animals were treated orally by gavage once daily at 09hOO with the test extracts at the 
median dose (120 mg/kg) of that used in acute studies using a bulbed steel tubing 
fitted to a syringe. The following parameters were monitored once weekly at 10hOO: 
mean arterial blood pressure (mmHg), blood glucose (mmol/l), body weight (g), food 
(g) and water intake (ml), volume of urine voided (ml), and urinary concentrations of 
Na+ and K+ excretion, urine urea and creatinine. 
In order to assess the effects of test extracts in preventing cardiovascular 
complications in diabetes, blood pressure (BP) was measured by the tail cuff method 
using IITC blood pressure program version 2.31 DPMI (IITC INC I Life Sciences 
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Instruments, Woodland Hills, CA, USA). The system employs an automatic scanner 
and pump, sensing cuff and amplifier to measure and count the pulse rate in the 
animal tail. The results are displayed as data plots and a summary of data of systolic, 
diastolic and mean arterial blood pressure on the computer screen. Small, medium and 
large restraining devices and 2 different tail cuffs (10 mm and 15 mm) were used to 
compensate for the increase in body weight during the 6 week experimental period. 
Measurements were done a constant temperature of 37°C maintained by heating 
lamps. Three blood pressure recordings of each animal were made and the average 
taken. Animals were restrained individually with tails exposed and placed through the 
tail cuff device to restrict movements during measurements. Prior to measurements, 
animals had been warmed for about 15 minutes to allow sufficient vasodilatation of 
the tail artery. The equipment was calibrated once before each day of mean arterial 
blood pressure measurements. 
2.5.2.1. Terminal studies 
After 6 weeks blood was collected from animals via cardiac puncture under halothane 
anaesthesia. Following blood collection, animals were killed under excess anaesthesia 
and liver tissue from each animal were quickly excised and blotted of blood. The 
hepatic tissue was quickly sliced into several portions of known weight and half the 
quantity transferred to liquid nitrogen. These were preserved at -80°C until required 
for hepatic glycogen analysis. The remainder of the hepatic tissue was fixed in 10% 
neutral buffered formalin for histological examination. Blood was centrifuged 
(eppendorf centrifuge 5403) and plasma separated and stored at -20° C until required 
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· for insulin, urea and creatinine assays. Liver, kidney, muscle and pancreatic weights 
were expressed per 100 g body weight of animals at time of sacrifice. 
2.5.3. Laboratory analysis 
2.5.3.1. Insulin assay 
Plasma insulin concentration was determined at Inkosi Albert Luthuli Hospital, 
chemical Pathology Laboratory (University of KwaZulu-Natal, Durban, South Africa) 
by electrochemiluminescence immunoassay method on the Hitachi modular EEE 
Analyzer (Hitachi, Tokyo, Japan) using diagnostic kits from Roche Diagnostics 
(Roche Diagnostics, Indianapolis, Indiana, USA). The immunoassay is a quantitative 
method for the determination of plasma msulin utilizing two monoclonal antibodies 
which together are specific for insulin. The lower limit of detection was 1.39 pmolll. 
the intra-assay analytical coefficient of variation ranged from 4.4% to 5.5% and inter-
assay coefficient of variation ranged from 4.7% to 8.<)010. 
2.5.3.2. Measurement of electrolytes, urea and creatinine 
Sodium and potassium concentrations were determined by ion activity using the 
Beckman Coulter (Syncmon LX20 Clinical Systems, USA). Urea and creatinine 
analysis were performed using the Beckman coulter instrument. Creatinine estimation 
employed the reaction of creatinine and sodium picrate to from creatinine picrate. 
Urea estimation employed the hydrolytic degradation of urea in the presence of 
urease. The methods used reagent kits from Beckman Coulter~ Ireland, Inc., and 
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measured using the Berclanan Coulter (Synchron LX20 Clinical Systems, Fullerton, 
USA). 
2.5.3.3. Effects of extracts on hepatic glycogen 
Hepatic glycogen levels were assessed quantitatively and qualitatively by biochemical 
and histological techniques, respectively to determine the effects of test extracts on 
glycogen synthesis after 6 weeks of treatment. 
2.5.3.3.1. Biochemical technique 
Hepatic glycogen levels were estimated by the methods of Hori et ai., (2006), with 
slight modifications. O.1g liver tissue samples were homogenized in boiling 1 ml of 
30% (w/v) potassium hydroxide (KOH) in centrifuge tubes for 20 minutes. 3ml 
distilled water and 4 ml absolute alcohol were added to the homogenate. Samples 
were then left to stand at room temperature for 20 minutes and centrifuged at 1000 g 
for 10 minutes. Samples were neutralized with 30% hydrochloric acid (HCI) and 2.5 
ml was added. 8 ml of 0.2% anthrone reagent made by dissolving 0.2 g anthrone in 
100 ml of concentrated H2S04 was added to Iml of sample and incubated in boiling 
water for ]0 minutes. Glycogen powder from oyster~ type II was used as standard. A 
standard glycogen stock solution was made by dissolving 10 mg glycogen standard in 
10 m1 distiUed water. By serial d~mtioIilS of the stock solution. standard glycogen 
samples were obtained to create a standard curve. Cary dual beam spectrophotometer 
using Cary Win UV Simple. Reads Application. software, vernon 3.00 (]82). was used 
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to read the absorbance, with wavelength set at 620 run after zeroing with reagent 
blank. 
2.5.3.3.2. Histological techniques 
Tissue embedding 
Hepatic tissue specimens were removed from formalin, cut into 2mm wide sections. 
These were placed in plastic cassettes and then quickly placed in ethyl alcohol. 
Histoprocessing was done in the H2500 microwave processor (Energy beam sciences, 
England). The sections suspended in alcohol were subjected to a temperature of 67°C 
for 30 minutes in a microwave oven at a power level of 450W. Specimens were then 
placed in isopropanol and subjected to temperatures of 74°C for 30 minutes. 
Specimens were then placed in paraffin at a temperature of 67°C for 30 minutes, after 
which old paraffm was decanted and fresh one added. Tissues were subjected to the 
same conditions for 30 minutes. Sections were finally imbedded in fresh paraffin wax 
and frozen using the Shandon histocentre2. Sample specimens were cut into 2Jlm 
wide portions using rotary microtome HM315, placed on surface of lukewarm water 
and mounted on a slide. A drop of albumin was added to the slide before mounting to 
allow specimen adherence to slide during staining. 
Pas staining 
Staining of sections was done according to Bancroft, Stevens and Turner, (1991). 
Specimen slides were briefly deparaffinized in xylene by dipping in fresh xylene 3 
90 
times, each 3 minute long. Slides were then rehydrated in descending grades of 
alcohol (l00, 95, 80, and 70%), each 1 minute long, and then placed in periodic acid 
for 5 minutes. This was followed by brief rinsing in distilled water. Slides were then 
placed in Schiff's reagent for 15 minutes. This was followed by rinsing in running 
water for 10 minutes. Slides were then immersed and kept in haemotoxylin for 5 
minutes, followed by rinsing in running water for 5 minutes. Slides were then 
differentiated in 1 % acid alcohol and dehydrated in ascending grades of alcohol (70-
100%), and xylene. A drop of DPX was added to the slide and mounted. Fields of 
interest were digitized with a 3CCD Sony colour video camera interfaced with the 
Nikon Optiphot photomicroscope (Nikon, Germany) that was linked to the Kontron 
Systems 300 image analysis system (Elektronik Imaging System, Kontron Elektronik, 
Miinchen Germany). 
2.5.4. Cell viability studies 
2.5.4.1. MTT assay 
To assess direct effects of test extracts on the kidney, the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was conducted on cell 
lines of kidney origin. The MIT assay is a quantitative colourimetric method based 
on the reduced cleavage of the water soluble monotetrazolium salt MIT to a purple 
formazan in metabolically active cells. The reduction of the MIT salt to formazan is 
done by the respiratory chain and other electron transport systems (Freimoser, Jakob, 
Aebi and Tuor, 1999). The porcine renal proximal tubular cell line, LLC-PK-l and 
Madin-Darby bovine kidney (MDBK) cells (Highveld biologicals, Lyndhurst, South 
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Africa) were grown and maintained at 37°C in Eagle's Minimum Essential Medium 
(EMEM) (containing 0.1 mM Hepes buffer) supplemented with 5% heat inactivated 
foetal calf serum, 1 % L-glutamine and 1 % penstrep-fungizone [complete culture 
medium (CCM)] (Delta Bioproducts, Kempton Park, South Africa). Once the cells 
reached confluency, they were detached from the culture flask (75 cm2) with 0.025% 
(w/v) trypsin and resuspended in CCM. Cell viability was determined in the presence 
of 0.2% (w/v) trypan blue in a haemocytometer. A 200-/.!l aliquot of the cell 
suspension (1.5 x 106 cells) was transferred into separate 96-well microtitre plates 
(Greiner Bio-one GmbH, Germany). Thereafter, the viability of cells incubated at 
37°C for 24, 36 and 72 hours, containing various concentrations of SBE, FTE, APE 
and P AE in separate wells was assessed (0, 100, 200, 400, 600, 800 and 1 OOO~g!ml, 
n = 6 for each dilution). The wells were aspirated after each incubation and washed 
with Hank's balanced salt solution (HBSS). All supernatants were discarded. The 
cells were resuspended in 100~1 CCM containing 1O~1 of MIT (5 mg.ml-1 MIT salt 
in HBSS) (Calbiochem, Darmstadt, Germany) and incubated for 4 hours at 37°C. 
After 4h, the plates were centrifuged (20 min, 2000 rpm at room temperature). The 
supernatant was removed and any resulting formazan crystals were then solubilized 
with 100~1 Dimethyl sulphoxide (DMSO). After one hour, the optical density was 
determined specrophotometrically using an ELISA plate reader (Bio-Tek Instruments) 
at 595 nm and a reference wavelength of 655nm. Absorbance was expressed as 
percentage cleavage activity. Percentage cell viability was calculated as mean 
absorbance of control cells/mean absorbance of treated cells. 
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2.6. Data presentation 
Data are presented as means ± SEM. Statistical comparisons were made using One-
way ANOV A, P < 0.05, with Dunnett's post test. Effects of test extracts were 
compared against effects in respective control groups at the corresponding time. 
Statistical tests were performed using GrapbPad Prism version 4.03 for Windows 
(GrapbPad Software, San Diego California USA). 
Based on their OGTI responses in non-diabetic rats, extracts were classified into two 
groups, namely, group A and group B. Group A extracts exhibited a dose-dependent 




3.0. RESUL TS 
3.1. Plant extraction yields 
Table 2 gives a summary of percent yields of crude extracts used in the present study. 
The percentage yield varied from 3.2 to 12.6%. 
Table 2 
Yield percent of crude extracts after ethanolic extraction 
Plant material Yield percent (%, w/w) 
H. hemerocallidea corm * 10 
F. thonningii bark 3.2 
P. americana leaf 7.6 
s. birrea bark 12.6 
Yield percent (%, w/w): Percentage weight of dry crude material obtained after 
extraction, over the weight of plant material before extraction. * H. hemerocallidea 
percent yield was calculated as weight of dry crude extract over wet weight of 
starting material 
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3.2. Acute studies 
3.2.1. OGTT responses 
3.2.1.1. Non-diabetic rats 
OGTT responses of standard drugs in non-diabetic rats are shown in Figures 6. 
Results show that blood glucose levels rapidly increased following glucose load (0.86 
g/kg). In vehicle treated non-diabetic control group, blood glucose concentration 
reached peak levels of 6.9 ± 0.2 mmollI, from fasting levels of 4.2 ± 0.1 mmol/l, 
within the first 15 minutes. All standard drugs exhibited hypoglycaemic effects 
compared with untreated control, which were statistically significant, P < 0.05. The 
hypoglycaemic effects of exogenous insulin (100 Ilg/kg, s.c.), were more potent than 
metformin (500 mg/kg) and glibenclamide (5 mg/kg). 
APE and SBE demonstrated hypoglycaemic effects that were dose-related during the 
fust 30 minutes of treatment. Based on this observation in OGrr responses in non-
diabetic rats, APE and SBE were classified as group A extracts. FTE and P AE were 
classified as group B extracts because they were devoid of dose dependent pattern in 
their hypoglycaemic effects. 
Group A extracts (APE and SHE) 
Effects of group A test extracts (APE and SBE) on glucose tolerance test in non-
diabetic animals are shown in Figure 7. By comparison to vehicle treated control 
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group, all groups treated with APE and SBE demonstrated significant hypoglycaemic 
effects. The extracts markedly reduced blood glucose in non-diabetic groups 30 
minutes after administration. Effects of APE lasted up to 45 minutes while those of 
SBE were sustained up to 120 minutes after treatment. In both extracts, the lowest 
doses (60 mg/kg) did not demonstrate significant blood glucose lowering effects 
compared with vehicle treated controls. Although less potent compared with standard 
drugs, these effects were statistically significant, P < 0.05, compared with vehicle 
treated controls. 
Group B extracts (FfE and P AE) 
OGTT responses for group B extracts (FTE and PAE) in non-diabetic rats are shown 
in Figure 8. FTE demonstrated significant hypoglycaemic effects, P < 0.05, during the 
first 15 and 30 minutes but showed no effects during the rest of the experiments. PAE 
exhibited hypoglycaemic effects beginning 15 minutes after treatment. However, the 
effects of the dose of 240 mg/kg were more prolonged to 120 minutes after treatment. 
Unlike group A extracts the lowest dose of group B extracts (60 mg/kg) decreased 
blood glucose in non-diabetic rats. 
Both groups of test extracts demonstrated antihyperglycaemic effects beginning at 15 
minutes of treatment, exhibiting peak effects during 30 to 45 minutes with glycaemic 
levels returning to baseline at 120 minutes. The maximal dose of 240 mg/kg 
demonstrated most potent antihyperglycaemic effects. 
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3.2.1.2. STZ-induced diabetic rats 
Figure 9 compares OGTT responses of standard drugs with vehicle treatement in 
STZ-induced diabetic animals. After glucose challenge (0.86 g/kg), blood glucose 
concentrations rose steadily within 30 minutes to peaks (32 ± 1 mmol/l, n = 6) in 
STZ-induced control animals. These hyperglycaemic levels declined slightly but 
remained elevated after 4 hours. Glibenclamide (5 mg/kg) did not exhibit any 
hypoglycaemic effects in STZ-induced diabetic animals, in contrast to effects 
observed in non-diabetic animals shown in Figure 6. Exogenous insulin 
administration (100 Ilg/kg) demonstrated the most potent effects, reducing blood 
glucose to 13.2 ± 0.8 mmol/l (n = 6), at the end of experiment a value that was 
significantly (P <0.05) high by comparison with control animals at the corresponding 
period (27.8 ± 0.7 mmolll, n = 6). Metformin reduced blood glucose to 14.2 ± 0.5 
mmolll (n = 6) at the end of the experimental period. Unlike in Figure 6, effects of 
hypoglycaemic effects of metformin in STZ diabetic animals were delayed starting 
later, at 45 minutes, but were prolonged to end of experiment. 
Group A extracts (APE and SHE) 
Figure lOA shows the effects of APE on glucose tolerance in STZ-induced diabetic 
rats. APE exhibited significant blood glucose lowering effects beginning 45 minutes 
after treatment, P < 0.05. These effects were dose-dependant and were more 
prolonged in comparison to effects observed in non-diabetic rats, shown in Figure 7 A. 
The lowest APE dose of 60 mg/kg had no statistically significant effects on blood 
glucose by comparison with control animals. As shown in Figure lOB, SBE also 
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demonstrated significant reduction in blood glucose levels, P < 0.05, which were 
dose-related. Like APE, in Figure lOA, these effects were prolonged to the end of the 
experiment. Unlike APE (Figure lOA), the lowest dose of 60 mg/kg demonstrated 
significant hypoglycaemic effects, P < 0.05, 3 h after treatment. 
Group B extracts (FTE and P AE) 
Illustrated in Figure 11 are the effects of group B extracts on glucose tolerance in 
STZ-induced diabetic rats. FTE exhibited significant blood glucose reductions, P < 
0.05, beginning 120 minutes after treatment, that were dose related. The 
administration of the lowest FTE dose (60 mg/kg) demonstrated significant 
hypoglycaemic effects beginning 4 hours after treatment. PAE significantly reduced 
blood glucose, dose-dependently, beginning 60 minutes after treatment, P < 0.05. The 
lowest P AE dose (60 mg/kg) showed significant effects 180 minutes after treatment. 
Hypoglycaemic effects of all group B extracts were sustained to the end of 
experiment. 
3.2.1.3. Summary of OGTT responses to test extracts 
Non-diabetic rats 
• APE and SBE demonstrated dose-dependent blood glucose lowering effects. 
• FTE and P AE demonstrated blood glucose lowering effects that were not 
dose-dependent. 
STZ-induced diabetic rats 
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Figure 6. 
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Effects of a single acute oral administration of vehicle and standard drugs on 
blood glucose in glucose-challenged non-diabetic rats. Values are means ± S.E.M. 
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Figure 7. Effects of a single acute oral administration of APE (A), and SBE (B) 
on blood glucose in glucose-challenged non-diabetic rats. Values are means ± S.E.M., 
n = 6, * significant values at P<0.05 vs control group at corresponding time. 
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Figure 8. Effects of a single acute oral administration of FTE (A) and P AE (B) 
on blood glucose in glucose-challenged non-diabetic rats. Values are means ± S.E.M., 
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Figure 9. 
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Time (min) 
Effects of a single acute oral administration of vehicle and standard drugs on blood 
glucose in glucose-challenged STZ-induced diabetic rats. Values are means ± S.E.M., 
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Figure 10. Effects of a single acute oral administration of APE (A), and SBE (B) 
on blood glucose in glucose-challenged STZ-induced diabetic rats. Values are means 
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Figure 11. Effects of a single acute oral administration of FTE (A), and P AE (B) 
on blood glucose in glucose-challenged STZ-induced diabetic male rats. Values are 
means ± S.E.M., n = 6, * significant values at P<O.05 vs control group at 
corresponding time. 
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3.2.1.4. Acute effects of test extracts on insulin release 
Table 3 shows the effects of acute administration of standard drugs and test extracts 
on insulin release (45 min) and blood glucose concentrations (60 min) in separate 
groups of non-diabetic rats, following a glucose load. As shown in the table 
glibenclamide and exogenous insulin significantly (P < 0.05) increased insulin release 
in comparison to vehicle treated non-diabetic rats. Metformin demonstrated no 
significant effects on insulin release in non-diabetic rats. All standard drugs 
demonstrated blood glucose lowering effects that were significantly (P < 0.05) 
pronounced after 60 min. 
3.2.1.4.1 Non-diabetic rats 
Extracts of groups A (APE and SBE) and B (FTE and PAE) did not affect insulin 
release in non-diabetic rats (Table 3). Glucose concentrations were, however; 
significantly lower (P < 0.05) in rats treated with APE (240 mglkg) after 60 min, but 
not in rats treated with SBE. Group B extracts (240 mglkg) did not affect blood 
glucose concentration after 60 minutes. 
3.2.1.4.2. STZ-induced diabetic rats 
Table 3 shows the effects of acute administration of standard drugs and test extracts 
on insulin and blood glucose concentrations in STZ-induced diabetic rats. In contrast 
to non-diabetic rats, exogenous insulin treatment significantly (P < 0.05) raised 
plasma levels of insulin. Neither metformin nor glibenclamide had any effects in 
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companson to vehicle treated STZ-induced diabetic rats. Blood glucose 
concentrations in rats treated with insulin and metformin were significantly (P < 0.05) 
reduced after 60 minutes. These effects were absent in STZ-induced diabetic rats 
treated with glibenclamide, in contrast to corresponding non-diabetic group. 
Group A (APE and SBE) and B (FTE and P AE) extracts 
Extracts of groups A (APE and SBE) and B (FTE and P AE) did not affect insulin 
levels in STZ-induced diabetic rats (Table 3). However, all extracts with the exception 




Effects of acute administration of test extracts at maximal dose of 240 mg/kg on 
plasma insulin release. Data are expressed as mean ± S.E.M., n = 6 rats in each group. 
*Significant values at P< 0.05 compared to corresponding vehicle treated control 
values. 
Groupffreatment Plasma insulin Blood glucose 
(nglml) [45 min] (mmol/l) [60 min] 
Non-diabetic 
Control 14A±0.5 5.6±0.2 
Glibenclamide 17.7±O.l* 4.7±O.l * 
Metformin 13.8±0.1 4.7±0.2* 
Insulin 18.9±0.2* 2.7±O.l * 
APE 14.5±0.3 4.5±0.2* 
SBE 14.1±O.l 5.2±OA 
FTE 14.5±0.2 5.8±0.2 
PAE 14.0±0.1 5.1±0.2 
STZ-induced diabetic 
Control 2A±0.1 30.8±0.6 
Glibenclamide 2.3±0.3 31.2±0.6 
Metformin 2A±0.2 26.3±0.8* 
Insulin 13.7±0.3* 25.7±0.8* 
APE 2.3±0.1 22.9±1.3* 
SBE 2.3±0.2 21.3±0.5* 
FTE 2.5±0.1 26.8±0.8* 
PAE 2A±0.1 23.0±0.7* 
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3.2.2. Acute renal effects of test extracts 
Effects of short term intravenous administration of test extracts on Na +, K+ and urine 
excretion rates in anaesthetised rats are depicted in Figure 12. Control animals were 
challenged with 0.077M NaCI at a rate of 9 mllh which allowed delivery of 693 
~mollh Na+. During the 4-h post equilibration period of sustained infusion of 0.077M 
NaCI, Na+ excretion and urine flow rates stabilised and approximated rates of infusion 
in the control animals. In groups treated with test extracts, infusate of extracts were 
added during the 1.5 h treatment period. 
3.2.2.1. Non-diabetic rats 
Group A extracts (APE and SBE) 
By comparison to corresponding control values, APE markedly depressed (P < 0.05) 
excretion rate of Na+ from the pre-treatment value of 619 ± 38 ~mol/h to 107 ± 25 
~mol/h, 30 minutes during the treatment period. K+ excretion rate was reduced from 
pre-treatment values of 248 ± 28 ~mollh to 42 ± 11 ~mol/h during the same period 
(Figure 12B). Urine flow rate declined from 10.0 ± 0.7 m1/h to 1.0 ± 0.2 m1/h 30 
minutes during post treatment (Figure 12C). APE-treated animals failed to revert to 
pre-treatment values of electrolyte and fluid excretion rates during recovery. SBE 
exhibited no effects on Na+, K+ excretion and urine flow rates. 
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Group B extracts (FTE and P AE) 
Shown in Figure 13 are the effects of intravenous administration of group B extracts 
on Na+, potassium excretion and urine flow rates in anaesthetised rats. FTE modestly 
elevated urinary Na+ excretion rate during the first 30 minutes of treatment (Figure 
13A). However, the difference was not statistically significant by comparison with the 
control values. Intravenous administration of FTE showed no effects on K+ excretion 
and urine flow rates in non-diabetic rats. 
P AE reduced Na + excretion rate by 30 minutes during post treatment from a baseline 
value of 644 ± 44 flmol/h to 437 ± 67 flIDol/h, by comparison with corresponding 
control value, P < 0.05, (Figure 13A). Animals returned to baseline values at the end 
of experiment. P AE significantly depressed K+ excretion rates after 60 minutes during 
treatment and recovery period. P AE demonstrated no effects on urine flow rate 
(Figure 13C). 
3.2.2.2. STZ-induced diabetic animals 
Results of effects of acute intravenous administration of test extracts on Na + and K+ 
excretion, and urine flow rates in anaesthetised STZ-induced diabetic rats are 
illustrated in Figure 14. During the 4-h post equilibration period control animals 
demonstrated significant reduced rates of Na+ excretion rate of approximately 255 
flmollh, by comparison to non-diabetic control rate of about 693 flmollh. K+ excretion 
rates were higher in STZ-induced diabetic rats by comparison to non-diabetic control 
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values. Urine flow rates were reduced to 6 mlfh in comparison to 9 mlfh in control 
non-diabetic rats. 
Group A extracts (APE and SHE) 
By comparison with corresponding control values, APE depressed Na+ excretion rate 
from a pre-treatment value of 242 ± 7 Ilmol/h, to 211 ± 9 Ilmol/h, 30 minutes during 
the treatment period, P < 0.05 (Figure 14A). These effects were sustained to the end 
of recovery period where further reductions occurred to 61 ± 7 Ilmolfh. APE infusion 
also depressed urinary K+ excretion rate from pre-treatment value of 445 ± 5 Ilmol/h 
to 377 ± 3 Ilmol/h, after 30 minutes during treatment (Figure 14B). Suppressive 
effects of APE on K+ excretion rate was sustained into recovery period. APE 
significantly (P < 0.05), depressed urine flow rate from a pre-treatment value of 6.0 ± 
0.3 ml/h to a post treatment value of 3.7 ± 0.0 mllh, after 60 minutes during the 
treatment period. These effects were sustained into the recovery period. 
During the first 30 minute treatment phase, SBE reduced Na+ excretion rate from a 
pre-treatment value of 249 ± 5 llIDol/h to 211 ± 7 llIDol/h, 30 minutes during the 
treatment period, which was significant by comparison with the corresponding control 
value, P < 0.05 (Figure 14A). Na+ excretion rates remained depressed, to 188 ± 9 
Ilmollh, P < 0.05, at the end of the experiments. Infusion of SBE reduced K+ 
excretion rate from a pre-treatment value of 466 ± 5 Ilmolfh, to 420 ± 7 J.lffiolfh 30 
minutes after treatment (Figure 14B). However, effects were only significant (P < 
0.05), after 60 minutes during treatment and these were sustained into the recovery 
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period where the final value was 372 ± 6 J.llIlol/h. Acute intravenous administration of 
SBE had no effects on urine flow rates in STZ-induced diabetic rats (Figure 14C). 
Group B extracts (FTE and P AE) 
Effects of administration of group B extracts on electrolyte excretion and urine flow 
rates in anaesthetised STZ-induced diabetic animals are shown in Figure 15. FTE 
reduced K+ excretion rate from a pre-treatment value of 257 ± 9 llmollh to 237 ± 8 
llmol/h, after 30 minutes of treatment (Figure 15A). However, this effect was not 
statistically significant compared with the control value, until 30 minutes during 
recovery phase. K+ excretion rates were sustainably depressed by intravenous infusion 
of FTE, P < 0.05, from 30 minutes during treatment phase to recovery period (Figure 
15B). Urine flow rate was unaffected by administration ofFTE (Figure 15C). 
By comparison with corresponding control values, PAE reduced Na+ excretion rate 
from a pre-treatment value of281 ± 6 llmol/h to 176 ± 9 llmol/h, P < 0.05,30 minutes 
after treatment (Figure 15A). During the same period, intravenous administration of 
P AE also reduced K+ excretion rates from baseline values of 508 ± 6 llmol/hr to 344 ± 
7 llmollh, and urine flow rate, from an initial value of 6.0 ± 0.4 llmollh to 5.0 ± 0.6 
llmollh. 
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3.2.2.3. Summary of acute renal effects of test extracts 
Non-diabetic rats 
• APE and PAE reduced Na+ and K+ excretion, and urinary flow rates. 
• SBE and FTE demonstrated no effects on Na+ and K+ excretion, and urinary 
flow rates 
STZ-induced diabetic rats 














































Figure 12. Na+ (A) and K+ (B) excretion, and, urine flow (C) rates in 0.077 M NaCI 
infused control non-diabetic rats, and rats administered APE and SBE at 0.06 ~g/min 
for 1 h 30 min. Values are mean ± S.E.M., n = 6. *significant values at P<0.05 vs. 































Figure 13. Na+ (A) and K+ (B) excretion, and, urine flow (C) rates in 0.077 M NaCI 
infused control non-diabetic rats, and rats administered FTE and PAE at 0.06 J..lglmin 
for 1 h 30 min. Values are mean ± S.E.M., n = 6. *significant values at P<0.05 vs. 

































Figure 14. Na+ (A) and K+ (B) excretion, and, urine flow (C) rates in 0.077 M NaCI 
infused control STZ-induced diabetic rats, and rats administered APE and SBE at 
0.06 ~g!min for 1 h 30 min. Values are mean ± S.E.M., n = 6. *significant values at 




































Figure 15. Na+ (A) and K+ (B) excretion, and, urine flow (C) rates in 0.077 M NaCI 
infused control STZ-induced diabetic rats, and rats administered FTE and P AE at 
0.06 J-lglmin for 1 h 30 min. Values are mean ± S.E.M., n = 6. *significant values at 
P<0.05 vs. control group at corresponding time. 
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3.2.3. Acute effects of test extracts on mean arterial blood pressure 
Figure 16 shows the effects of acute intravenous administration of test extracts on 
mean arterial blood pressure in non-diabetic rats. Control animals were challenged 
with 0.077M NaCI intravenously infused at a rate of 9 mllh. The mean arterial blood 
pressure values of control animals stabilised at approximately 120 mmHg during the 
4h post-equilibration period. 
3.2.3.1. Non-diabetic rats 
Group A extracts (APE and SBE) 
Figure 16A shows the effects of acute intravenous administration of group A extracts 
on mean arterial blood pressure in anaesthetised non-diabetic rats. APE mediated the 
most potent vasodepressive effects, in comparison to SBE in non-diabetic rats. APE 
reduced MAP values from pre-treatment values of 120 ± 2 mmHg to post-treatment 
levels of 112 ± 1 mmHg during the fIrst 30 minutes of treatment. APE mediated 
vasodepressive effects, P < 0.05, which were sustained during the recovery period and 
did not revert to pre-treatment levels. 
Intravenous infusion of SBE resulted in transient vasodepressive effects, P < 0.05, 
reducing pressure from 121 ± 2 mmHg to 115 ± 1 mmHg after 30 minutes of 
treatment. MAP rose gradually during the last 30 minutes of treatment period to reach 
values at the end of experiment that compared to the pre-treatment data. 
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Group B extracts (FTE and P AE) 
Shown in Figure 16B are the effects of intravenous administration of group B test 
extracts on blood pressure in anaesthetised non-diabetic rats. FTE demonstrated 
transient effects reducing blood pressure from a pre-treatment value of 119 ± 1 mmHg 
to 98 ± 1 mmHg during the first 30 minutes of treatment. Animals failed to attain pre-
treatment values during recovery period, with fmal values being 109 ± 0.8 mmHg. A 
similar vasodepressive pattern was observed in rats treated with P AE. P AE treatment 
reduced the blood pressure from a pre-treatment value of 123 ± 1 mmHg to f 101 ± 1 
mmHg. Unlike FTE, animals attained pre-treatment values during recovery. 
3.2.3.2. STZ-induced diabetic animals 
Figure 17 shows the effects of acute intravenous administration of test extracts on 
blood pressure in anaesthetised STZ-induced diabetic rats. Control animals were 
challenged with 0.077M NaCI intravenously infused at a rate of 9 ml/h. Control 
diabetic rats demonstrated steady mean arterial pressure during the 4h post-
equilibration period. However, these values were lower by comparison to control non-
diabetic rats. In treated groups infusates of extract solutions were added during 1.Sh 
treatment period. 
Group A extracts (APE and SBE) 
The effects of group A test extracts on blood pressure are shown in Figure 17 A. APE 
demonstrated sustained vasodepressive effects significantly reducing blood pressure 
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(P < 0.05) from an initial value of 113 ± 7 nunHg to 109 ± 8 nunHg during the fIrst 
30 minute of treatment period by comparison with corresponding control value. 
Vasodepressive effects of APE were prolonged into the recovery period. Animals 
treated with APE exhibited severe hypotension and failed to recover. The mean 
arterial blood pressure of the group treated with APE was 67 ± 4 nunHg at the end of 
experiment. 
Intravenous administration of SBE demonstrated vasodepressive effects that were 
transient with peak reductions in blood pressure observed 60 minutes during treatment 
phase, P < 0.05. SBE reduced blood pressure from a pre-treatment value of 109 ± 5 
mmHg to a peak reduced value of 82 ± 3 mmHg. Unlike APE, the effects of SBE 
were reversed during recovery period. 
Group B extracts (FTE and P AE) 
Figure 17B shows the effects of group B extracts on mean arterial pressure in 
anaesthetised STZ-induced diabetic rats. Group B extracts demonstrated a similar 
transient vasodepressive pattern to group A extracts. FTE reduced blood pressure 
from a pre treatment value of 111 ± 2 mmHg to a post-treatment value of 97 ± 1 
mmHg, after 30 minutes of treatment which was signifIcant by comparison to the 
corresponding value of control group, P < 0.05. FTE reduced blood pressure to an 
optimum value of 86 ± 7 mmHg at 60 minutes during treatment. P AE reduced blood 
pressure from a pre-treatment value of 110 ± 3 mmHg to 90 ± 2 mmHg after 30 
minutes of treatment. During recovery period, the effects of group B extracts were 
reversed. 
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3.2.3.2.1. Summary of mean arterial pressure effects of test extracts 
Non-diabetic rats 
• APE, SBE, FTE and P AE demonstrated acute vasodepressive effects 
• Vasodepressive effects of APE and FTE were sustained into recovery period. 
SBE treated groups recovered. 
STZ-induced diabetic rats 
• APE, SBE, FTE and P AE demonstrated acute vasodepressive effects 








' ...... ~ w ...... " _-T 
" "... (/11- * ', ......... r.... ... 
, * --' ...... _-_ ...... - -_ .. - * - ------Jr- * 
* * * 
50~--~--~--~--~--~---r--~ 
B I • Control 
...... 
... ----.. --.- FTE '" * ...-: .. :f~-"': .... ----.-.-- .. --,,, ... - * ----." E "" * _ • .,- * * * .. -.-- PA ,~ -.. ;. .. ~
~ ...... * 
* 
50~---r--~----P---.---~--~--~ 
30 60 90 120 150 180 210 240 
Time (min) 
Figure 16. Effects of acute intravenous administration of APE and SBE (A) and FTE 
and PAE (B) on mean arterial pressure in anaesthetised non-diabetic rats. Values are 
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Figure 17. Effects of acute intravenous administration of APE and SBE (A) and FTE 
and P AE (B) on mean arterial blood pressure, in anaesthetised STZ-induced diabetic 
rats. Values are mean ± S.E.M., n = 6. *significant values at P<O.05 vs. control group 
at corresponding time 
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3.3. Chronic studies 
3.3.1. Effects of test extracts on long term blood glucose concentration 
3.3.1.1. Non-diabetic rats 
Table 4 shows the effects of chronic administration of vehicle and test extracts on 
blood glucose in non-diabetic rats at the end of 6 weeks of treatment. Initial blood 
glucose concentrations were similar in all groups. Standard drugs, glibenclamide and 
metformin, significantly reduced (P < 0.05) blood glucose concentrations in non-
diabetic rats, by comparison with the control group. 
Group A extracts (APE and SBE) 
Oral administration of group A extracts once a day for 6 weeks had marginal blood 
glucose lowering effects in non-diabetic rats (Table 4). Although, APE and SBE 
reduced blood glucose concentration in non-diabetic rats at the end of 6 weeks, these 
were not statistically different from corresponding control values. 
Group B extracts (FTE and P AE) 
Also shown in Table 4 are the effects of group B test extracts on blood glucose 
concentrations at the end of 6 weeks of treatment in non-diabetic rats. FTE 
demonstrated the most potent blood glucose lowering effects after 6 weeks of 
treatment, in comparison to corresponding control values, P < 0.05. Treatment with 
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P AE for 6 weeks reduced blood glucose in non-diabetic rats but levels did not reach 
statistical significance. 
3.3.1.2. STZ-induced diabetic rats 
Animals became diabetic 24 hours after induction by i.p. administration of STZ and 
this was sustained for the rest of the study period. Seven days after induction of 
diabetes, vehicle treated diabetic controls exhibited fasting glycaemic levels of 24.6 ± 
1.5 mmoVI (n = 60), compared with 4.2 ± 0.1 mmoVl (n = 6), P < 0.05, in the 
corresponding no-diabetic control, and citrated buffer treated controls. STZ-induced 
diabetic rats exhibited marked polyuria, polyphagia and polydipsia. Furthermore, 
diabetic animals begun to exhibit severe wasting compared with the control animals. 
Table 4 also summarises effects of chronic administration of test extracts on blood 
glucose in STZ-induced diabetic animals. Vehicle treated STZ-induced diabetic 
control rats exhibited 5-fold more glycaemia than vehicle treated non-diabetic rats. 
While metformin significantly reduced blood glucose concentrations, P < 0.05, in 
STZ-induced diabetic rats, glybenclamide demonstrated no effects. 
Group A extracts (APE and SHE) 
In contrast to non-diabetic rats, oral administration of APE and SBE (120 mg/kg) 
once daily, for 6 weeks markedly reduced blood glucose concentrations in STZ-
induced diabetic animals at the end of 6 weeks of treatment. 
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Group B extracts (FTE and P AE) 
FTE and P AE significantly reduced blood glucose concentrations in STZ-induced 
diabetic rats, P < 0.05, compared with STZ-induced diabetic control animals at the 
end of 6 weeks (Table 4). 
3.3.1.3. Summary of effects of test extracts on chronic blood glucose 
concentration 
Non-diabetic rats 
• APE, SBE and P AE demonstrate mild hypoglycaemic effects that were not 
statistically significant. 
• FTE reduced blood glucose concentrations. 
STZ-induced diabetic rats 
• APE, SBE, FTE and P AE reduced blood glucose concentration in diabetic 
rats. 
3.3.2. Chronic effects of test extracts on mean arterial blood pressure 
Table 4 also shows effects of chronic administration of test extracts on mean arterial 
pressure, after 6 weeks in non-diabetic rats. Blood pressure values remained 
unchanged in control non-diabetic rats at the end of 6 weeks in comparison to the first 
week. 
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3.3.2.1. Non-diabetic rats 
Group A extracts (APE and SBE) 
As shown in Table 4, APE and SBE reduced mean arterial pressure in non-diabetic 
rats. In comparison to control values, the effects of SBE were significant, P < 0.05, 
while those of APE were, however, not statistically significant. 
Group B extracts (FTE and P AE) 
Also shown in Table 4 are effects of group B test extracts on blood pressure in non-
diabetic rats. Chronic administration of group FTE reduced mean arterial pressure in 
non-diabetic rats, P < 0.05. In contrast, PAE did not demonstrate vasodepressive 
significant vasodepressive effects in non-diabetic rats after 6 weeks. 
3.3.2.2. STZ-induced diabetic rats 
Table 4 also illustrates the effects oflong term administration of test extracts on blood 
pressure in STZ-induced diabetic rats. STZ-induced diabetic control rats exhibited 
higher mean arterial pressure values than control non-diabetic animals. 
Group A extracts (APE and SBE) 
Long term treatment with group A test extracts significantly reduced blood pressure in 
STZ-induced diabetic rats by comparison to control diabetic rats, P < 0.05 (Table 4). 
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Group B extracts (FTE and P AE) 
Like group A extracts, all group B test extracts (120 mg/kg) reduced blood pressure in 
diabetic rats in comparison to control values, P < 0.05. 
3.3.2.3. Summary of effects on long term blood pressure 
Non-diabetic rats 
• APE, SBE and FTE reduced blood pressure in non-diabetic rats 
• P AE had no effects on blood pressure in non-diabetic rats 
STZ-induced diabetic rats 
• APE, SBE, FTE and P AE were vasodepressive in STZ-induced diabetic rats. 
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Table 4 
Weekly blood glucose concentration (mmol/l) and mean arterial pressure (rrunHg) in 
separate groups of control and treated non-diabetic and STZ-induced diabetic rats. 
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3.3.3. Effects of test extracts on long term renal function 
3.3.3.1. Non-diabetic rats 
Effects of chronic administration of test extracts on Na+ and K+ excretion and urine 
flow rates per 24h in non-diabetic rats are shown are in Figures 18 and 19. Animals 
were treated once daily at 09hOO for 6 weeks. Control animals were administered with 
deionised (3 ml/kg). 
Group A extracts (APE and SBE) 
Figure 18 illustrates effects of chronic administration of group A extracts (120 mglkg) 
once daily for 6 weeks on Na+ and K+ excretion and urine flow rates per 24h, in non-
diabetic rats. APE significantly reduced Na+ and K+ excretion rates in non-diabetic 
rats. APE reduced urine flow rate in non-diabetic rats but this was not statistically 
significant. SBE failed to show any effects on renal Na+ and K+ excretion rates, and 
urine flow rates in non-diabetic rats compared with control animals. 
Group B extracts (FTE and P AE) 
Effects of chronic treatment of non-diabetic rats with group B extracts on Na+, K+ 
excretion and urine flow rates per 24h are shown in Figure 19. None of group B 
extracts had any effects on Na + and K+ excretion and urine flow rates, in non-diabetic 
rats during 6 weeks of treatment. 
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3.3.3.2. STZ-induced diabetic rats 
Effects oflong term administration of test extracts on renal Na+ and K+ excretion, and 
urine flow rates per 24h in STZ-induced diabetic rats are shown in Figures 20 and 2l. 
Control diabetic rats had reduced urinary Na+ excretion rates compared with control 
non-diabetic rats. Na+ excretion rate in control STZ-induced diabetic animals was 
approximately half that of non-diabetic control rats, while K+ excretion rates was five 
times lower. STZ-induced diabetic rats were polyuric, exhibiting seven times more 
urine flow rate, compared with non-diabetic control groups. 
Group A extracts (APE and SBE) 
Figure 20 shows effects of long term treatment of group A extracts to STZ-induced 
diabetic rats on Na+, K+ and urine flow rates per 24h. APE reduced Na+ and K+ 
excretion and urine flow rates in STZ-induced diabetic rats, P < 0.05 (Figure 20). In 
contrast, chronic treatment of STZ-induced diabetic rats with SBE did not have any 
effects on Na+ and K+ excretion, and, urine flow rates. 
Group B extracts (FTE and P AE) 
Figure 21 illustrates the effects of long term treatment of group B extracts to STZ-
induced diabetic rats on Na+ and K+ excretion and urine flow rates per 24h. Group B 
extracts had no effects on Na+ and K+ excretion, and urine flow rates. 
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3.3.3.3. Summary of effects on renal function 
Non-diabetic rats 
• APE depressed Na+ and K+ excretion rates in non-diabetic rats but its effects 
on urine flow rate were not significant 
• SBE, FTE and PAE had no effects on chronic Na+ and K+ excretion, and urine 
flow rates. 
STZ-induced diabetic rats 
• APE depressed Na+ and K+ excretion and urine flow rates. 
• SBE, FTE and PAE had no effects on Na+ and K+ excretion, and urine flow 
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Figure 18. Na + (A) and K+ (B) excretion, and, urine flow (C) rates in non-diabetic 
rats, chronically administered with APE and SBE at 120 mglkg once daily for 6 
weeks. Values are mean ± S.E.M., n = 8. significant values at P<0.05 vs. control 
group at corresponding time. 
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Figure 190 Na+ (A) and K+ (B) excretion, and, urine flow (C) rates in non-diabetic 
rats, chronically administered with FTE and P AE at 120 mglkg once daily for 6 
weeks. Values are mean ± S.E.M., n = 8. *significant values at P<0.05 vs. control 
group at corresponding time. 
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Figure 20. Na+ (A) and K+ (B) excretion, and, urine flow (C) rates in STZ-induced 
diabetic rats, chronically administered with APE and SBE at 120 mglkg once daily for 
6 weeks. Values are mean ± S.E.M., n = 8. *significant values at P<0.05 vs. control 
group at corresponding time. 
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Figure 21. Na+ (A) and K+ (B) excretion, and, urine flow (C) rates in STZ-induced 
diabetic rats, chronically administered with FTE and P AE at 120 mg/kg once daily for 
6 weeks. Values are mean ± S.E.M., n = 8. *significant values at P<0.05 vs. control 
group at corresponding time. 
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3.3.4. Effects of test extracts on plasma creatinine and urea concentrations 
Effects of chronic treatment of test extracts on plasma concentrations of creatinine 
and urea in non-diabetic and STZ-induced diabetic rats are depicted in Table 5. 
3.3.4.1. Non-diabetic rats 
Group A extracts (APE and SBE) 
As shown in Table 5, APE significantly increased plasma creatinine concentration by 
comparison to respective control values, P < 0.05. APE demonstrated no effects on 
urine and plasma concentrations of urea in non-diabetic rats. SBE reduced plasma 
creatinine concentrations which was statistically significant by comparison with 
control rats, P < 0.05, but had no effect on plasma urea levels. 
Group B extracts (FTE and P AE) 
Group B extracts significantly reduced plasma creatinine concentrations in non-
diabetic rats, by comparison with control values, P < 0.05. FTE demonstrated no 
effects on plasma urea concentrations whereas P AE significantly reduced plasma urea 
concentrations, P < 0.05, by comparison with control values. 
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3.3.4.2. STZ-induced diabetic rats 
Table 5 shows the effects of chronic treatment of test extracts on plasma creatinine 
and urea concentrations in STZ-induced diabetic rats. STZ-induced diabetic control 
rats exhibited increased plasma creatinine and urea concentrations in comparison to 
non-diabetic control rats. 
Group A (APE and SBE) and B (FTE and P AE) extracts 
Like in non-diabetic rats, APE significantly increased plasma concentrations of 
creatinine in STZ-induced diabetic rats, but demonstrated no effects on plasma urea. 
The rest of test extracts significantly reduced plasma creatinine, and plasma urea 
concentrations in STZ-induced diabetic rats, P < 0.05. 
3.3.4.3. Summary of effects on creatinine and urea concentrations in 
plasma and urine 
Non-diabetic rats 
• APE increased plasma creatinine concentration but did not alter plasma urea 
concentration 
• SBE and FTE reduced plasma creatinine concentrations but showed no effects 
on plasma urea concentration. 
• P AE reduced plasma creatinine and urea concentrations. 
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STZ-induced diabetic rats 
• APE increased plasma creatinine concentration, but had no effects on plasma 
urea concentrations. 
• SBE, FTE and P AE reduced plasma creatinine, and plasma urea 
concentrations. 
3.3.5. Effects of test extracts on plasma sodium and potassium levels 
3.3.5.1. Non-diabetic rats 
Also shown on in Table 5 are the terminal Na+ sodium and K+ levels after 6 weeks in 
non-diabetic rats. 
Group A extracts (APE and SBE) 
As shown in the Table 5, none of group A extracts had any effect on plasma Na+ and 
K+ levels in non-diabetic rats. 
Group B extracts (FTE and P AE) 
None of group B extracts influenced plasma Na+ and K+ levels in non-diabetic rats 
(Table 5). 
138 
3.3.5.2. STZ-induced diabetic rats 
Also shown in Table 5 are the terminal plasma Na+ and K+ concentrations after 6 
weeks in STZ-induced diabetic rats. There was no difference in the plasma 
concentrations ofNa+ and K+ between non-diabetic and STZ-induced diabetic control 
groups. 
Group A (APE and SBE) and B (FTE and P AE) extracts 
None of test extracts had any influence on plasma Na+ and K+ concentrations in STZ-
induced diabetic rats. 
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Table 5 
Influence of long tenn treatment of test extracts to non-diabetic and STZ-induced 
diabetic rats on terminal plasma concentrations of creatinine (llmolll), urea (mmol/l), 
Na+ (mmolll) and K+ (mmol/). Data are expressed as mean ± S.E.M., n = 8 rats in 
each group. * Significant values at P< 0.05 compared to corresponding control values. 
Groupffreatment Creatinine Urea 
Non-diabetic 
Control 55±3 9±1 142±2 3.6±0.3 
APE 68±6* 9±1 143±3 4.5±0.4 
SBE 32±4* 10±1 142±2 4.2±0.2 
FTE 36±2* 8±0.7 143±2 3.2±0.1 
PAE 36±2* 5±0.2* 144±1 4.7±1.5 
STZ-induced diabetic 
Control 86±6 223±1.0 142±1 4.0±0.2 
APE 97±5* 165±0.3* 142±3 3.0±0.1 
SBE 46±12* 122±0.8* 143±2 4.0±0.1 
FTE 73±9* 111±0.6* 143±2 4.1±0.2 
PAE 65±8* 105±1.0* 143±3 3.6±0.1 
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3.3.6. Effects of test extracts on water and food intake, and weight changes 
3.3.6.1. Non-diabetic rats 
Table 6 depicts water and food intake, and percentage body weight changes in non-
diabetic and STZ-induced diabetic rats at the end of 6 weeks. 
Group A extracts (APE and SBE) 
APE had no effect on water and food intake in non-diabetic rats. However, APE 
significantly increased, P < 0.05, percentage weight gain in non-diabetic rats. Chronic 
treatment of SBE to non-diabetic rats had no effect on water intake, but significantly 
reduced, P < 0.05, food intake in non-diabetic rats in comparison to non-diabetic 
control rats. SBE also markedly increased percentage body weight gain which was 
statistically significant, P < 0.05. 
Group B extracts (FTE and P AE) 
As shown in Table 6, chronic treatment of FTE to non-diabetic rats for 6 weeks 
stimulated increased water intake which was statistically significant, P < 0.05, in 
comparison to non-diabetic control rats, but had no effect on food intake. However, 
chronic administration of FTE increased body weight gain in non-diabetic rats. In 
contrast, P AE had no effects on water and food intake, and percentage weight gain in 
non-diabetic rats. 
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3.3.6.2. STZ-induced diabetic animals 
Table 6 shows the effects of chronic administration of test extracts on water and food 
intake, and body weight gain at the end of 6 weeks, in STZ-induced diabetic rats. 
Control STZ-induced diabetic rats exhibited polypphagia evidenced by increased food 
intake by nearly 100% over control non-diabetic rats. Diabetic animals also exhibited 
polydipsia (Table 6). In comparison to control non-diabetic rats, water intake was 
elevated by nearly 400% in control diabetic rats. Vehicle treated control diabetic rats 
exhibited severe wasting by comparison with vehicle treated non-diabetic rats. These 
characteristics in STZ-induced diabetic rats were sustained for the duration of the 
study. 
Group A extracts (APE and SBE) 
As shown in Table 6, chronic treatment of APE extracts significantly reduced water 
intake in STZ-induced diabetic rats P < 0.05, in comparison to control STZ-induced 
diabetic rats. Moreover, APE reduced food intake in diabetic rats in comparison to 
control values, P < 0.05. Chronic administration of APE reduced body wasting and 
promoted a body weight gain of nearly 1 %. 
After 6 weeks of daily treatment with SBE, water and food intake significantly 
reduced in STZ-induced diabetic rats in comparison to vehicle treated diabetic rats P , 
< 0.05. SBE promoted a modest but significant increase in body weight gain in STZ-
induced diabetic rats 
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Group B extracts (FTE and P AE) 
FTE reduced both water and food intake. These effects were statistically significant, P 
< 0.05, compared to control STZ-induced diabetic rats. FTE also significantly 
promoted body weight gain in STZ-induced diabetic rats, P < 0.05, by comparison 
with non vehicle treated diabetic control group. (Table 2). 
PAE mediated significant reduction in water intake, P < 0.05, by comparison with 
control STZ-induced diabetic rats, but had no effects on food intake in these animals 
(Table 7). P AE also significantly ameliorated wasting, P < 0.05, in diabetic rats. 
3.3.6.3. Summary of effects of test extracts on water and food intake, and 
weight changes 
Non-diabetic rats 
• APE had no effect on water and food intake, but increased body weight. 
• SBE had no effect on water intake but reduced food intake while promoting 
body weight gain. 
• FTE increased water but not food intake. FTE increased body weight 
• P AE had no effect on water and food intake and body weight 
STZ-induced diabetic rats 
• APE, SBE and FTE reduced water and food intake, and increased body 
weight. 
• P AE reduced water intake, but had no effects on food intake. P AE modestly 
increased body weight. 
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Table 6 
Effects of long term treatment of test extracts on body weight, fluid and food intake 
after 6 weeks. Data are expressed as mean ± S.E.M., n = 8 rats in each group, * P< 
0.05, compared to control values at week 6, respectively 
Parameter 
Water intake Food intake Body 
(ml/24h) (g/24h) wt(%) 
Groupffreatment wkl wk6 wkl wk6 wk6 
Non-diabetic 
Control 23±3 24±1 27±3 28±1 14±2 
Glibenclamide 24±2 22±2 26±2 20±1* 37±3* 
Metformin 24±4 26±1 28±3 21±1* 45±2* 
APE 23±1 23±3 25±4 26±3 30±1* 
SBE 23±2 25±1 26±1 23±1* 25±2* 
FTE 22±1 30±1* 27±4 30±1 27±2* 
PAE 24±3 25±2 25±2 27±0.4 13±2 
STZ-induced diabetic 
Control 77±4 93±2 38±2 45±2 -22±2 
Glibenclamide 73±6 92±4 37±4 47±1 -19±2 
Metformin 72±5 31±2* 39±1 31±2* 21±4* 
APE 74±2 62±2* 42±1 34±1* 1±0.1 * 
SBE 69±3 62±3* 39±3 31±2* -6±3* 
FTE 71±5 55±3* 40±2 37±3* -3±1 * 
PAE 75±2 66±4* 37±2 39±2 -12±1 * 
Wkl , wk6 denote week 1 and week 6, respectively 
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3.3.7. Terminal insulin levels 
3.3.7.1. Non-diabetic rats 
Table 6 shows the effects of chronic administration of test extracts on insulin release 
in non-diabetic rats after 6 weeks. The pattern shown in Table 6 is generally similar to 
that of acute effects in Table 3. As shown in the table glibenclamide significantly 
increased insulin release in comparison to control non-diabetic rats, P < 0.05. 
Metformin demonstrated no effects on insulin release in non-diabetic rats. 
Group A (APE and SBE) and B (FTE and P AE) extracts 
None of test extracts had any long tem effects on insulin release in non-diabetic rats. 
3.3.7.2. STZ-induced diabetic rats 
Table 8 also shows the effects of chronic administration of group A test extracts on 
long insulin release in STZ-induced diabetic rats. Insulin concentrations in STZ-
induced diabetic rats were markedly low in comparison to non-diabetic control rats 
Glibenclamide and metformin had no effects in comparison to control STZ-induced 
diabetic rats. 
Group A (APE and SBE) and B (FTE and P AE) extracts 
As shown in the Table 8, none of test extracts had any effects on plasma insulin 
release in STZ-induced diabetic rats. 
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3.3.7.3. Summary of effects of test extracts on terminal plasma insulin 
Non-diabetic rats 
• None of test extracts had any effects on terminal plasma insulin in non-
diabetic rats. 
STZ-induced diabetic rats 
• None of test extracts had any effects on terminal plasma insulin in STZ-
induced diabetic rats. 
3.3.8. Effects on liver glycogen 
3.3.8.1. Non-diabetic rats 
A summary of hepatic glycogen levels are shown in Table 7 and Figure 22. The figure 
shows representative pas stained hepatic micrographs comparing density of glycogen 
stores in hepatic tissues of treated and untreated animals. Results of Pas staining 
showed glycogen and other periodate-reactive carbohydrates a magenta colour while 
cellular nuclei became blue. 
Group A extracts (APE and SBE) 
Chronic treatment of APE to non-diabetic rats significantly increased hepatic 
glycogen compared with control values, P < 0.05. In contrast, SBE induced a slight 
increase in hepatic glycogen levels in non-diabetic rats, which was not significant. 
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Group B extracts (FTE and P AE) 
As shown in Table 7, FTE and PAE significantly, (P < 0.05), raised hepatic glycogen 
concentrations in non-diabetic rats by comparison with control rats. 
3.3.8.2. STZ-induced diabetic animals 
Non-diabetic animals generally exhibited high levels of hepatic glycogen compared 
with diabetic animals (Table 7). Animals treated with standard drug metformin 
exhibited higher hepatic glycogen levels than groups treated with test extracts. 
Compared with control non-diabetic rats, STZ-induced diabetic control rats had 
reduced hepatic glycogen levels. 
Group A (APE and SBE) and B extracts (FTE and P AE) 
All test extracts, significantly increased hepatic glycogen in STZ-induced diabetic 
rats, by comparison with STZ-induced diabetic control group, P < 0.05. The deeper 
the magenta colour intensity in Figure 22, the higher the glycogen levels. Based on 
this, Figure 22 shows that groups treated with test extracts (Figure 22C) generally had 
improved glycogen storage than those treated with vehicle (Figure 22B). 
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3.3.8.3. Summary of effects of test extracts on hepatic glycogen 
Non-diabetic rats 
• APE, FTE and P AE increased hepatic glycogen concentration. 
• SBE had no effects on hepatic glycogen concentration. 
STZ-induced diabetic rats 
• APE, SBE and FTE increased hepatic glycogen concentration. 




Effects of chronic administration of test extracts, at 120 mg/kg, on terminal plasma 
insulin levels (ng/ml) and glycogen levels (mg/IOO g, liver tissue). Data are expressed 
as mean ± S.E.M., n = 8 rats in each group. * Significant values at P< O.OS compared 























































Figure 22. Liver micrographs pas stained showing magenta coloured glycogen stores 
(A) vehicle treated normal rats, (B) vehicle treated diabetic (C) extract treated diabetic 
(magnification x20). 
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3.4. Cell viability studies 
An in vitro study illustrating the percentage viability of MDBK and LLCPK-I cells, 
exposed to graded concentrations (l00 - 1 000 ~g/ml) of test extracts for varied 
incubation periods (24, 48 and 72 hours), relative to vehicle treated controls, is shown 
in Figures 23 to 26. 
Group A extracts (APE and SHE) 
APE induced marked cell growth promotion in MDBK cell lines but cell death in 
LLCPK-1 lines (Figure 23). Cell growth in LLCPK-I seemed to be strongly 
dependent on incubation time, whereby increased cell viability (up to 200% relative to 
untreated cells) was observed in cells incubated for 72 hours. MDBK cells exposed 
for 24 hours demonstrated mild cell death. While lower APE concentrations exposed 
to LLCPK-I cells at minimal incubation period (24 hours) promoted cell proliferation, 
higher doses at higher incubation periods exhibited severe cytotoxicity, inflicting 
LLCPK-1 cell death by up to 97%, P < 0.05. 
SBE demonstrated cytotoxicity in both cell lines (Figure 24). However the cytotoxic 
effects were moderate in MDBK cells (l0.4 to 49.4% cell death) compared with 
LLCPK-l cells where it was more severe (22.7 to 63.9%). 
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Group B extracts (FTE and P AE) 
Effects of exposure of MDBK and LLCPK-l cells to FTE are shown in Figure 25. 
FTE demonstrated promotion of cell growth for both types of cell lines. This growth 
was, however, modest in both MDBK and LLCPK-l, and appeared to be dose-
dependent. 
In contrast to FTE, P AE induced reduction in cell viability of both MDBK and 
LLCPK-l cell lines (Figure 26). However, the effects were more marked in MDBK 
cells, 35.3% to 74.2%. MTT demonstrated that all test extract except FTE were 
cytotoxic towards LLCPK-l cell lines but had mild cytotoxic effects on MDBK cells, 
exceptPAE. 
3.4.1. Cell viability results summary 
• APE increased cell growth in MDBK cell lines but promoted cell death in 
LLCPK -1 cell lines. 
• SBE and P AE were cytotoxic to both cell lines 
• FTE promoted cell growth in both cell lines 
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Figure. 26. Effects of exposure of (A) MDBK and (B) LLCPK-l cells for 24,48 
and 72 hrs to graded concentrations (100 -1000 flg/ml) of PAE on cell 
viability. Cells were cultured in 96 micro-well plates and incubated at 
37°C. Percentage cell viability was expressed relative to vehicle treated 
cells n= 6 replicates; * significant, P<0.05, by comparison to untreated 
group 
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3.5. Summary of aU results 
• APE, SBE, FTE and P AE possess acute and long term hypoglycaemic effects 
in STZ-induced diabetic rats 
• APE, SBE, FTE and P AE increased hepatic glycogen concentrations in STZ-
induced diabetic rats 
• APE, SBE, FTE and APE had no effect on insulin release in non-diabetic and 
STZ-induced diabetic rats 
• APE, SBE, FTE and P AE exhibited short and long term vasodepressive effects 
in diabetic rats 
• APE increased plasma creatinine concentration, while SBE, FTE and P AE 
reduced plasma creatinine, concentrations in diabetic rats. 
• APE promoted MDBK cell proliferation, but was cytotoxic to LLCPK-l cells 
• SBE and PAE were cytotoxic to MDBK and LLCPK-l cell lines 





The present study investigated the effects of ethanolic extracts of Hypoxis 
hemerocallidea (APE), Sclerocarya birrea (SBE), Ficus thonningii (FTE) and Persea 
Americana (P AE) on blood glucose, renal function and mean arterial blood pressure 
in non-diabetic and STZ-induced diabetic rats. Results demonstrated that all test 
extracts possess short and long term hypoglycaemic effects in non-diabetic and STZ-
induced diabetic rats. While some plants demonstrated adverse effects on renal 
function, others appeared to be renoprotective. By exhibiting cardio-renoprotective 
effects, some of these test extracts may possess therapeutic potential in the 
amelioration of cardiovascular and renal complications in diabetes. 
4.2. Hypoglycaemic effects 
Both group A (APE and SBE) [Figure 7] and B (FTE and P AE) [Figure 8] extracts 
demonstrated hypoglycaemic effects in non-diabetic rats. We suggest that the 
mechanisms of these hypoglycaemic effects were mediated independent of insulin 
release. This is evidenced in Table 3, where none of the extracts stimulated insulin 
release in non-diabetic rats. While the insulin secretagogue glibenclamide and insulin 
increased plasma insulin concentrations in non-diabetic rats, metformin, like the test 
extracts, demonstrated no effects on insulin release (Table 3). This suggests that the 
mechanisms ofhypoglycaemic effects of group A and B extracts closely mimic that of 
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metformin. Metformin is a biguanide that lowers blood glucose without stimulating 
insulin release (British National Formulary, 1995). It mediates hypoglycaemic effects 
by sensitizing target tissues cells to insulin action and blocking hepatic 
gluconeogenesis (Pari and Satheesh, 2006). It also increases expression or activities of 
GLUT -4 transporters which also enhances glucose uptake by muscles (Sim6 
and Hernandez, 2002). Other possible mechanisms of hypoglycaemic effects of test 
extracts, however, cannot be ruled out. For example, reduced peak blood glucose 
concentrations in non-diabetic groups treated with test extracts might suggest that test 
extracts mediate rapid peripheral tissue utilisation of glucose. The rapid reduction of 
glucose levels in extract treated groups may suggest a synergistic effect of test extract 
to endogenous insulin effects since non-diabetic rats had intact functional ~-cell mass. 
Moreover, the absence of insulin stimulation by test extracts suggests possible 
mediatory effects via a decrease in the secretion of counteregulatory hormones and 
increased glycolytic enzymatic activities, in addition to increased glucose utilisation 
in the peripheral tissues (Kumar, Banu, Murugesan and Pandian, 2006). 
By comparison with non-diabetic control group, some non-diabetic treated groups 
attained maximal blood glucose concentrations 15 minutes later than control group, 
after glucose challenge (Figures 7B and 8). Although brief, this may be a result of 
delayed absorption of glucose into blood from the gut. Ortiz-Andrade, Garc' la-
Jim'enez, Castillo-Espa-na, Ram'rrez- Avila, Villalobos-Molina and Estrada-Soto , 
(2006), stated that delaying absorption of glucose after a meal is one of the effective 
ways to control postprandial hyperglycaemia. The presence of tannins in food blocks 
its digestibility and consequently, delays its absorption. Subsequently blood glucose 
concentration is reduced (Aganga and Mosase, 2001). Phytochemical studies by Eloff, 
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(2001), and, Osadebe Okide and Akabogu (2004) have shown the presence of tannins 
in S. birrea bark and P. americana leaf extracts, respectively. 
The demonstration of acute hypoglycaemic effects of test extracts APE, SBE, FTE 
and P AE in STZ-induced diabetic rats (Figures 10 and 11) is a significant fmding in 
the present study. Since these animals are devoid of functional p-cells, these results 
eliminate insulin involvement in the mediatory roles of test extracts. Indeed, these 
observations are supported by results shown in Table 3, which show that none of test 
extracts in the present study stimulated insulin release in both non-diabetic and STZ-
induced diabetic rats. The lack of insulin release in diabetic animals, induced by STZ 
destruction of pancreatic p-cells, could account for sustained elevated glycaemic 
levels and late hypoglycaemic effects of test extracts in these animals. 
In the present study, glibenclamide demonstrated hypoglycaemic effects in non-
diabetic rats (Figure 7) but exhibited no effects in STZ-induced diabetic animals 
(Figure 9). This observation corroborated that pancreatic p-cells were destroyed by 
STZ administration. This is further supported by absence of effects on plasma insulin 
levels in diabetic rats (Table 3). Moreover, this offers further evidence that 
hypoglycaemic effects of test extracts were independent of insulin release. 
Glibenclamide is a potassium channel blocker that stimulates insulin release in the 
pancreatic p-cells and belongs to a class of hypoglycaemic agents called 
sulphonylureas (Babichev, 1999). 
Group B test extracts (FTE and P AE) demonstrated hypoglycaemic effects in both 
non-diabetic and STZ-induced diabetic rats. These effects were dose dependent in 
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STZ-induced diabetic rats but not in non-diabetic rats (Figures 8 and 10). The reasons 
for the discrepancy remain to be determined. The dose-dependent effects of P AE are 
consistent with the findings of Antia, Okokon and Kon, (2005) in alloxan-induced 
diabetic rats. 
Previous studies have demonstrated that extracts of S. birrea and H hemerocallidea 
have potent hypoglycaemic effects (Ojewole, 2003; Ojewole, 2006). Other studies 
have shown that aqueous extracts of P. americana possess antihyperglycaemic and 
antihyperlipidaemic effects (Gallagher, Flatt, Duffy and Abdel-Wahab, 2003). 
However, these studies did not establish the effects of extracts on plasma insulin and 
hepatic glycogen levels. Therefore, findings of the present study will help unravel 
mechanisms by which the extracts from these plants mediate hypoglycaemic effects. 
SBE and FTE demonstrated long term hypoglycaemic effects in non-diabetic rats after 
6 weeks (Table 4), while effects of APE and PAE were not statistically significant. 
The lack of statistical significance of long term hypoglycaemic effects of some test 
extracts (APE and PAE) in non-diabetic animals (Table 4) may be best explained by 
the trend shown in short term acute studies in non-diabetic animals (Figures 7 and 8). 
In these studies, hypoglycaemic effects of these test extracts at the median dose of 120 
mg/kg, were of short duration, lasting between 1 and 2 hours and, therefore, may 
explain failure to detect lower glucose levels as these would have returned to baseline 
at time of measurement in chronic studies. Such rapid effects, however, suggest use to 
in the management of acute hyperglycaemic episodes. 
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As evident in Table 7, none of test extracts increased plasma insulin levels in non-
diabetic animals. This suggests that the long term hypoglycaemic of both group A and 
B extracts in non-diabetic rats is independent of insulin release, and probably similar 
to that of metformin. In long term studies, the present study monitored postprandial 
glucose as opposed to fasting glycaemia. This is because postprandial glucose 
presents a better reflection of glycaemia in diabetes than fasting glycaemia (Baron, 
1998). Moreover, it is postprandial glucose concentration in diabetes, which is 
strongly associated with diabetic complications (Gadsby, 2002). 
Group A (APE and SBE) and B (FTE and PAE) test extracts exhibited significant 
chronic hypoglycaemic effects in STZ-induced diabetic rats after 6 weeks (Table 4) 
without affecting plasma insulin levels (Table 7). Like in non-diabetic rats, these 
hypoglycaemic effects may be mediated via mechanisms similar to that of metformin 
as previously explained. 
In the present study, all the test extracts promoted hepatic glucose conversion into 
glycogen in STZ-induced diabetic rats compared with the control group (Table 7). 
Therefore, the long term hypoglycaemic effects of the test extracts might partly be 
due to conversion of blood glucose into stored glycogen in the liver and muscle. The 
mechanism(s) by which test extracts enhance conversion of glucose to glycogen 
remain to be established. However, these effects might be due to stimulating activities 
of enzymes involved in glycogen synthesis such as hepatic glycogen synthase 
(Arambewela et al., 2005). These authors pointed out that increased glycogen storage 
suggests increased glucose uptake from blood and its subsequent conversion into 
glycogen. Hypoglycaemic investigations by Ghosh et al., (2004), on Ficus 
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bengalensis revealed mediatory effects via conversion of glucose into glycogen. 
These fmdings, of glycaemic effects of a plant species belonging to the same genus as 
F thonningii adds credence to the present results. Therefore, this is the first study that 
has linked observed hypoglycaemic effects of the present medicinal plants to 
glycogen synthesis. Previous studies have established hypoglycaemic effects of other 
medicinal plants as being mediated via similar mechanisms (Musabayane, et al., 
2005). The control of the synthesis and breakdown of glycogen in the liver is central 
to the regulation of blood glucose levels (Chakrabarti et al., 2005). Moreover, 
Chakrabarti et al., (2003), asserted that assessment of hepatic glycogen level may be 
considered as the best marker for evaluating the antidiabetic activity of any drug, as it 
indicates that peripheral free glucose is being stored in the liver in the form of 
glycogen. In diabetes mellitus, glycogen synthesis is compromised (Emilien et al., 
1999), resulting in persistent hepatic gluconeogensis which results in hyperglycaemia. 
The lack of capacity to store glycogen in STZ-induced diabetic rats observed in the 
present study is consistent with fmdings by many investigators (Singh, Vats, Suri, 
Shyam, Kumria, Ranganathan, Sridharan, 2001; Ramachandran, Kandaswamy, 
Narayanan, Subramanian, 2003; Adisakwattana, Roengsamran, Hsu and Yibchok-
anun, 2005). 
The hypoglycaemic effects observed for some of the plant extracts may be partly 
attributed to the presence of flavonoids in the test extracts. Previous studies by Jung et 
al., 2006, showed that flavonoids possess potent antihyperglycaemic effects. 
Moreover, Jung and colleagues, (2006), demonstrated that flavonoids, hesperidin and 
naringin promoted increased mRNA expression of hepatic glucokinase in the db/db 
mice, a significant enzyme in the metabolism of glucose. The presence of bioactive 
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compounds such as flavonoids in test extracts is responsible for most long term 
antihyperglycaemic effects because of their unique antioxidant effects (Argolo, et ai., 
2005; Czinner, Hagymasi, Blazovics, Kery Szoke and Lemberkovics). Using ethanol 
as a solvent of extraction, AsIan et ai. , 2006, were able to isolate more total phenols 
including flavonoids from Helichrysum plicatum ssp. plicatum capitulums extracts, 
compared with water extraction. In addition the ethanolic extract demonstrated the 
most potent hypoglycaemic effects than the aqueous extract. 
Other groups of chemical compounds with known antidiabetic effects include 
triterpenes (perez and Vargas, 2002), flavonoids (Singab et ai. , 2005; Jung et ai., 
2006) and saponins (Li, Qu, Wang, Wan and Tian, 2002). The present study did not 
evaluate phytochemical composition of test extracts, but other investigators have 
established the presence of these groups of compounds in Ficus species, (Chiang et 
aI., 2005), P. americana, (Ramos et ai. , 2004) and S. birrea (Ogbobe, 1992). 
H hemerocallidea has been shown to possess potent antioxidant effects. Furthermore, 
studies have revealed that it is inhibitory on cycloxygenase-2 catalysed prostaglandin 
synthesis (Steenkamp, Gouws, Gulumian, Elgorashi and van Staden, 2005). 
Hypoxoside and rooperol, two major compounds isolated from H hemerocallidea 
were recently shown to possess potent antioxidant effects by Laporta et al. , 2007. 
Since hypoglycaemic activities may be associated with antioxidant properties 
(McCune and Johns, 2002; Sabu and Kuttan, 2002), the long term hypoglycaemic 
effects of APE in the present studies might be partly attributed to these properties. 
The present studies have established that group A and B extracts possess 
hypoglycaemic effects in non-diabetic and STZ-induced diabetic rats. These effects 
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may be mediated by mechanisms that are extra-pancreatic, involving glycogen 
synthesis, and probably mimicking those of metformin. Food intake is an important 
behavioural component in blood glucose control in diabetes mellitus. Results 
illustrated in Table 6 show that the some test extracts decreased food intake in 
diabetic animals. Control STZ-induced diabetic rats exhibited hyperphagia by 
comparison with treated diabetic groups and normal animals. These observations were 
consistent with those ofNamkoong, Kim, Jang, Han, Park, Koh, Lee, Kim, Park, Park 
and Lee, (2005). Further studies are needed to confirm this, but we speculate that this 
phenomenon may be mediated, partly, by reduced levels of hormone leptin (Sindelar 
et ai., 1999). Leptin is an adipocyte hormone that regulates reduction of food intake in 
part by inhibiting hypothalamic release of neuropeptide Y (NPY) (Yahya, Xiao, 
Chance, and Sheriff, 2006). The reduced fat stores as a result of excessive lipid 
catabolism to generate energy in the diabetic state, may be responsible for depleted 
leptin levels (Havel, Uriu-Hare, Liu, Stanhope, Stem, Keen and Ahten, 1998), and 
hence hyperphagia in diabetes, via increased expression of hypothalamic NPY. Havel 
et ai., (1998), also observed a decrease in leptinaemia 24 hrs after induction of 
diabetes attributed to changes in glycaemic levels and not due to wasting. 
It is also tempting to speculate that, perhaps, in the present study the extracts could 
have direct inhibitory effects on AMPK activities or could act via inhibition of ghrelin 
activities. Studies have revealed that AMPK plays a pivotal role in the regulation of 
energy whereby its inhibition reduces food intake (Andersson et ai., 2004). AMPK 
acts mainly in the hypothalamus and its actions are partly influenced by ghrelin, a 
stomach derived hormone peptide. Further studies are clearly needed to support these 
speculations. 
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4.3. Renal effects 
In acute renal studies, APE and P AE significantly depressed sodium and potassium 
excretion, and urine flow rates in non-diabetic and STZ-induced diabetic rats (Figures 
12, 13, 14 and 15). Increased sodium retention may suggest increased reabsorption 
probably mediated via activation of Na+, K+-ATPase on the proximal tubular cells. 
About 60% sodium reabsorption occurs in the proximal tubular cells (Nabel, 2003). 
In long term studies, APE was consistently suppressive on electrolyte and urine flow 
rates in non-diabetic and STZ-induced diabetic rats (Figures 18 and 20). These results 
coupled with increased plasma creatinine concentrations (Table 5) may suggest that 
APE compromised renal function in non-diabetic and STZ-induced diabetic rats. 
Significant increase in serum creatinine and urea level is indicative of renal function 
impairment in diabetic animals (Shinde and Goyal, 2003). Moreover, in vitro studies 
demonstrated that APE was significantly cytotoxic to proximal tubular cells despite 
promoting growth in distal cells (Figure 23). In contrast SBE, FTE and P AE did not 
affect electrolyte excretion and urine flow rates in long term studies in non-diabetic 
and STZ-induced diabetic rats. Although SBE and P AE reduced cell viability to renal 
cells in in vitro studies, they reduced plasma creatinine concentrations in in vivo 
studies (Table 5). This suggests that they may possess renoprotective effects. 
Low urinary sodium and fluid excretion rates observed in STZ-induced diabetic 
animals in the present study is evidence of renal derangement 1 week after diabetes 
induction (Figures 20A and 21A). A number of studies have established that STZ-
induced diabetes results in renal derangement leading to fluid and electrolyte retention 
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(Musabayane, Ndhlovu and Balment, 1995). Generally, STZ-induced diabetic animals 
exhibited pronounced antinatriuresis compared with non-diabetic animals. This was 
because in long tenn studies, increased diuresis results in reduced blood volume. This 
modulates sympathetic stimulation of renin and, subsequently, angiotensin II 
production whose effects are to promote sodium and fluid retention (Francois and 
Coffman, 2004). Since aldosterone mediates sodium retention and is produced in the 
presence of angiotensin II, its levels are expected to rise in diabetes mellitus. 
Moreover, hypovoleamia caused by excessive fluid excretion can induce secretion of 
vasopressin (Bunag, Tomita and Sasaki, 1982), to stimulate water retention. Indeed, 
studies have confrrmed that vasopressin levels are elevated in diabetes mellitus 
(Ahloulay, Schmitt, Dechaux and Bankir, 1999). 
Some test extracts demonstrated cytotoxic as well as renoprotective effects in the in 
vivo studies. For example while promoting cell death in LLCPK-l cells (Figure 23B), 
APE demonstrated cell proliferation in MDBK cells (Figure 24A). The cytotoxic 
effects of APE on LLCPK -1 are supported by in vivo findings on plasma urea and 
creatinine after 6 weeks of chronic treatment, which showed an increase in plasma 
creatinine concentrations in non-diabetic rats (Table 5). Other than APE, the present 
findings show that all test extracts reduced plasma levels of both urea and creatinine 
compared with vehicle treated diabetic animals. This finding suggests the test extracts 
under investigation may be renoprotective. 
It is known that weak acidic compounds tend to decrease mitochondrial activity by 
causing mitochondrial depolarization (Ignatius and Claes, 1996). Since, SBE is known 
to contain many acidic compounds (Braca et al., 2003; Somova, Shode and Mipando, 
167 
2004), the decrease in cell viability observed in this study may be due to acidic 
compounds. In the in vivo situation, these acidic compounds may not be significant in 
renal function. Indeed, SBE treatment did not have any significant effect on renal 
fluid and electrolyte handling in non-diabetic and STZ-induced diabetic rats (Figures 
18 and 20). Moreover, SBE decreased plasma creatinine concentrations in in vivo 
studies. 
Our cell culture data clearly support this finding as MIT reduction is increased in the 
presence of FTE, especially at the higher concentration (Figure 25). Our data also 
confirm the lack of toxicity of FTE on renal cells derived from two species, viz 
porcine and bovine. The findings of the present study suggest that FTE is a useful 
agent in increasing glucose uptake by renal cells and glucose studies are needed to 
verify these. Our data indicate that FTE has potential to reduce plasma levels of 
creatinine in patients with diminished renal function and reduce cardiovascular 
complications and renal complications as well. 
In vitro studies indicated reduced cell viability which is suggestive of cytotoxicity of 
test extracts to the cell lines. It is, therefore, interesting that although P AE reduced 
viability of both cell lines (Figure 26), results of in vivo studies demonstrated that 
P AE was not renotoxic as evidenced by reduced plasma concentrations of creatinine, 
in animals chronically treated with P AE (Table 5). Thus, we speculate that P AE may 
contain cytotoxic compounds which caused reduced cell viability in vitro, although 
these effects were inadequate to cause significant injury in in vivo investigations. 
Indeed, some extracts of P americana have been reported to contain bioactive 
compounds that are cytotoxic (Abe et ai. , 2005). The cell culture provided an 
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experimental model to assess cytotoxicity and metabolic activities of test extracts on 
the two cell lines. Initially the MTT [3-( 4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay was used as a measure of cell viability and 
proliferation, with the mitochondrial succinate reductase system being the major 
contributor to MIT reduction (Slater, Sawyer and Straeuli, 1963). However, recent 
evidence shows that most MTT reductions occur extra-mitochondrially with MTT salt 
crossing the intact plasma membrane to be reduced intracellulary (Bermas and 
Dobrucki, 2002). Other investigators have shown that most of the cellular reductions 
of MIT are dependant on microsomal enzymes and not only on succinate 
dehydrogenase (Berridge and Tan, 1993; Berridge, Tan, McCoy and Wang, 1996; 
Mann, Gerstein, Pogue, Bosch and Yusuf, 2001). This microsomal requires NADH 
and NADPH and is not affected by respiratory inhibitors (Berridge and Tan, 1993). 
This clearly indicates that cellular reduction of MIT is related more to the glycolytic 
rate, and thus NADH production, than to respiration, and is therefore primarily a 
measure of the rate of glycolytic NADH production (Bertuzzi, Bensi, Mayer, 
Niebylski, Armario and Gauna, 2003). 
The present study has demonstrated that apart from APE, all the test extracts may 
have cardio-renal protective properties. It is noteworthy however, that the doses of 
test extract used in in vitro studies cannot easily be extrapolated in in vivo studies. 
Liang and Knox, (2000) advised caution when interpreting data from isolated tubular 
cell cultures because during in vivo studies tubular cells are exposed to complex 
neurohormonal microenvironments as well as various biophysical forces that are, to a 
large extent, absent in in vitro settings. 
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4.4. Antihypertensive effects 
Figures 16 and 17 show that acute treatment with group A (APE and SBE) and B 
(FTE and P AE) test extracts reduced mean arterial blood pressure in anaesthetised 
non-diabetic and STZ-induced diabetic rats. There are many factors that could 
suppress elevation of blood pressure. Firstly, the presence of flavonoids in the test 
extracts may playa vasodepressive role by inhibiting effects of angiotensin II. Actis-
Gorretta et al., (2003), showed that flavonoids inhibited angiotensin I converting 
enzyme effects, thereby preventing formation of angiotensin I to angiotensin II. 
Interaction of Angiotensin II with its AT I-receptors mediates vasoconstriction and 
inactivation of a vasodilator, bradykinin (Coppey et al., 2006). Furthermore, 
flavonoids impair vascular smooth muscle cell growth which is necessary for 
atherogenesis (Moon et at., 2003), and subsequently, hypertension and other 
cardiovascular diseases. Studies by Ajay, Achike, Mustafa and Mustafa, (2006), 
showed that quercetin, a flavonoid, highly prevalent in human diet improved 
vasorelaxation in isolated rat arterioles from animals with established diabetes. 
According to Ajay et ai., (2006), the vasorelaxant effects of the flavonoid were due to 
their antioxidant effects. Morello, Vellecco, Alfieri, Mascolo and Cicala, (2006), 
showed that galangin, a flavonoid demonstrated vasorelaxant properties on isolated 
rat thoracic artery whose effects were mediated via nitric oxide dependent and 
independent mechanisms. Indeed, antihypertensive effects of H hemerocallidea have 
been attributed to reduction of peripheral resistance (Ojewole, Kamadyaapa and 
Musabayane, 2006). As aforementioned P. americana has been reported to mediate 
vasodilation via inhibition of calcium mobilisation through voltage dependent 
channels (Owolabi et ai., 2005). 
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As pointed out by Hall, (2003), the kidney function is particularly crucial in long term 
regulation of hypertension, hence the observed acute vasodepressive effects of test 
extracts suggest significant mediation via reduction of peripheral resistance, probably 
by vasodilation ofthe resistance vessels, in spite of acute sodium retention. Song et ai, 
(2004), observed that administration of rosiglitazone, a thiazolidinedione, resulted in 
blood pressure decrease. However, this was accompanied with fluid and electrolyte 
retention. Since, antinatriuresis and anti diuresis are frequently associated with 
hypertension, Song, et ai., (2004), attributed vasodepressive effects of rosiglitazone, 
partly to vasodilation. The vasodepressive property of rosiglitazone was reported in 
earlier studies by Komers and Vrana, (1998). 
P. americana has been reported to mediate vasodilation via inhibition of calcium 
mobilisation through voltage dependent channels (Owolabi et ai., 2005). 
Long term antihypertensive effects of test extracts were significant in STZ-induced 
diabetic rats (Table 4). Since the test extracts demonstrated potential to lower blood 
glucose concentrations, the long term antihypertensive effects of extracts maybe 
secondary to long term hypoglycaemic effects of test extracts. Studies have shown 
that efficient control of blood glucose is associated with a reduction in mean arterial 
pressure (Richards, Donnelly, Nicholls, Ikram, Hamilton and Espiner, 1989). 
Chronic hyperglycaemia evokes an increase in intracellular calcium concentration 
which increases vessel smooth muscle contractions and therefore, peripheral vascular 
resistance. Furthermore, increased glycaemic levels activate the sodium glucose co-
transporters in the kidney tubules. These transporters mediate active glucose uptake 
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from blood while reabsorbing sodium (Sowers and Epstein 1995). An increase in 
blood sodium levels mediates water retention which results in increase in blood 
volume and consequently, hypertension. According to Coppey et aZ., (2006), elevated 
glycaemia evokes increases in tissue angiotensin II, which mediates oxidative stress, 
endothelial insult, and disease pathology including vasoconstriction, thrombosis, 
inflammation, and vascular remodelling. 
As in diabetes, reactive species generation is an important factor in the aetiology of 
hypertension (Vasdev et af., 2002). Since presence of flavonoids, widely believed to 
possess antioxidant properties, are present in test extracts, long term control of blood 
pressure can be partly attributed to control of reactive species generation. Moreover 
Adeboye and colleagues, (1999), reported that P. americana leaf methanolic extract 
demonstrated hypotensive effects in Sprague-Dawley rats. 
Hyperglycaemia stimulates increased tissue production of angiotensin II, which 
mediates endothelial damage and vasoconstriction (Coppey, Davidson, Rinehart, 
Gellet, Oltman, Lund, and Y orek, 2006). The increase in blood pressure in the 
untreated diabetic animals might be due to increase in peripheral vasoconstriction as a 
result of renin-induced angiotensin II production. Involvement of angiotensin II in 
hypertension in diabetes was supported by findings by Brands and Cloud, (2003), who 
stated that its increase early in diabetes is partly due to renin whose secretion is 
mediated by glucose through changes in nephron sodium chloride delivery and partly 
through osmotic induced diuresis. Indeed, STZ-induced diabetic rats exhibited a 
reduced urinary sodium excretion rate (Figures 20A and 21A) in comparison non-
diabetic rats (Figures 18A and 19A). However, this was not reflected in plasma 
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concentrations of sodium and potassium (Table 5). Long term hypertension in STZ-
induced diabetes observed in the present studies is consistent with findings by Hakim 
and Goya, 2000, Majithiya and Balaraman, 2006, Haidara et al., 2004, and Ishihara et 
ai., 2000. Although animals exhibited severe diuresis and therefore, reduced blood 
volume, blood pressure increases have been observed even during diuretic conditions 
(Brands and Fitzgerald, 2001). However, hypertension in experimental STZ-diabetes 
is not a common occurrence (De Angelis et al. 2000; Maeda et ai., 1995; Fazan et al., 
1997). De Angelis and others, (2000) pointed out that the decline in blood pressure in 
STZ diabetes is attributed to reduced blood volume as a result of hyperglycaemia-
induced diuresis while low heart rates are due to modifications in the functions of the 
sinoatrial node. Nonetheless, a number of factors favour development of hypertension 
in experimental STZ-diabetes. Firstly, hyperglycaemia induced - production of 
reactive species generation compromise bioavailability of nitric oxide, thereby 
depriving the vascular system of endogenous endothelium dependent relaxation. 
Secondly, hyperglycaemia mediates release of renin leading to subsequent production 
of angiotensin II which mediates vasoconstriction and therefore increases vascular 
resistance. Moreover, hypovoleamia caused by excessive fluid excretion can induce 





Hypoxis hemerocallidea (APE), Sclerocarya birrea (SBE), Ficus thonningii (FTE) and 
Persea americana (PAE) demonstrated hypoglycaemic effects substantiating their 
folkloric usage of these medicinal plants in the management and treatment of diabetes 
mellitus and its complications. The hypoglycaemic effects of the plant extracts are 
probably mediated via mechanisms that are independent of insulin release. The present 
study established hepatic conversion of blood glucose into glycogen as one of the 
mechanisms of hypoglycaemic effects. 
Furthermore all test extracts exhibited vasodepressive effects. It is suggested that 
mechanisms of hypotensive effects of the group A (APE and SBE) and B (FTE and P AE) 
extracts are through reduction of peripheral resistance. This suggests that in addition to 
ameliorating hyperglycaemia, the extracts have potential to manage hypertension, a 
cardiovascular complication that frequently occurs as a result of diabetes mellitus. 
Although Hypoxis hemerocallidea was hypogJycaemic and hypotensive, it demonstrated 
toxic properties to the kidney function. However, Sclerocarya birrea, Ficus thonningii 
and Persea americana demonstrated cardio-renoprotective properties, in addition to 
hypoglycaemic effects. 
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5.1. Shortfalls of the present study 
The present study had some limitations that created obstacles in unravelling the 
mechanisms of some observed biological effects of plant extracts. The present study did 
not monitor reactive oxygen species generation or levels in tissues, glycosylated 
haemoglobin, lipidaemia, enzymes of glucose homeostasis and glucosuric levels. Some 
plant extracts mediate their antihyperglycaemic effects via inhibition of renal glucose 
reabsorption in the kidney. Hence such mechanisms can only be established if urine 
glucose is monitored. Therefore, glucosuria should have been monitored, although 
monitoring of urine glucose levels is not usually recommended for glycaemic control. 
Renal hormones such as aldosterone and vasopressin should have been measured to 
determine the influence of test extracts on these. The present study did not assess 
presence of bioactive compounds in test extracts with known biological therapeutic 
effects e.g. flavonoids. 
5.2. Recommendations for future studies 
The recent study established that glycogen synthesis is the one of the mechanisms of the 
hypoglycaemic effects of the test extracts under investigation. Future studies should 
investigate mechanism(s) by which plants mediate hepatic glycogen storage. Hepatic 
glucokinase and other enzymes involved in glycogen synthesis should be measured to 
determine the effects of test extracts on these. 
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Further studies need to be carried out to isolate and investigate the individual active 
principles. Some medicinal plants are known to possess both hyper- and hypoglycaemic 
constituents. Therefore, isolation of the individual compounds would optimize the 
therapeutic effects of the plant. 
Food intake is an important component in blood glucose control. Future studies need to 
be carried out to establish the cause of reduced food intake after administration of test 
extracts in the STZ-induced diabetic animals. Future studies should investigate effects of 
test extracts on ghrelin and AMPK. 
Currently, studies are being undertaken to establish specific mechanisms of 
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Previous obsemIIioas jJIdicate tbII Fials IItcnItiItp 
(Blume) [M<nceae) IIeID-bU em.:u may be UIIIful iD Ibe aID-
troI of diabetes mrl6IUS. AccordiD&lY. we iD~ iD lOme 
experimeoIal8llilDlll J*ldiama Ibe dl'CCII of F. rIfoNtiItp IlCm-
t.k etIumolic extract (PJ"E) 011 ra.I aod c:MIiovascul. fuDc-
tioas as complic.aions of cUbecea. er.t ~ toknoce 1l:1li 
were c:oocb:Ied iD sepuate J10UlII « ooa4abdic IDII S'IZ-
IIeaItJd dilbetic rars ai'IQI atucoee toed (0.86 g.q-'. p.o.) after 
1&-11 fast, followed by nriou Pm doee$ (60. 120. lOCI lAO 
mg,q-'). Raa IIaled wilb deioaized W1ItCr (3 ~ p.o.). (W 
metformin (SOO m,.k,-J p.o.) KIIed as ~ ... aaIed pol-
ilive 00IIIr0Is, reapectiftly. Blood gIucoIe _ moaiUlRlCl • IS-
min u.rv.ts for abe tint bclur. I0Il bourIy tbaafter for 3 h. 
Acut.c dfCCII 01 FIE 011 kidaey functioo ad _1ItICriII blood 
pressure (MAP) weft invesQpted in ~ rib cbal-
Jeuaed wid! hypocooic aaI.iDe lifter , 3.S-b eqaih1nliola for 4 b of 
1 b COIDOI, 1.5 h IR:IImeD., lOCI 1.5 b recovety paioda. Pm was 
lidded to die iafuufe cbiDa abe II'eIIImIeU period. CIInlaic dI'ect5 
01 FIE were studied iD iDdi¥idDally awed rib IreMed dIily .nib 
FJ'E (120 mg,q-J. p.o.) for five weeP. ~ty ofPI'E ... 
.....,.. by cly&-ftIdIctioa c::oIorimettic (M'IT) MIl)' 011 MDBK 
_ lLCH{1 kidDey ce1lliDetexpoecd for 24 b, 48 b,...t 72 b to 
Il'ICIed CODCeIIlIIl:iOlll 01 abe em.:t. MYGCIIdiII CiCIIIIK'tiJe per-
formance _ evaluated 011 ra iJobtcd IIrialIlJlllclc Itripa. PrE. 
Addreu~ to ProfeuorC.T. M"'~ Dis-
cipline of H_ PllyaiolOl)'. WaMlIe c-pua, SdIooI of 
Medical ScieDces. UDi'lUlity of KwaZuIu-Nml. PriVite Baa 
X54OO1. o.ut. 4000. South Africa; Tel.: (27) (31) 260 797S; 
Po: (27) (31) 260 7132; E-auil: ~yuec(ituba.lC.ZI, 
ClllllSllbayaneftbobMil.com 
like mdfonnin, ~ blood glucose levels in IIOD-dilbetic: 
aDd S'J'Z.diIbdic lib. Both acure lOCI c:hroaic FIE treMIIIcID 
cId DOt affect Ieml ftmc:tioa. In ¥ibn ICIIdies cIemoasInttd IbM 
FJ'E iDcnued MDBK ce1l meIIboIic ICIivity by III .-. of 
IS .. (72 b). aDd 1LC1'K1 JIIirrond abe CDIIIroIs. Acut.c iDnve-
oous infusioa of P'f'2 ftlduoed abe MAP from 119 ± 1 mmHa to 
98 ± 4 IIIIIIfII. 1be MAP aIJo .,. ftIIb:ed IDoupouldle five-
week ~ IDly paiod. PTE Il1o pn:dJced CiouceutllDo .... 
cIrperdeut DepIive iDOtropic aDd caClDUClOpic eIfecu 011 ra 
~ eIcaricalIy 00_ ldt-. IIIIl .... ,.-0JUIIy baMias 
riabt-. MriIlIllUde)llel*lDoas. Our exptriIDaJIIl fiDdiDp IIIC-
pst IbM FI'£ poaesaea reno- IDd anti~protective effects in 
diabetes mellitus. 
Keywords Fiau thotrrtiIItii. edJaootic extract, diabetes 
mellitus. rmalllJd awdiovlSCUlar effects 
1NTR0DUCl10N 
We haw: peviously reported thai Ficus tlwllllingii 
(Blume) [Monceae) stem-blrt edaanolic extnlCt reduces 
blood &I\JC01e i. DOft-diabetic and diabetic l'IIS after five 
weeks elpOlllre.!I) Because diabeles is often associated 
willi impaired lcidney function and cardiovascular disor-
ders. 8ppI'ClIIriae ,oats in the cootrol of diabetes mellitus 
usin, F. thonninlii should iDcludc DOt only replatiDg 
blood glUCOlie, but also the prevention or alJeviaIioo of 
these compIic:Irioos. Ac:cordin&ly. the CUReIIt study was 
desipcd to establish in 5(JIIIe experimental ..um.I para-
digms lbe effccts of F. tltorutingii bark ethanolic extracts 
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(FIE) not only on blood sJucosc, but also renal and CIi'-
diovascub£ fuoctions. Thus. die maiD purpoee of the 
present study was to investigate the effects of abort-tam 
(acute) and long-lenD (cbroni<:) Idminislralion of FIE on 
renal fluid and electrolyte baDdling, IS wen as on blood 
IRSSW'C in male Wisw Rl5. Available evidence lU"eats 
chat some berbel exlndS may interfere with the c:ooceD-
trating and diluting mec:buisms of tububIr ttIDSpOrt pr0-
cesses ill the proximal tubule and di$t.Il tubule cells and/or 
on other protein components of tubular cell mem-
bnDes.I2,3) Indeed. previous studies in ow lIixntories 
show that some crude plaut extracts impair !he reaal han-
dling of fluid and eJectrolytes.I.) Thus, we furtha' specu-
lated that FIE iDtJueaces tubuJ. ~oa and 
secretion by altering 1Ubular epitbelial cells' viability. 
Therefore, the second objective was to assess the effects of 
FIE on cell viability 00 previously validaled porc:iDe prox-
imal tubule and bovine distal1Ubule cellliDes. Cell culture 
systems provide • good model for tile evallIIIioD of cyt0-
toxicity of vuious compounds. We, therefore. employed 
!he exteusively \lied in vitro cell culture tecImiques of the 
proximal (UC-PKI) IDd distal tubule (MDBK.) cellslS-7) 
to SIUdy Fl'B-iDduced reaal effcets. The teclmique mimics 
!he in vivo stale, as these cell !iDes maintain similar bio-
cbcmicaI function of levels of marbr enzymes exhibited 
by freshly isolated cells.11} We also assessed !he effet;ts of 
FIE on JlomeruIar fillralioD rate (GfR), all indiCltlX" of 
renal tubular function.!9·IO) Pmthennore. the study iovesti-
gared the influence of FIE on blood pressure, a panmeta' 
associattld with the deterioration of ItidDey fuoctioo in dia-
belie palieots.lll) In an effort to shed mere light CIa the 
plausible mec:baaism(s) throusb wlUch FIE may affect 
blood pressure, we have also investipud the effects of 
FIE on myocardial conlrllCtility in vitro. 
MA TERJAlS AND METIlODS 
Prep.ration 01 Plant utract 
Pieces of FiclU thoMiItgii stem-berks wa'e identified 
by Prof. H. BaijDllh, the fOl'1Det Oticf TaxOllOlDisllCwa-
tor" of the University of Durban-Westville's Deputmcnt of 
Botany. A voucher spccimen of the plaut has beeo depos-
ited in the University's Botany Departmental Habarium. 
The acm-t.rb were air-dried 111 room temper1llUn: IOd 
milled into fine powcia' with • CCIIIIIlaCiai blender. The 
powdered stem-t.rt wasllllllenled in 9S'll dbaDol foc 24 h 
(with occasional sbakina) aod filta'ed. The fillnlte was 
concentrated UDder Rduced pressure in a lOUry ev~ 
at 60 ± I "C. The crude, powdery FiclU tlwMingii stem-
bark cthaDoIic extnICt (FIE) was used throughout this 
study without funhea- purificatioa. 
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Ani.mals 
Male W'ISW rats (250-300 g body weight) maintained 
under IaborlIDy c:ooctitions of taDptnIUrC, humidity, and 
12 h ligbtI12 b dark rqime at the Biomedic:al Resource 
Unit, University of KwaZulu-NataI, were used. The rats 
wa'e ~ to baCh food (Epol-diel 4700, Epot South 
Africa) and wiler ad libitum. Etbic:al clearance was 
obcained for this study from the Univasity of KwaZulu-
Natal's Ethics c:ommittec:. 
Experimental Desiga 
Oral glucose tolerance test (OOTn IhIdies were 
carried out in male, noo-diabetic, aad stJeptoUlIOCin 
(~ diabetic W'JStar rats (250-300 g body 
weight). In vivo studies 00 reaal function and blood pres-
sure wa'e c:anied out in non-diabetic and sttepWzococin 
(STZ)-induc:ed diabetic rats, while the in vitro effects of 
the plaat's extract wa'e cooduaed 00 kidaey c:eIJ lines 
lLC-PKl and MDBK. Effects of FIE 011 myocardial coo-
tractile performaoce wae evaiualtd 00 rat isolated attial 
musde SIrips. 
Ioduc:tion or Diabetes Mellitus 
Diabetes mellitus was induc:ed in !he diabetic group of 
rats by inlrlpCrit.oneal injections of S1Z (60 mg.q- I) in 
cieraae bufi'tt, pH 6.3. Vc:hicle (cilnM bufi'tt}-treated ani-
mals actrJd as c:ootroIs. Animals daat exhibited glucosuria 
afttt 24 h, tested by urine test SIrips (Rapidmed I>iapos-
tics, Saadtoo, South Africa), wa'e c:oasidemI dillbetic. 
Plasma glucose c:onceotratioo of 25 mmolL- 1 measured 
after one week was considered as a stable diabetic state 
before our experiJDental procedures. 
Series 1: OGIT 
The rIllS used were divided into the foUowing groups 
for OG'IT: non-diabetic: CODU'OI, II'ealed noa-diabetic::, 
c:ootroI S'J'Z.tteatcd dUIbeIic, aod trc:aIed STZ-diabetic: rII1S 
(a = 6 in each group). Rats tteatcd with deionized water 
served (3 mL.kg-I, p.o.) served as coauoJ .mmaIs. All of 
the IIlima1s were St.llrVed for 18 h before being orally 
acared with Jluc:oee (0.86 g.kg-I, body weisbt, p.o.), fol-
lowed by FIE at various doses (60. 120, aod 240 mg.q- I, 
p.o.). To establish wbethtr FIE poueaes pbIrmaco1oai-
c:al activities c:ompanbIe 10 syatbdic: hYJKIIIycemic: drugs 
already in use. studies were CODduc:ted in sepIrate groups 
of non-diabetic: aod STZ-dilbetic rats onJly treated with 
Pbytomedicine 391 
medonnin (500 mg.kg- I, p.o.). Blood samples W'eI'e 001-
lected from the tail veins of the animals II is-min intervals 
for the first hour, aDd hourly tbereaftI:r for the subsequent 
3 b for glucose measwements using BayC'Z's gluoomaer 
Elite- (Elite (Pty) Ltd, Health Care DivisiOll, South Africa). 
Series 2: Reoal Function 
Acute Studies 
Male Wistar rats were divided into groups of 
untrealed control and treated rats (n .. 6 ill each group). 
Rats were uaestbetiz.cd by an iatroperitonea1 injection of 
Trapanal (sodium s- ethyl-(l-metbylbutyl).2-thioblrbitu-
rate, Byk Guldea. Koostaoz. Oamany) at a dose of 
0.11 g.kg-I and ttacbeocomiz.ed to maintain clear airway 
CDIry. The rightju,war vein was cannulated with polyeth-
ylene tubing (iel. 0.86 mm; o.d 1.21 DUll, Portex, Hytbe, 
Kent, UK) to allow inttaveaous infusioo of o.ern M NaCl. 
The urinary b\addC'Z of eacb rat was also cannuliled with 
similar calibre polyetbeoe tu.bing via an incision in !he 
abdominal wall The body tempenture of each mimal was 
maintained .. 37 t IOC with a heated table. 
The cootrol group of animals (n = 6) was placed on a 
continuous infusion of OJJ77 M NaCl at 9 mL·b - I (Harv.-d 
syringe infusion Pump 22). Following an initial equilibra-
tion period of 3.5 h, eight consecutive uriBe collections 
were made iDlO pre-weiJbod plastic vials at »miD inter-
vals OVC'Z !he subsequent 4 h for measurements of urine 
flow and Na+ and r excretion rates. 1be control group of 
rats was designed to cbcck the scabiJity of mW function. 
Treated Group 
Reual effects of" the crude plant's extract WI}:;) wae 
studied in a group of rats followillg a 3.5 b cquiliInboa 
period. FIE soIuboo was pIqIIII'e:d by usiD8 a modified 
mecbod that bas been previously deacribed. 112.131 The extract 
was fresbly dissolved in diJDedIyI sulfoxide (OMS(), 2 ml) 
and IIOIlD.IIl saline (19 ml) before use in eacb cae. Urine 
samples were coIlecIed fer 1 h (control period) fer !Ile8SUIe-
meats of urine flow IIId Na+ aDd r ex.<:ICCioa nile$, foIJow-
ing wbic:h !be exnact solution was iofused III 0.06 ~·min-I 
for 1.5 h (II'eatmeIlt period). resultiDg in • 10Cal doee at 
18 g.kg-I (fer a 3OO-g fIl). The animals wae dJeD switched 
back to the~ alooe for the _t 1.5 h (~ period). 
Blood Prasun MQSW"eIDeDts 
Test groups of rats Were surgically prepIftd as 
....... ,....;Jv.,.,I F", tN ftIOft.1 .,,,A • .co • • ~ th.t _ .............. i ....... 
cannula (Portell, i.d. 0.86 mm; o.d. 1.27 mm) was also 
iDserttJd inro the left oommon carotid artery to pemtit die 
RCOrding of mean arterial blood pressure at 3O-mio inter-
vals (Statham ML T 0380, Ad Instruments, compatible 
with the PowC'ZLab System ML41~, Australia). 
Chronic Studies 
Wistar rats (250-300 g body weight) were housed 
individually at die Biomedical Resource Unit. University 
of KwaZulu-Natal, in Makrolon polyc:arbonate metabolic 
cages (TecJmiplats, South Africa) that were cleaaed 
daily. AU animals were maintained on a 12 h darkIlight 
cycle and allowed free access to water and food (£pol-
diet 4700, Epol, South Africa). In those animals in whicb 
the effects of PTE were investigated, !he rats were 
treated with PTE (120 mg.k,!, p.o.) daily for five weeks 
at 09h00. Control rats were siDtilarly treated with dis-
tilled water (3 mL.q-!). Urine volume and total urinary 
outputs of Na+ and r were detennined from 24 h sam-
ples for all groups. 
Blood Presaare Me8SURIIIeIlts 
Mean arterial blood pressure (MAP) was monilOred 
every third consecutive day for five weeks at O9bOO using 
DOll-invasive tail cuff method with photoelectric sensors 
(DTC Model 31 Computftiz.ed Blood Pressure Mooitor, 
Life Sciences, Woodlud Hills, California, USA). The unit 
worts with nTC hardWlR system to ~ blood pres-
sure IIId heart rate in cooscioos rats. The aaimals bad been 
warmed in 811 eaclosed chamber (llTC Model 303ac Ani-
mal Test Ownber, nTC Life Scieoces, Woodland Hills, 
California. USA) for 30 min • ± 3O"C before caking BP 
readings. 
TermiDal Studies 
At the end of the five-week plants' extnICts treat-
ment period, blood glucose was measuml from the tail 
veins of all groups of DOD-fasted animals using Bayer's 
&Iucometer EliIC- (Elite (Ply) LId, Health Care Divi-
sion, South Africa). Blood samples were also collected 
from all groups of aaimals by cardi.: puncture into indi-
vidual pre-coolcd bepmnized containers. Separated 
p1uma was analyzed for Na+, K+, creatinine, and urea 
cooccnlrations. Blood for insulin was coUected into 
plain tu.bes, and the separated serum was stORd i8 a Bio 
Ultra freezer (Malltinckrodt, Ohio, USA) at -70"<: until 
.0'C'." .d 
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Analytical Methods 
Measurement of ElectrolyteS, Insulin, and Glomerular 
Filtration Rate 
Urine volume was detamiDed sravimetticaUy. Na+ 
and K+ concentratiOllS wen detmnined by ion activity 
using the Beckman Coulter (SyocbroD LX20 Clinical 
Systems. FuI1ertoa, California, USA). Urea and creaciDine 
analyses wen perfonned using the Beckman Coolta" 
instrument. CreatioiDe eatimalioo employed the reactioo 
of crealinine and sodium picrate to form aatiDine picrate. 
Urea esUmatioo employed 1be bydrolyUc; depadatioo of 
urea in the pre&eDCe of urease. The methods used mtgeIIt 
DIS &om Beckman Coultu, 1Jeland, Inc., and measured 
using Beckman Coultu (Syocbroo LX20 Clinical Systems. 
FulIatoo, California, USA). Glomerular filtration rate 
(GFR). as assessed by aeaainine clearaoee, was calculated 
from measurements of uriJwy aad plasma c:oocentralions 
of creatiDiDe aDd uriPe flow rate in the fifth week. 
Plasma insulin concenlnltioos were measured by Ccat-
A-CCUOt procedure usiq a tit from DiagDo6tic Products 
Corporation, Los Angele$, USA. This is a solid-pbasc radio-
immunoassay procedure besed 00 insuJin.specific anlibody 
immobilized to the wall of a polypropyleue tube. The Iowa-
limit of detcctioo was SS PS-JDI. - 1. 1Dter- _ iDtra-asaay 
coefficients of variatioo were 8.1 % (n = 20) aDd 8.3% 
(D = 20), respectively. 
Series 3: Cell Culture Studies 
UC-PKI and MDBK cells were grown aDd main-
tained at 37"C in Eagle's Minimum Essential Medium 
(EMEM) (cootaiui.oaO.1 DIM Hepes buffer) lUppIemented 
with S% beat inactivated foetal calf sma, I ~ L-
glutamine, aDd 1% peuslRp-tungizooe [complete cullUre 
medium (CCM)J (Delta Biopoduct.s. South Africa). Oooe 
the cells reached COIIftuenoe, they were ddacbed from the 
culture flask (7S cm2) with O.02S~ (wlv) trypsin IIJd 
resuspended in CCM. Cell Viability was detennined in the 
presence of 0.2% (w/v) uypan blue in a haemocytometer. 
A 200-J.Il aliquot of the ceD suspeasiOD (1.5 x 106 cells) 
was transferred into sepII1IIe 96-wd1 microcitu pIaIes 
(Greiner Bio-ooe GmbH, Germany). 'IbcRaftcr, the via-
bility of cells incubated at 37"C for 24, 36, aJd 72 hours. 
cootaining various CODoeIIInIIions of FIE in separare 
wells, was assessed (0, 100, 200, 400, 600, 800, IIJd 
lOOOJ.ll mL- I , n = 6 for each dilUlioo). 1be wells were 
aspirated after each incub.don IIJd wuhcd with Hank's 
baJanad salt solution (HBSS). All superDataats were 
disc.dcd. 1be cells were resuspmded in 100 J.ll CCM 
containing 10 J.ll of M'IT (3-(4,5-dimelhyltlUazol-2-yl)-
2,5-diphenyltetrazolium bromide) (i.e., 5mg.mr' MIT 
salt in HBSS, Calbiocbem, Darmstadt. Gamany) IIJd 
incubated for " b at 37CC. Aftu 4 b, the plates were centri-
fuged (20 min. 2000 ipIIllt room temperatUre). The super-
natant was laDoved, aad any resulting formazan crystals 
wae then solubilized with 100 111 dimedly\sulphoxide 
(DMSO). After ODe boor, the optical density was detrnnined 
spectrophotometrically using an ELISA plate reader 
(BiG-TeAt Instrumeols) at S9S nm aad a reference wave-
IeDgth of 6SS om. Absorbaoce was expressed as percentage 
cleavage activity. Percentage ceD viability was calculared 
as the mean absorbece of control ceUsimean absorbance 
of treatr.d cells. 
Series 4: Isolated Atrial Muscle Strips 
In order to throw some ligilt on the plausible mecba-
oism(s) by which FIE may influeoce blood pressure. we 
studied the effects of the extract OIl rat isoJafcd atrial muscle 
strips. 1be W'1Star I1IfS used wen sacrific:ed by stunning and 
exsanguinItioo. The left and riJk atrial muscles of the ani-
mals were isoIafed and IDOUD1cd a dcsc:ribcd by 0jew01e,u4) 
The isolated left atrium of each rat was impaled OIl a thin 
plalinum wire electrode and suspended under an applied 
resting tensioo of 1.0 g in a 300ml Ugo Basile organ-bath 
containing Krebs-Henseleit physiological solution (of 
composition. in mmoIIL NaCI, 118; KO. 4.7; NaH~4' 
1.28; N~, 25.0; MgCI2, 1.2; ~, 2.52; aDd 
glucose. S.5S. pH adjusted to 7.4) maintained at 34 ± tOC 
and continuously aerated with carbogeo (9S~ O2 + S~ 
C~ gu mixture). Each left atrial muscle prqlIIratioIl was 
eleclricalJy driven with square wave pulses of 5 msec 
dunboo at a fiequeocy of 3 Hz IIJd supnmaximal volt-
ages of 5-10 volts, delivered by an SRI stimulator. The 
spontaneously beating rigilt atrium of the animal was also 
set up unda' the same physiological, experimeDtai coodi-
tions. Two isolated dectricalIy drivCD left atrial muscle 
strips IIJd two isolated spontaneously-beating rigilt atrial 
muscle preparations, were always set up at a time (ODe 
used as Ihe test and the other as the cootrol) to allow for 
changes in the aIriaI muscle sensitivity. The atrial muscle 
prepar1Iboos were left to equilibrate for 4s-!JO min (during 
which time the bathing physiological solution was 
cban&ed every 15 min) before they wen cballeaged with 
FfE OF any of the reference drop used. The test IIbial 
muscle JlRl*8lions were tteared with scqueatialIy 
applied, Jl1Ided ccooenlratioos of the extract andIOF refer-
c:ooe drup IIICd, wbiIe the cootrol atrial muscle strips wen 
Ireafed with volumes of disIiIled water equivaleol to the vol-
umes of bath-applied FfE (S-80 g.mL -I). The electrically 
provoked IIJd spontaneous cootractioos of the atrial mus-
cles, as well as the FIE- (1IJd refereace dru,}-iDduced 
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responses of the aDial muscle preparaboos. were ~ 
isomeUically by meIIIIS of Ugo Basile fon;:c-dispIaccmcDt 
ttaDSducers aad pcD-writiDg 'Gemini' recorders (model 
7070). 
DATA PRESENTATION 
All daIa are expressed as meIIIIS DCIDdIrd aror of 
means (SEM). Cell viability was expressed as a pcrccol-
age relative to COIltrol cells DOt exposed to any of the test 
compouuds. Data obtained from test rat isolared atria 
treated with FIB 8l00e, as well as those obIaincd from 
deionized water-treated control alrial Slrips. were pooled 
aad compared wilb thOle of rdereoce drup. A stIIistical 
comparison of the diff~ betweca FI'E aad respective 
controls was performed with GnpbPad IDSw Softwve 
(version 3.00, GrapbPad Soft~ San Die&o, Califomia, 
USA) using one-way .... ysis of variaDcc (ANOV A; 9SCfJ 
coofidcuce intcrv81), followed by Tuby-KnDa multiple 




Figure lA ~ the 0GTr responses ill ICUtcly 
treated non-diabetic DIS with respective cootrol animals. 
Oral administration of vlrious doses of FI'E (60, 120. aad 
lAO mg.q-I) dec:eased the blood glucose ccoc:eotrItiODs 
ill I dosc-dcpcudcnt IIUIIUICI". with all dOIC'4 cxating maxi-
mum effects aftec 60 miD. The hypogl~ effect of 
FIB was still sipificant by the end of the 4 b experimen-
t8l period. A simibr paaem. of bypoglycemic effects was 
obscrvc:d with metformin. Untreated coolrOl IlOIl-CUbdic 
nItS exhibited sipifiCllldy hish plasma sIacose OODCeDtra-
lions by COIDJ*ison with treated uimals. The plasma glu-
cose cooccalrlllioos of the coottol, IlOII-di8bccic; DIS 
iDcrea&cd 10 6.8 ± 0.3 mmoIL - I by 30 miD from a bueline 
value of 4.2 ± 0.1 mmolr1 before dowly decliDing to 4.3 ± 
0.1 mmolL - I (a = 6) after 4h. a v8luc that was Iipifi-
candy deVIled wilen c:ot:npmd to animals adminiSbnd 
the highest dose of FfE • the COITCSpOIIdin, period. 
Similarly, oral .tmiDi&ttatioo of VlIrioua doses of FIE 
(6Q, 120. aad 1M) mg.q-I) dec:eased blood glUCOlC 
CODCCIItralioos of S1Z-treated diabetic nItS ill a dosc-
dcpendcut IIWIIICI" by 4~ miD IIDIil the end of Ibc .. h 
experimeot8l period (sec Fip"e 18). The sJuc<- COIICCIl-
tntions of S1Z-tnIUed diabetic control animals orally 
10eded wilb g1UC01e did DOt significandy dcclioc by Ibc 
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Fipn 1. CooIj*i1Oll ~ OG'IT IMpCDeS in sepu1Ile groups 
of (A) DOIMIi.tJdic IIId (8) (ST.Z}Uc:IIcd di.IbeCic 
fits treIIId with paded doles ~ Pm witb COIIIrOI aaimaIs 
ImIted with deiaoized WIfa' or poIilive coaIrOIs IreIIed willi 
mecformia. Values 1ft praaIIed 18 _. aad w:rtical las 
iDdicaIe SE of ~ (D • 6 in each 8JOUII&). .p < 0.01 by 
comparisoo willi CXJIIlroI mimals. 
marbd reductions ill blood glucose conceotrabons by 
4S miD UDti1 the cod of the 4-h expcrimeotal period. 
ID those 8Ilimals ill which Fl"E was chrooically 
administered (120 mg.q-I, p.o.) dIily for five wecb • 
O9hOO, !be mean plasma coocentrabon of glucose was sig-
DificlDdy dec:eased ill noo-diabctic and STZ-induccd dia-
betic rats by !be end of the experimental period in 
comparisoo with respective cootrol IDimals at the ~ 
spooding time (sec Table 1). 
ReaaI FDDCtioD Tests 
Urine flow aad Na+ excretion rates ranged from 9 to 
10 mLh-laad 619 to 660 11moUel, respccbve1y, ill vdUcle-
iIIfused control aaimals duriDg the 4 h post-equilibration 
period, v81ues that compced with the iafusion rate 
(9 mL.b- 1 and 693 jUDol.h-l • respectively). Je+ excretion 
rue was 8lso scable Ibroughout the post-cquilibration 
period, ranging from 226 to 2.S6 pmol.h-I• No sipificaut 
changes in reoal fluid flow and electrolyte excretion rates 
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Na+(mmol) 14l±l 143 :t2 14l± 1 143:t2 
K+ (1lUDOl) 3.62:t0.34 3.2UO.13 3.762:0.21 3.10:t0.Ol 
Urea(mmoI) 1S±1 14±2 33:t4 3I:t5 
CraIi.aioe (pmol) 91U as:t2- 102:14 94±7-
Gluc:oee (mmol) 7.7±0.2 5.5:t0 .• - 36.6:t0.3 28.0:10.5-
GFR (ml.miD-1) 2.64±0.02 2.9UO.03 0.7:1:0.2 1.4:10.3-
-p < 0.01 by comparison with respective c:ootrol.umals. 
were observed in animals that were acutely created with 
FIE. Compared with the CODtrol rats, the FTB-treatcd 
animals attained stable Na+ excretion and urine flow rate, 
which approximated the infusion rates throughout the 
experimental period. Similarly, the melD weekly urine 
volume aad the uriDary Na+ and K+ outputs were not sig-
nificantly different between animals chroAi<:ally treated 
with FI'E (120 mg.tg- I, p.o.), and IlJItreatcd rats. Uri-
nary creatinine and urea outputs were DOt significantly 
different betweell the c:oatrol and treated rats throughout 
the five-week experimental period. However, FI'E treat-
ment significantly reduc:cd (p < 0.01) plasma creatinine 
concentration, unlilte plasma urea conceDtration that 
was DOt altered (see Table 1). By the end of the five-
week period, FI'E administration signific:apUy elevated 
(p < 0.01) the GFR value in STZ-trealed diabebc rats, 
but the increase in non-diabetic rats did DOt achieve sta-
tistical significaac:e. 
Hemodynamic Studies 
Acute infusion of hypotollic saline to control animals 
did not show any significant variations in the mean Ilterial 
blood pressure throughout the 4-b post~lIilibration 
period. However, acute inttavenous infusion of FIE at 
120 J.Lg.h- t foe 1.5 b reduced the mean arterial blood 
pressure from a mean pl'C-lrealIDeIJt value of 119 ± 1 
mmHg to 98 ± 4 mmHg (n = 6) by the end of treatment. 
The hypotensive effect of FIE persisted during the post_ 
II'eIbDeIIt period to a mean value of 110:1 411U11Hg at the 
eod of the expcrimeot (see Figure 2A). The mean arterial 
blood prasure (MAP) changes _ IODJ-term (cbrooic) 
FIE treatments are Ihown in Figure 28. Chronic IraibDeDt 
of the I1tlS wilb FIE (120 mg.tg-I daily for five weeks, 
p.o.), caused significant decreases in MAP in oon-diabetic 
and S1Z-treatcd diabetic rail througbour Ihe srudy period 
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F;,.- 1. FifcdS of chronic Fm trabneat on mean artaia1 
blood pressures in (A) noHillbeUc or (B) S'J"Z..iDduced diabetic 
I'IlS. Valuea - preIQfCd as JDeII'II aod ¥U1icII '*' iodic:ale se 
of JDtaII5 (n = 6 in eadI poup). ~ < 0.01 by comparison with 
COIIIrOIIIIimaIs. 
in c:omparisoa wilb control rats at the ~ 
period (Figure 2). 
CELL CULTURE S'I1JDIES 
The M1T assay is a quantitative colorimetric medtod 
based on the reduced cleavage of the WaIa' soluble 
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m6notettazolium salt MTI to • purple formazan in met-
abolically active cells. !be M1T salt is actively trans-
ported into metabolically viable ceDs. Both Figures 3A 
and 3B show the viability of LLC-PKI and MDBK cells 
treated with various concenttatiollS of FI'E after 24, 48, 
and 72 bours. There was DO tolticity DOted iD both cell 
lines after treatmeIIt with FI'E. In figure 3A,u.c·PKl 
cell metabolism was iDcRased with iocreased doses of 
Frn (600-1000 11,.mL-1) for all iDcUbaliOD time peri-
ods. In contrast, the MDBK cells (Figure 3B) show 
iDcreased metabolism for all concentration.s of FI'E. 
'Ibere was a significaul iDcrcase in metabolism and cell 
viability after n -b incubatiOD, with significance being 
more prooounccd at the bi,best concentrations (800 and 
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,..,. 3. VUibiJiey of (.4.) lLC-PIC I aDd (9) MDBK QdJ liDea 
IIated widJ FIE. 1bc CldJs _ bated with 100. 200, oiOO. 600, 
10), or 1000 III FIB.. Cell viIbiJity WIS deumined by Ibe 
Trypban blue exclusion aay. Values for IIIIIraled CXIMrOl _ 
1IikaI. l~. EICb dole repretCaIS !be mean ollix 1mImlcnts, 
wbile Ibe YCrticII 11m denoce IUDdwd erron or 1he means. 
Rat Isolated Atrial Muscle Strips 
!be cardiac effects of FIE Ire sboWD in Figure 4. 
lbis figure sIlows !bat FI'E (s-80 mg.mL- 1) produced 
concenttatioa-ceIlfCd, neptive cbrooocropic (Fizure 4A) 
and inouoplc (Figure 48) effects on rat isoI.ated spontane-
ously ~ right· md eJectricllly dO_left- atriallllUlCle 
strips. rapeccively. 1be ~ effects ofFrE 
were DOt modified by badI-appIied IIIqline (1~-1~ M). 
suggesting that the cardia-inhibitory effects of the pial's 
extract Ire unlikely to be mediated through choIiDCrJic 
mechanisms. 
DISCUSSION 
10 the present study, we have evaluated the effects of 
short-tam (acute) and og-tum (chronic) orallJ'elbDCUts 
of Ficus tItoNWtgii Sfem·bark ethaaolic ex1rIct (FIE) on 
cardiovascuIar systems and kidney functions of nIlS. !be 
major findings of Ibis study, Ip8I1 from COIIfirmiDJ our 
previous obsavaIioas of the hypoglycacmic effects of oral 
adIni.nisntioos of the pIaat' s exnct,(lJ show that Pm 
decreases blood pressure wilhoot significaal iaflllCDCCS on 
J 0, 
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F.....4. Efrecll or teqUeIIIiaDy applied ar'Ided conceo-
IIIiIioas 01 FI'E (S-80 ma-mL -I) 011 !be (A) I1IlC 8IId (I) force or 
CXlIIIraCIionJ of ~ iIoIlIed spnn!WWlU1Iy beIIiD& rillbl- IIId 
eIecIricIIIy dri_ Ieft...n.r IIIUICIe Itripa. mpecci vdy. EICb 
point n:p"eIaIlI Ibe DICIIl or PrIO ~. wtUIe die 
YeI1icaI bws dmofe IIancbrd erron of the meaN . • p < 0.05, 
•• p < 0.01, ••• p < 0.001 w:nus c:omrol 
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renal fuDction in DOnDoteulve rats. The management of 
diabetes mellitus widIout side effects is a global challenge. 
thus increasing the demand for UlUI'al proWcts with 
antidiabetic activity.115J c.diovascular aDd raW compli-
cations .-e the ~ cauaes of mortality in diabetes melli-
tus.(l6) We sugat thal the use of Fm in !be CODlrOl of 
diabetes mellitus may be beoeficial wbeo hypertensioo 
and compromised renal fuoction co-exist This is sipifi-
cant coosideri.og the fact that dilbeles mellitu5 is usoci-
atcd with cardiovascular complicatioos aod deleriOl'llion 
of kidney dysfuoction in diabetic patientslJ7) aDd experi-
mental aoimalsYl-lDI ~ore, the ~t of dia-
betes with FIE has the pocentialto address both renal ad 
cardiovascular proteCIioII. Conventionally, l'CIIOpI'OteCtion 
is achieved tbroup a reduction in blood pressure widl 
antihypertensive re,uueos.[17. 21-231 Of DOle in the paeat 
study is the hypoceosive effect of PIE witbout altaiDg 
kidDey function, iD contrast to previous reports of 
impaired renal functioo ' following the admioiscracioo of 
some hypoglycac:mic plat eX1l'lCtS. [."..) A siguificaot 
iocrease iD OfR IS assessed by creatioioe dQl'8lX".e IDCl a 
coocomitaot decreaIIe in plasma creatinine COPCCDtratioo 
was observed for the STZ-iDduccd diabetic group Ireated 
with FIE ov« the five-week period. This fiodiDg is signif-
icant, given the fact that aome aobhypert.eosive ... ts 
(e.,., thiazide diurc:tics) and 8-blocbrs iDOueoce glycae-
mic control in a deleterious 1IlIUIIIeI'. (2S) Evidence from 
biomedical literature sugests that some herlIaJ extracts 
have protective effects against cardiovucw. disease iD 
diabetes. (1J6) We aod sevual other auchors have previously 
used aeaboine cleannc:e in rats to JIlOIlitor GFR. 19.1CU7.21) 
It is likely that cbrOllic FIE tratmeut iDcreased c:raIiniDe 
secretion as evidenced by iDcrascd MDDIC cell metabolic 
activity. HoweYel', further studies are required to establish 
the mechanism(s) through which PrE mIuces plasma cre-
atinine levels. The oelJ culture studies provide an experi-
mental model to assess cytoCOxicity and metabolic activity 
of FTE iD the two renal cell Ii.oe$. Initially, the M1T 
assay wao; used as a measure of cell viability and prolifera-
tioo, with rhe mit.oc:hoodrial reduction by succinale reduc-
tase system beiD, the major contributor to M1T 
reduction. (29J Howev«, recent evideoc:e shows that most 
M1T reduction occurs extra-mitocbondrially with M1T 
salt CI06Sin& the intlcl ~ mcmbraDcs to be reduced 
intraceUuWiy.(lO) Other investipcn have shown that 
IDOIil of the cellw.: reductioos of M1T are depeodeot on 
microsomal eozymes and DOt caly on auccioate debyclro-
genase.(JO-J2) This mic:rosomaI rcductioe requires NADH 
and NADPH and is DOt affected by respiraIory iohibi-
ton.l3l) This clearly iDcIicItes that cellular redaction of 
M1T is related IIIOl'e to the aJycolytic rate. and thus 
NADH productioo, than to respinlioo, and is therefore 
primarily a measure of the rate of glycolytic NADH 
productioo.(32) Our cell culture data clearly support this 
finding. as MTT reductioo is increased iD the presence of 
PTE, especiaUy at the hiper coocentralioos. Our data also 
confirm the lack of toxicity of FTE on renal cells derived 
from two species. viz.. pig and bovine. The findings of the 
present study sugest that FIE is a useful agent in iDcrcas-
iDg glucose uptake by renal cells ad glucoIe upcab stud-
ies are aeedcd to verify this pbcnomcnon. Our data 
indicate that FIE has the potential to reduce plasma levels 
of ~ in patients widl diminished renal function 
aDd reduce cardiovascular aDd rmaI complicatioos as well. 
The elevation of plasma creatinine is a risk factor for the 
devdopmeal of c..movasc:uJarl331 and cad stage renal[)4) 
diseases. FIE reduced mean arterial pressure in normoten-
sive rats without sipificant effects on reaaI fluid ad elec-
trolyte handlin" suggesting that the cardiovascular effects 
of PIE are nwli.red throop iDOueDCCS on components of 
the cardiovascular system. We suggest that the c.dio-
inhibitory effects of FIE may contribute, in pert at 1elSt, 
to the bypolellSive of the plant' 5 extraCt. This bypothesis is 
supported by our fiodiDJS from experiments on isolated 
guinea-pig atrial muscle strips which demoostraltd signif-
icant Deprive chroaocropic and inocropic, cardiodcpra-
sant effects of FIE. In cooclusion, our experimcDtal 
findiop suggest that FTE possesses reoo- and cardio-
protective effects in diabdcs mellitus. 
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ardiovascular Topics 
Cardiovascular effects of Persea americana 
Mill (Lauraceae) (avocado) aqueous leaf extract 
in experimental animals 
JAO OJEWOLE, DR KAMADYAAPA, MM GONDWE, K MOODLEY, CT MUSABAYANE 
Summary 
The cardio"asclliar ('ff('cls of P<'I"St!1I III11<,ri("(/lItl liII 
(Lallnlc('a(') aqllL'OlIs Il'af exlracl (pAE) ha,'(, been h,,·l's-
ligated ill some ('xl)('rillll'ntal allilllal I)aradigllls. The 
effl'cts of PAE on 1II~'ocardial contrJctlle I)erformanc(' 
was l" 'aillated on gllhl('a I)ig isolated alrialmllscle strips, 
while Ihe vllsodilalory ('ffeels of the 1)lalll exlracl weI"(' 
('xamill('d 011 isolat('d IlOrhll v('ins and Ihor:leic :Iorlie 
rings of h('a lthy norlllal Wistar r:lls ill ,·ifm. Th(' hypo-
lensi\"e (anlihYI)erlensive) effect of I"he 1.l:ull exlracl was 
exalllin('d in heallhy norlllotensl\'(' alld h)'I)('rtellsl\'(' Dahl 
sall-s(,lIslll\"(' mls ;11 ,';1"(1. 
P {llI/ er;Ctlllll aq u('ous leaf extracl (25-1100 IIIg/ llll) 
IlI"0duc('d cOllcelllralioll-d('l.endellt. slgllincalll (p < 
O.O~.OOI).lIegative illolropic alld lIegali\"e chrollotropic 
effects on gui ll('a pig isolat('d electrically driwn 1('[1 alld 
SJlOlllalleousl~' bl'ltliug right lurial IIInsci(' 1)l"('paraliolls, 
resp('cliv('I~'. i\loreowr, PAr r('dueed or abolished, ill a 
(' ollcelll ralion-dependenl lIIa ll ller. the I.osiliv(' inolro-
pic alld (' hronolrol'!c r('sl,olls('s of gllinea I)/g Isolal-
cd alrial IIIUScJl' slrlps Illduced by noradr(,lIalinl' ( A. 
10'''-10'' i\I). alld calcium (Ca'" S-4t1I11I\1). PAr (50-1(00 
IIIg/ IIII ) :llso sigllificallll~' r('duc('d V) < 0.05-0.(0 1) or 
aboJishl'd. ill 11 COllcelltralioll-ti('pelldelll manlier. Ihe 
rh~' thlllic, SJIOIlIalll'Ous. 1II~'ogellk ('ollll":lcliollS of JIOrtal 
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"eins isolaled from health~' norlll:ll \Vistar rals. Like 
a(·('tylcholinl' (A ·h. 11t'-10" I). Ihe 1.lant ('xtract (25-
ROO mg/ml) produced concelltration-r('latl'd relaxaliQns 
of isolat('d endotheliulII-(onlaining Ihoracic aortic rings 
pre-conlracted with 1I0radrenaline. The "asorelaxant 
em'cts of PAE in Ihe isolated. l'ndotheliulll-iniact aortic 
rillgs were lIIark('dh" inhibited or llllnulled b\" N"-nitro-
L-arglnhl(' methyl ('~Ier (L-NA IE. 14)-' M), a ~itrlc Qxidl' 
sYllthase Inhibitor. Furthermore. PAr (2HOO lng/kg II") 
caused dQse-relatl'd. Iransil'nt bUI signifirant redllctlons 
V) < 0.05-0.(01) ill Ihe systemic arlt'rial blood pressure 
and hl'arl rail'S of thl' anaeslhl'tisl'd IIQrlllolensiw and 
hYI'l'rlensiw rals used. 
The I"('sults of this laboratory anilllal stud\' Indicate 
that PAr caused bradycardi:l. \'asorel:lXatlQn ~nd hYJIO-
1(,lIslon in Ihe IIulInlllalian experinwnlal mQdels used. 
Till' ' ":lsorl'l:lX:lnl :I('lion of PAE was l'ndolll('liulII dt'pen-
d('nl. and W:lS. Ihl'refor('. possibl ~' depl'lIdl'nl 011 Ihl' 
synlhe is alld r('lease of nitric oxid(' (NO). Th(' vasore-
laxant efreels of PAE apl)eared to cQntribute signin-
Cllllll~" 10 Ih(' hYJIOI('nsl\'e (anfih~'pertensiw) eff('cts of 
thl' plant extract. How(" 'l'r. th(' findings 411' I his stud,' 
It'nd 10 sUgg('st Ihal P f11t/{'r;cf//1(/ Il'llf CQuid be used as ;1 
nalural suppl('menlary I"('lIledy in essential hYJll'rtension 
and certain cases Qf cardiac dysfunctlons In sollie rural 
Africa comlllunities. 
(m1fOV{lScJAfr2007 ~ 18 : 69-76 WWW.CVjS3.CO.za 
in our currcnt pharmaeo-chcmieal exploration of AfriC<ln 
medicinai plants, we ha\'c cxamincd in our laool1ltorics som 
o f Ihc frcquc ntly used oUlh rric1In mcdic inal plants tor 
their chemical const ilucnts ilnd "harma ologica l a lions, "'. 
in an attempl to establish a scicntific basis for thcir fo lk-
loric, ethnomcdiea l uses, Onc of such commonly used 
Ati-ieml mcdic inal plants is PCf"I"ea al11ericana Mill (family: 
Laul"accac), 
p . (1II Il'ri<'f1na, otherwisc known as thc avocado pear, 
Mex,can avocad~ and so on, is a medium-sizcd singlc-
stcmlllcd, tc rrcstnal , c reel. perennial. deciduous trec i - 20 
min hcight. Although a nat ivc of Centra l IIIcrica (Mcxico), 
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P all/ericana is now found in most trol)ical and subtropica l 
countrics o f the world . The branchcs arc fissured and grey. 
but the twigs arc grcen and smooth. The 15-25-em long 
and 10-20-em bro~ld leaves with well .... leveloped I)etiok s 
are spirally arranged o ften clustered ncar the bnlllch cnds. 
narrowly to broadly elliptical or obo\·ate. and are usually 
point d at the tip." 
Thc grecnish-yel low flowers arc bornc on branchcll 
eOml)aet panicles. which are shorter than the l cave~ . The 
often pear-shaped one-sccded fru its tire vnriable in size and 
hape a cording to the variety, up to I L em long and u ' ually 
shiny and grcen. or brownish when ripc. Thc flc ' h is soft , 
o ily, greenish or yellow surrounding one hlrge, loose round 
sced." Thc avocado is now cultivated comm reially as a fruit 
crop in many eountrics o fthc world . In many parts of Africa. 
the ti'uits of the avoctldo are much ought aftcr by humans 
and some animals as \',"uable foodstuff. Bcsides the oil. 
avocado fruit pulp contains carbohydrates and more protcin 
than many other fruit s, while it s contents of vitamins A and 
B arc high.".l1 
In addi tion to the nutritional value of its fruit . thc \cayes 
and other morpho logical paJ1s o f P alller'icalla po ' sess 
mcdic inal properties and arc \\ idcly uscd in traditional 
mcdicines of many Afri~1Il countrics. For examplc , thc fruit 
pu lp is catcn as an aphrodisiac and as an emmenagogue 
in South Africa ,'l whilc a hot-\\~I ter extract of the \cm'cs is 
Wken orally as a diuretic tI nd for hypertens ion in many West 
African countric '. " In somc other parts of the world various 
morphological I)arts of P americana havc been cmployed for 
11 wide range of human ai lments. Products o f thc plant havc 
been effectivelv lIsed for the managemcnt, control and/or 
treatment of an;enorrhoca. anacmia. insolllnia. hyperlil)ida -
mia. hypertension. diabetes mell itus. diarrhoea, dyscntery. 
gastritis. peptic U\cCI"S. bronchitis, cough, hepatitis. and so 
forth.'w 
Preyious studies on thc .. vocado h .. ve shown that letlf 
extracts of P amencalla possess a catalogue of pharmacolog-
ical activities. including ana lges ic. 'lIlli-int1ammatory. anti-
diabetic. hypoglyc .. emic, hypotens ive and antihypertensive 
properties.'''''' The pr,,'Sent stud. WilS prompted by the claim 
of some traditional health practi tiOilel ' in K waZulu- atal 
that de oction' and infus ions of ayoeado leaves arc effe tive 
remedies for the managelllent and/or control of hypertension 
and ccrtain cardiac di sorders. 
The a im ofthc present study was, therefore . to investigate 
Ihe c""diac. "ascular and antihypertensive (hypotensive) 
effects of P americana aqueous leaf ex tmct in cxperimenta l 
animal paradigms. with a view to providing a I harmacologi-
ctll justification (or otherwisc) for the cthnomcdical uses of 
the pl:lI1t leaf in the managcment, control andlor treatment 
o f cssential hypertension and eert'lin cardiac dysfunctions in 
some rura l African comlllunities. 
Materials and methods 
The experimental protocoillsed in this study \WIS approved by 
thc ethics committce of the Uni\'crsity of Durban-Westvillc 
and conforms to the Guide to the Cat'(' and U~e of Animal. 
ill Re\('ardl allli T",aelling." 
Plant matcrial and preparation 
Fresh leaves of P americalla werc co llected fi'OIIl a play-
ground behind Willowpark C ntre along Umbil Road in 
Durb,m, between January ,lnd June 2003. The leaves were 
identified bv Prof H Baijnath. the lo rmer chief taxonomis 
curator of tilc Departmcnt o f Bolany. nivcrsity of Durban-
Weslvi lle. liS those of P americana Mill (family: Lauraccae). 
A voucher specimen of the plant has been deposited in th 
Botany Departmental Herbariulll . 
Room air..uried leaves ( I kg) of P amcricana werc milled 
in a Waring comlllerc ial blender. The powdercd leaf was 
maceratcd in di stilled wat r and extracted twi . on each 
occasion with 2.5 I of distilled water at room temperature for 
48 hours. with occasional shaking. The combined distilled 
water ex tracts were concentrated to dryness at 60 ± 1°C in 
a rotary evaporator. Freczc drying and soh 'ent elimination 
under rcdu cd pre <;sure finally ga\'e 21.50 g (2 .15% yield) 
o f a light-brown. powdety aqucous leaf extract. This crude 
extract was uscd in our study without furth I' purifi ation. 
Aliquot portions of the residuc from the aqueous extract 
were weighed and dissolved in distilled watcr for usc on each 
day of our experiments. 
Animal material 
Hcalthy male Dunkin-Hartley guinca pigs (CoI'ia porcdlll~) 
weighing 300-450 g. and healthy young 'lllult mal Wistar 
rats (Raftllf lIorl'£'gicll f) wcighing 250- 300 g were uscd. The 
animals were kcpt undcr laboratory conditions of tcmpera-
turc. humidity and light ,lIld were lIlIowed free access to food 
( tandard p lI et di ct) and w<ltcr ad l ibituIII . All the animals 
were fasted for 16 hours. but allowed free acccss to w,lter 
before the eommenccment of our experiments. Guinea pig 
isolated alrial musclcs were used for the i ll I'ilro cvalll<ltion 
of the effects of the aqueous extract on myocardial ontm til-
ity. wherC'lS mt isolatcd porta l veins and thorac ic aortic rings 
were used to examine the \nsorelaxant cftecls of the extract. 
Normotcnsivc (norma\) Wistar. ,lIId hypertensivc Dahl salt-
sens iti\'c rats wcr used for the ill I·i.-o ilwestigation of the 
hypotensi\'c (anlihypertens i\'c) e ftect of thc ,1qUCOUS ex tract. 
Isolated muscle experimcnts 
Guiflea pig muscle strips 
The guinea pigs \\'crc sacrifi ced by stunning and exsanguina-
tion. Thc left and right atria l mu ' Ics of dlc animals were 
i olated and mounted as previously describcd by Ojewolc." 
The isolated le ft atrium of each guinea pig was impaled 
on a thin platinum wi re elcctrode and suspended under 
an applied resting tension of 1.0 g in a 30-ml Ugo Basile 
organ-bath containing Krebs-Hcnseleit physiologica l solu-
tion (composition in mmol/L pH adjusted to 7.4 : NaCI. 11 8: 
KCI. 4.7: Na H,PO •. 1.28: NaHCO,. 25.0: MgCI,. 1.2: Cact,. 
2.52: glu ose. 5.55) maintained at 34 ± I °C and continuollsly 
aemtcd wi th carbogen (95% 0 1 + 5% CO, gas mixtu re). 
Each left atrial muscle preparation was electrically driven 
with square wave pulses of 5-l11s dunltion at a frequency of 
3 Hz and a slIpramaximal vo ltage of 5- 10 . deli vcred by 
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an SRI stimuhltor. The spontaneously beating right atrium 
of the anima l was also set up under the smne physiological 
experimental conditions and allowed to Ixxlt spontaneously. 
Two isolated electrically drivcn leti atrial muselc strips and 
two isolated spontancously beating right atria l musele prepa-
rations were always set up at a time (one as the test, and the 
other as the control) to allow for changes in the atrial muscle 
sensitivity. 
The atrial muscle preparations were le ft to equilibrate for 
45-60 min (during which time the physiologic.:11 bath solu-
tion \\"<IS changed every 15 min) before they were challcnged 
with P. E or any of the re fcrcnce drugs used . The test atrial 
Illusele preparations werc treated with scquentially applicd 
graded concentrations of PAE and/or re fer nce agonist 
drugs uscd whcreas thc control atTial musele strips were 
trC<lted with vo lumcs of distilled water (0 . 1-0.6 ml ) equiva-
Icnt to the volumes of b<lth-applied PAE o lution used. The 
electrically I rovokcd ,md spontancous contractions of the 
atrial mu eles. as well as the PAE- and reference agonist 
drug-induced responses of the atrial muscle preparations 
were recorded isometrically by means of go B<lsile force-
displacement transduccrs and pen-writing Gemini recorders 
(model 70 70). 
Rat port(III'eiIlS 
The rats were sacrificed by stunning ami eXSllnguination. The 
abJomen o f each rat was quickly opcned by midline incision, 
and the intestines were pulled asidc. The portal ve in of each 
rat. with an i ll , iflllcngth of approximately 2 cm, was elc.1ned 
of cxtraneous connective allli fatly tissues and then removed 
from the anilmll. Each isolated portal vein ' \"<1' suspended 
under ,Ill applied resting tension of 0 .5 g in a 30-1111 Ugo 
Basile organ bath conta ining Krebs-Henseleit ph. siologi-
C:II solution. Two isolated venous ti ssue prcparations (one 
control and the other PAE- or reference drug-trent d test ) 
were always set up in order to make allowances for changes 
in the venous tissue sensiti,·ity. Control venous Illuscle 
strips were treated with disti llcd watcr only (the vehicle in 
which PAE and referencc drugs w~re dissolved). Th "enous 
tissue preparations werc allowed to equi librate for ~5-6() 
min (during which time the phys io logical bath solut ion was 
changed every I - min ) before they were challenged with 
PAE or any of the reference drugs used. The plant extmct-
(25- 800 I1Ig/ml ) and refercnce drug-induccd responscs of the 
venous smooth muscle preparations were recorded isometri-
cally by means of Ugo Basile force-disphlccmcnt transduccr.< 
and pen-writing Gcmini recorders (model 7070). 
Rat tllOmdc oort(I rings 
The nab' were sacrificed by decapitation. Thc descending 
thoracic aorta o f ellch normotensivc rat was quickly and 
carefully excised and placed in a Petri dish filled with ice-
cold Krebs-Henscleit physiological solution. The aorta was 
eleaned of extraneous fat and conncctive tis ' ucs and cut 
into rings approximately 3-4 nUll in width . All dissecting 
procedures were carefully done to protect the functional 
endothelium from inadvertent damage. In ome aortic 
rings, the endothelial layer was mechanically removed by 
gently rubbing the lumina l surfacc three times with distilled 
water-moistened cotton wool, to llowed by s ix timcs with a 
small. plastic tubing. A pair of nit isolated aortic rings. one 
with intact functional endothelium. and the other olle with 
endothelium denuded. were a lways sct up in parallel for 
appropriate comparison. 
Each of the isolated endothclium-conta ining and endothe-
lium-denuded aortic rings WaS suspended under an app lied 
resting tension of 1.0 g in a 30-ml Ugo Bas ile organ-b.1th 
containing Krebs-Henseleit phys io logical solution main-
tained at 36 ± 1°C and continuously aerated with carbagen 
(9 -% 0 2 + 5% CO,). The aortic tissue preparations were le ft 
to cquilibnrte for 45-60 min (during which time the phys io-
logical b.1th solution was changed every 15 min) befo re they 
were challenged with gnlded conccntnltions o f PAE or any 
of the re ference drugs used. At the end of the equilibration 
period the aortic ring prepanations were initially contracted 
with !xlth-applied no radrenaline (10-' M). 
Endothelia l integrity and successful removal o f the func-
tional endothelium was assessed by the presence or absence. 
respectively. of rehlxant response to lIcety lcholine ( 10-' M). 
ACh-induced relaxation ~ 5% was taken as sati sfactory 
removal of the functional endothelia l layer. uch endothe-
I ium-denuded aortic muscle preparations were used in this 
study. fter the subsequ nt wash-out and equilibration 
period of 30 lIlin. cumulative dose-response curves were 
obtained with noradrenaline in aortic rings with and without 
endotheliulll . 
Subsequently, 20-min pretreatmcnt o f the aorti c muscl 
prel>arations with graded concentnltions o f the plant extract 
(25-800 m" ml) was carried OUI before thc next cumula-
tive additions of noradrenaline (10-10- 10-' M) to the !xlth 
fluid. After the addition of each concentration, a 1>lateau 
responsc lin obtained before the addition of the next 
higher dose in all C:lses o f cumulatively applied noradrena-
line concentrations. Consecuti,'c dose-rcsponse curves were 
takcn at 3D-min intefl'als, during which time the physiologi-
ca l bath solution was changed thr e to fi ve times until thc 
tension de" eloped returned to bas.11 Icn:1. 
Fo llowing 20-min incubation ofth lIortie ring preparations 
with the plant extr<lct (25-800 m • mI). the artcrial relaxant 
effect of PAE was examined on endothelium-containing and 
endotheliulll-dcnuded aortic ring preparations pre-contraetcd 
with ' equenti,llIy applied or cUmulntil"ely administered 
noradrenaline (10-10_ 10" M). The e ffect o f the vehicl in 
which PAE and th ... reference drug used w ... re dissolved 
(distilled wate r). was also tested. After ellch challenge. thc 
~orti ~ ring~ were washed threc to five times with fresh phys-
1010'JIcai solution and allowed to equilibrllte to r 30 min 
beforc they were cl l<lllenged again with any of the reference 
drugs or PA E. The contractile and/or relaxant effects of all 
the re ference drugs. as well as PAE-induced relaxations of 
the isol;ltell aortic ring preparations were recorded isometri-
cally by means of Ugo Basile force-displacement transducers 
and pen-writing Gemini recorders (model 7070). 
'~hok"'a"imal experiments 
orlllotensive Wishlr and hypertensive Dahl sa lt-scnsitive 
rats weighing 250-300 g wcre used. Before the cOllllllence-
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ment of our experiments, the sa lt-sensitive rats were placed 
on 4% saline water and normal fooJ (standan! pellet diet) 
for six to ight wceks (during which time the arterial blood 
pressure of the animals rose to between 170/ 130 and 19011.JO 
mmHg). Salt-sensitive rats with arterial blood pressure 
~ 170/ 120 mmHg werc considcred to be hypertensivc and 
used in this study. 
L1ch of the normotensivc and hyperterlsivc rats was 
anaesthctised with intl1lperitoneal injection of 0 .11 • kg of 
T rapanal"' [sodium 5-cthyl-( l -methylbutyl)-2-thiobarbitll-
rate). Thc right fcmoral vein was cannulated with a sm~rll 
polythene annula for the administration of the plant extra t 
and rcfcrence drugs. In order to minimise blood coagulation, 
heparin (500 units/kg) was intravcnou ' ly administered to 
the animal. and flu shed in with 0 .2 ml of 0.9% wlv sodium 
chloride so lution. The Icft ca rotid "rtery of cach flit was also 
cannulated and connected to a four-chmlllel Gmss polygm ph 
for systemic arterial blood pressure rccording. The trachea 
o f each rat was cannulated for artificial respimtion. but the 
animal was allowed to breathe spontaneous ly. The rats body 
tem perature was maintained at 36 ± 1°C with an incandes-
ccnt lamp placcd ovcr the abtlomen. 
After 20 min stabi lisntion pcriO<.l systemic arterial blooJ 
pressure (systolic. diasto lic alld mean arterial pressures) 
and heart rate of each rat were mensurcd and l\."'Cordcd. 
The c tfects of PAE lllld the rc ference drugs [acctylcholine 
(0.5-4 .0 ~Iglkg iv) and noradrcnal ine (0.5-4.0 ~t !¥kg iv») on 
svstcmic artcrial blood pressurc and hearl flIles (calculated 
f~om the ECG limb lead II recording <II a fast paper speed 
of 25 nun/sec) wcre recorded by mcans of u four-channel 
Grass polygraph recorder (modcl 790 ). In some of the rats. 
thc hypotcnsive (depressor) effect ofPAE (2S-WO mglkg i\") 
was examined aner atropiniSll tion [pretrea tmenl of the rats 
with atropine sui, hate ( 1.5 mglkg ip) I 24 hOll rs before 
usc). Because PAE mill othcr drug used in thi s study \\ere 
dissolvcd in di still cd waler. flits trcaled with di tilled water 
(2 ml/kg iv) alone were used as contro l animals under the 
Slime experimental conditions. 
Compollnds and drugs used 
The fo llowing compounds nnd drugs wep used: P (/Illeri-
C(/fW aqueous leaf cXlract, acctylcholine chloride (S igma. 
England): (-)-noradrcnaline hydrochloride (Sigma. England); 
atropine sulphate ( igma. England): "-nitro-L-arginine 
methyl cstcr (L- AME) (Sigma . England ): Trapamrl< [sodi-
um 5-clhy l-( l -rncthylbutyl)-2-thiob<lrbituratc) (Byk Gulden. 
Konslanz. Germany); (±)-prol ranolol hydrochloride ( igma. 
England): ca lcium chloride and pOlassium chloride ( igrmr. 
England). The drug ' were dissolvi:d in distilled water each 
day at the beginning of ollr experiments . Drug conecntra-
tions and doses quoted in the text refer to the "'ll ts, cxcept 
PAE. and denote fina l ol'cian bmh eonc("llIration in the ill 
\'ifro experimcnts. 
Data analYSis 
Data obtained from tcst guinea pig i 'o lnted atria, rat isolated 
portal vc in , aortic ring strips, and all<lesthctised nonnoten-
si\'c ami hypertensivc rats trcated with PAE a lone. as well as 
those obtaincd from distilled wll tcr-tre<ll.:d control isolated 
atria, porta l ve ins, aortic rings and anacsthetised rats, 
we rc pooled and expressed as means (± EM). Statistical 
comparison of thc di fl"ercnces between I> E- and refcren c 
drug-treated test means. and distilled watcr-treated control 
mcans. was performcd wilh GraphPuci InStat oftware 
(vers ion 3.00, GraphPad Software, San Dicgo. Cllifornia, 
U A) using one-way analysis of variance ( NO A: 9S% 
confidence interval). fo llowed by Tukey-Kra11ler 11lultiple-
comparison tests. Valucs of p ~ 0.05 were takcn to imply 
stat istica l significance. 
Results 
Isolated muscle experiments 
Guillea p ig IIIlIscle prepllrflfiollS 
Sequcntial administrations to thc bath fluid of relatively 
low to high concentrations of P, E (2S~ 00 Ill" ml) signifi-
cantl. reduced (I' < 0.05-0.00 I ) or abolished thc force of 
contractions of guinea pig isol<lted electrically driven Icft 
atrial muscle prcparat ions in a concentration-related manner 
(Fig. I ). The ncgati,'c inotropi effect of PAE on these musel 
strips was nOI affected by prior exogenous adl11inistr<lti n of 
atropine to the bath fluid . 
I the sam ' onccntration rangc, the phlilt extract also 
significantly reduccd (p < O.OS...{).ool) or abolished thc mte 
of contraclions of guinca pig isolatcd spontaneously beating 
right atrial Illusclc preparations in a conccnlration-dcpendent 
manncr (Fig. 2). Howcver, the ncgutivc ehronolropie ffect of 
PAE on these muscle stril)S was not antagonised byatropinc 
which reduced or abolished thc negativc chronotropic cite t 


























PAE Concentration (mg/ml) 
Fig. 1. Effects of graded concentrations of PAE 
(25-800 mglml) on guinea pig isolated electrically 
driven left atrial muscle strips. Vehicle (distilled 
water)-treated control preparations received the 
same volume of PAE solution only. Each point 
represents the mean of eight observations, while 
the vertical bars denote standard errors of the 
means . • p < 0.05; •• p < 0.01 ; ."p < 0.001 vs vehicle-
treated control. 
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Fig. 2. Effects of graded concentrations of PAE (25-
400 mg/ml) on guinea pig isolated spontaneously 
beating right atrial muscle strips. Vehicle (distilled 
water)-treated control preparations received the 
same volume of PAE solution only. Each point 
represents the mean of eight observations, while 
the vertical bars denote standard errors of the 
means. ' p < 0.05; " p < 0.01; ".p < 0.001 vs vehicle-
treated control. 
atrial muscle prepamtions examined. PAE si~nificant ly 
reduced (p < 0.05-0.00 I) or abolished like propranolol, the 
posi tive inotropic and chronotropic effects of noradremoline 
0 11 all eight other isohlted atria l muscle strips tested. The plant 
extract also signifiemllly (p < 0.05-0.001) inhibited or abol-
ished calcium-induced pos itive inotropic and chronotropic 
responses on all other nine atrial mu scle strips e:"amined. 
Rut pOfH,' ve;tls 
Sequential administl1ltions to the !Alth tluid of relatively 
low to high concentrations of PAE lliways induced conccn-
tration-dependent, biphasic ctleclS on the amplitude and 
frequency of the rhythmic myogcnic contrnctions of the rat 
isolated porta l veins. The biphasie eficcts produced by PAE 
always consistell of an initial slight but significont (p < 0.05) 
contraction (stimulation) of short duration. to llowed by a 
secondary. longer-lasting and signincmll (p < 0.05- 0.{lO I ) 
rclax'lt ion (inhibition) of the venous musele prepamtions 
(Fig. 3) . At the snme concentration range. the plant extmct 
also inhibited or abolished in a concentrution-dependent 
manner. contractions of the venous musele prepnrations 
induced by noradrenaline or potassium. 
Rut {lOrti!' rillg strips 
Cumulative add itions of graded conccntrations of noradrena-
line to the bath tluid provoked concentration-dependent 
contractions of both endothclium-containing <md endothe-
liulll-denuded normotensive rat isolated norti ring strips. 
with n maximum of 3.76 ± 0.30 g tension developed. 
Acetylcholine provoked concentration-related signineant 
re laxlItions (p < 0.05-0.00 I) of cndothelium-containing 
aortic ring prep<lnltions pre-contracted with buth-applied 
noradrenaline, but did not significuntly rclnx (p > 0.05) 
endothelium-denuded aortic ring prepurations pre-cotllracted 
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Fig. 3. Effects of PAE (800 m9/ml) on rhythmic 
myogenic spontaneous contractIons of rat isolated 
portal veins. Vehicle (distilled water)-treated control 
preparations received the same volume of PAE 
solution only. Each point represents the mean of 
eight to 10 preparations, while the vertical bars 
denote standard errors of the means. ' p < 0.05; " p 
< 0.01; ".p < 0.001 vs vehicle-treated control. 
Likc acetylcholine. PAE produced concentration-dep"nd· 
ellt, significa nt relaxations (p < 0.05-0.001) of the endothe-
liurn-contuining aortic ring preparations prc-contracted with 
nomdrclKlline (Fig. 4). but did not relax endothelium-denud-
ed <lortic ring prepnwlions pre· contracted with bath-applied 
noradrenaline. Moreover, the plant extract shifted cumula-
tively administered noradrcnaline concentration-rcsponse 
curves to the right in a non-parallel and non-compet itive 
fashion, and suppressed NA-induccd maximal contractions 
of endothelium-containing aortic ring musele preparations. 
Ten minutes ' prior incubation of the endothel ium-intact 
aortic ring tissues with L-NAME. a nitric oxide synthase 
inhibit.or. inhibited or abolished PAE- or ACh-indueed 
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PAE Concentration (mglml) 
Fig: 4. Arterial relaxant effects of graded concen-
tratIons of PAE (SQ-800 mg/ml) on noradrenaline 
(~Ct" ~)-induced. co~tractile responses of endothe-
hum-Intact aortIc nngs from normal rats. Vehicle 
(dist.illed water)-treated control preparations 
receIved. the same volume of PAE solution only. 
Each pOint represents the mean of eight observa-
tions, while the vertical bars denote standard errors 
of t~e means. ' p < 0.05; .'p < 0.01, "'p < 0.001 vs 
vehIcle-treated control. 
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·fABI.E I. EFFECTS OF PAE ON S\'STE IIC AlnERIAL BLOOD PRESSllRE A D IIEAR"f RATES or NORi\lOn:NSI\'E 
RATS. EACII \~\LlI [ REPRESENTS THE ME.-\ (± SUI) OF OBSERVATIONS FROM EIClfT RATS 
Co/Y/iOlYlSclIlar Before tl'ecumelll; 
After /reatmem : PA£ (25-4()() mg/kg iv) 
pafY1meler cOl/trollY/lilt's 25 50 100 100 ./00 
Systolic BP (mm Hg) 124.5 ±4.6 11 2.5 ±4.4 9 1.6 ± 4.6* 73.4± 4.1·· 58.5 ±4.0··· 42.6 ± 304··· 
38A±3.1"· 
31.4 ± 3.0··· 
Mean BP (nun Hg) 111.4 ±4.1 98.8 ± 4.7 84.3 ±4.S* 66.5±4.0** 51.4 ± 4.1·" 
Din tolic (null Hg) 94.3 ±4.0 80.4 ± 4.2 68.5 ± 4.0· 56.4± 4.3·* 44.3 ± 4.3··· 
lieart rate (bealS min) 396.6± 18.6 3M.8 ± 18.2 332.3 ± 15.4· 302.8 ± 14.4** 283.5 ± 12.3··· 242.7 ± 11 .5··· 
.p <0.05: •• p< 0.01; ***p < 0.001 vs control. 
"!ABLE 2. EFFECTS or PAr 0 SYSTEMIC ARTERIAL BLool) PRESSURE AN I) IIEAR"f RATES or UYPERTE SI\'E 
RATS. [AOI \ :'\LlIE RD>RES ENTS TlU !\lEA (± SUI) or 08SER\:~nONS t'RO!\l EICln' RATS 
Cordiom clIlar Before treatment: 
After trea/mellt · PA£ 1!5-4()() mg/kg ;v! 
pafY1meter cOl/trol vailles 25 50 I()() ~()() ./00 
Systolic Bp (mmHg) 188.2 ± 6.4 173.6±6.6 156.4 ± 6.3* 140.6±6.0" 124A±4.S·" 101 .3 ± 4.8··· 
Mean BP (nuIIHg) 146. ± 6.1 132.4 ± 6.4 120.6± 5.8* 10004± 5.2·· 92.5 ±4.0··· 76.7 ±4.4··· 
Diastolic (mmHg) 12004 ±6.3 106.4 ± 4.0 91.3±5.1* 78.5 ± 404·· 64.3 ± 4.2··* 50.5 ±4.0··· 
Heart rate (bea - mill ) 424.6 ± 20.4 39 1.4 ± 18.6 356.5 ± 16.0· 318.2± 15.2** 286.4 ± 14.6·" 23604 ± 12.5"· 
.p < 0.05: "p< 0.01; ."p< 0.001 vs control. 
relaxations of the cndotheliuJll-containing aortic rings pre-
contracted with noradrenalinc. Ten minutes' prior incuba-
tion of the aortic ring tissues with atropinc sulphatc also 
inhibitcd or abolished acetylcholinc-induced relaxations o f 
the endotheliuJll-containing aortic ring preparations pre-
contractcd with noradrcna line . 
Whole animal expcrimcnts 
Acute intravcnous admi nistrations of P E into anaesthctiscd 
nonnotcnsiye and hypcrtcnsive mts produccd transicnt , 
dosc-related signi ficant reductions (p < 0.05--0.00 I ) in the 
syslcmic arterial blood pressurc and heart nltes o f Ihc rats 
(Tablcs I. 2). The tran ' icnl hypotcnsivc \antihypertensivc) 
dTcct o f thc plant extract persistcd for 12-85 min, depending 
on the PAE dose administcred. Furthermore. the plant extrac l 
dosc-dependently inhibitcd or abolished the pressor effccts 
of noradrenalinc on systcmic artcrial blood pressure and 
hca rt ratcs of the animals . Pre-trcatment of thc nonnoten-
si \'c and hypcrtensivc nIts with atropinc ulphate abolished 
or markedly reduced thc depressor cffccts of ac tylcholinc 
on systcmic arteria l blood pressure and heart rates of the 
animals. Howcver. the dcprcssor ctrccts o f PAE on blood 
pres'urc and hcart I1Ites wcre not (lffccted by pre-treatmcnl 
with atropine sulphate . 
Discussion 
The resu lts of this study indicate that the aqueous Im f cx tract 
of P a m ericana possessed cardiodcpressant , vasorelaxmll 
and hypotensive (antihypertcnsi\'c) effects in the eXI crimcn-
tal animal paradigms uscd. These observa lions are in agree-
mcnt with thc findings of somc of the earlicr investigntors 
who have reported vasorehl xant" and hypolcnsivc 15 cffccts of 
the leaf cxtract in cxperimcntal animalmodcls. 
Furchgott and Zawadzki" first dcscribed the invoh'c-
mcnt of the endothelium-derived relaxing fuctor (EDRF). 
which was subsequcntly determincd to be nitric oxide or 
NO dcrivatives synthes ised from guanidine groups of L-
arginine.""" Endothelium-dcpendent relaxation. which has 
been demonstrated in many vascular preparations, ineluding 
som~ \iein~. atterics and microvascular vessels, occurs in 
response to ,timulation by a variety of substances. such as 
acetyleholinc, adenine nucleotides," th rombin , substance P," 
ca lc ium ionophore A23 187. bradykinin and hi stamine." The 
vasod ilalillion effccts of cndothelium-del cndcnt substances 
can be inhibitcd by se\-.::ral L-al'Jinine analogues. su h 
as N-monomClhyl-L-arginine (L- M 1A) and NG-nitro-L-
'Irginine methyl ester (L- AME)."""·'" 
Endothelial nitric ox idc play' a vita l role in the control o f 
vasomotor tonc and structure.= O n th olher hancl vascu-
lar tone plays an important rolc in the rcgulation of arteria l 
blood prc<;sur". The (!c\'e1opmcnt and maintenance of hyper-
tension has been -uggested to involve a reduced endotheli-
um-dcpendel1t \ 'asodilator influence on the vascular tissuc." 
Imp,linllent of endothclium-dependent vascular re lax,ltion 
in human and experimental hyp rtension has been observed 
by Luscher and Vanhoutte," and thc ability of nitric oxidc to 
maintain vascular tone has be n , hown to be deficient in this 
condition .::>"''' Becausc 0 is ,I potcnt \·asodilator. a d ficien t 
production anll/or release of endothe lium-Jerived NO wi ll 
rcsu lt in diminished vasodi lator tone. thus allowing vascular 
resiSl<lI1cc to rise, ,Uld this. in turn. wi llle,ld to elevated blood 
prcssure. ",. 
Relaxation of vascular smooth muscle by NO involves il 
scries of step'. itric ox ide is formed in functiolJ.11 endothe-
lium by the activation of nitric o,xide synthase ( OS). which 
uscs L-arginine as a substrate. Oncc forllled NO eli ffiL'CS 
o ut of the endo thclium. with somc cntcring lhe underlying 
vascular smooth Illusc le where it binds to and activates solu-
ble gmUlylatc cyclasc.'" This cnzyme ctllll lyscs the convcr-
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sion of guanidine triphosphate (GTP) to cyclic t:;uanidinc 
monphosphatc (eGMP), which in turn. callses re klxation of 
the \lascu lar smooth muscle cells."'.::>1..ld·' 
In pathological conditions of the enrdiovHseular system, 
there is a dysfunction inthc intcgrity of the vascular endothe-
lium with a subsequent reduction in the release. bioavailabil-
ity and/or action of nitric oxide." NO re lease and fi.lIlction 
have been shown to decrease in cardio\'ascular diseases. such 
as hypertcnsion." atherosclerosis" ,lilt! congestive heart fail-
urc.JJ Thereforc. the dcvelopmcnt of vasodilators which can 
restore the level and integrity of NO in the vascular system 
would potcntially contribute to the trc.:ltmcnt of thcsc cardio-
vascu lar diseases ." 
In thc present study. the plant extract. like acetylcholinc. 
causcd concentmtion-dcpendent relaxation of the normoten-
si\'c nit isobted cndothclium-containing aortic ring prcpara-
tions prc-contracted with nomdrenaline. This vasorelaxant 
property would appcar to havc contributed, atlc.:lst in part. to 
the antihypertensive (hypotensivc) e ffect of the plan t ex trac!. 
The artcriallllllsclc rclaxlint dfect of the extl1lct disappeared 
by remova l ofthc functional cndothelium. 
Furthermore. pre-treatment of the endotheliul1l-contain-
ing aortic ring prcparations with L-NAME. a nitric oxide 
synthasc inhibitor. inhibited or abolished the \'a orelaxant 
effect of PAE. Takcn together, these observations wou ld 
appear to sut:;gcst that the vasorelaxant c ff-ect of the extract. 
like that of acctylcholine, was dependent on the formation 
and/or synthes is and release of endothel ium-derived nitric 
ox ide, since removal of the functional endothelial cel ls led to 
the absence of relaxant response to PAE in the endothelium-
dcnuded aortic ring preparations. Thc 'e obserl'a tions arc in 
agreement with thc findings of Martin fit 01 .. '· Ignarro fit al .• " 
Kang fit al .. y,.;s Baisch ct al." and Yin fit 01." 
Thc prescnt study also uggests that the endothelillm-
dcpendent v,lsorelaxant effect of PAE could be med iated via 
cndothelial NO signaling ill the aortic ti ssue preparations. 
Howcvcr. the relcase of endothelial NO and the opening 
of potassium channels ha\'c also ix."Cn implicated in the 
vasorelaxant ctleets of extracts Ii'om somc other medicinal 
plants.J<>.4' 
Noradrena l inc-induced contractions of blood vcssels have 
bcen shown to be partly due to ca lcium release from intmcel-
lular storagc sites and paltly due to the intlux of extracellular 
ca lcium into the cel l via receptor-gate<1 channels fo llowing 
alpha, (u,)-adrenoccptor activation." In the present study. 
cndothelium-containing aortic rings pre-contmeted with 
NA in Krebs-Henscleit solutio ll with and without 1I0 rmai 
calc ium concentrations were rclaxed by exogenous :,dditions 
of PAE or acety lcholinc. Morcover. the non-p<lrallel shift of 
the noradrcnaline concentration-response curves to the rit:;ht 
by the plant ex tract seems to suggest a mechanism of non-
competitive u,-adrenOCCI)tor blockade. This hypothesis is 
in eonsomlllce with the work of Abreu el al." on ethanolic 
extract of Jatropha gov~:11Ji(lolia Linn in rats. 
Thc findings of the present study indicnted thnt PA E 
induced vasorelaxntion in normotcnsive mt isol,lIed portal 
veins and endothe l ium-colltaining aortic rings, nnd causcd 
hypotension in anaesthetiscd, normotensive and hypertcnsiv,; 
rats . Although a,-adrenoceptor blockade may have parti<llly 
contributed to the hypotensive eff-cct of the plant extract, 
the experimental evidence obla ined in thc present study 
tcnds to suggest that \'asorelaxation might largely 11<I\'e been 
responsible for the hypotensivc action of the plant extract. 
This v,lsorelaxant eff-ect of the extmct was probably mediated 
through endothelium-dependent NO production and cGM P 
release. and not relatcd to acti\'ation of vascular endothelial 
muscarinic receptors. 
A lthough thc precise mechanism of the hypotensive 
a ti on of PA E could not be establ ished in thc present 
study. we exeluded in\'oh'ement of cholinergic mechanisms. 
However. a complica ting f..lctor in the intcrpretation of the 
data obtained in the hypotensivc cxperiments was the brady-
cardia associated with the reduction in systcmic arterial 
blood pressure of thc mts. Firstly. the reduction in heart rate 
could. on its own. have been the cause of the hypotension. 
However. b,lsed on the results obtained from th nIt isobted 
aortic rings, it would sccm unlikely that the fall in artcrial 
blood pressure produced by PA E was solcly dependent on 
reduction in heart I1Itc. Second ly. the observed tmns icnt. 
sccondary re Aex tachycardia accompanying the fall in arte-
rial blood pressurc would probably suggest that the plant 
extmct did not affect centml cardiovascular ccntrcs and/or 
bmin cardiovascular receptors. The plant extract may. there-
fore, also have had a direct effect on the sinus node of the 
heart. or on the central ncrvous system control machinery of 
arteria I blood pressure. 
P americana has been repolted to contain many bioac-
tive chemical compounds, including polyphenolics. tannins, 
coumarins, Aavonoids. tritcrpcnoids. phytosterols (espe-
cially Il-sitosterol). biotin. a-tocopherol, ca rotcne, ascorbic 
acid. sCOI olctin. quercetin, o il s. organic acids and inorganic 
substances such as c'l lcium . magnesium. zinc and phos-
phorus. "'" Howcver. our present statc of knowledge of the 
chemical constitucnts of the Icaf extnlct is limited. It is there-
fore impossible for us at thi s stage to identify with certainty 
thc \'asorclaxant and antihypeltensive constituent/s of PA E. 
Although we speculate that one or more of the major chemi-
ca l constituents of the plant [namcly tlavonoicls, Jlo lyphe-
nols. tannins. cOllmarins (cspeeially SeOI}olctin and other 
cOllmarins). triterJlelloids and phytostcrols l may poss ibly 
have aceountcd for the obscrved eardiodepress3 nt. vasorc-
I:lX<lJ1t and antihypeltensivc properties of the plant extract. 
there arc no sutfie i Ilt scientific data at present to justify this 
speculation. However. the experimental evi Icnce obtained 
in thc present study showed that P americal1a aqueous Icaf 
exlmct produced significant ca rdiodcprcssant. vasorelaxant 
and hypotensive (antihypc,tcnsive) cff-eets in the I<lbomtory 
animal paradigms used. 
I n conclusion. the findings of the prescnt laboratory 
animal study lend pharmaco lO<Jic.ll support to the suggested 
anecdotal ethnomedieal uses o f P americal1a aqucous leaf 
tmct as a natural supplementary remcdy ill the manage-
menl. control andlor trcatment of hypcrtcnsion and certa in 
cardiac disonlers ill somc rural A ti'ic,1 communities. 
The authexs are grateFu Ito Prof H BaUnath For the identification of Pel' ea 
(llI1e ,.;ClIIlU 1e.1fused in this study and to Dr E Mutenda For her assistance in 
the extraction processes. 
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Hypoglycaemic effects of Hypox;s 
hemerocatlidea (Fisch. and C. A. Mey.) 
[Hypoxidaceae] corm ethanolic extract in 
rats 
Univel sity of Kwa Zulu·Natal. Du~ban. KwaZul..J· atal. South Africa. 
PI~VJG'_IS studles in our !abOrd1.0r'€'s suggest tha~ HYPOX15 hemeroca[Udea ccrm (African Po tato) extract 
n'E A ().~Tp.n1ial in the managemenr of dlabe'",~ mel.itus. Accordingly, we Investigated the short-term 
,:.' 7 <. ~1 ""YP':JX1S hemerocaliidea corr'" ett'anolic c "ude extract IAPE) on blooe glucose levels of Wistar 
:'f~ • ::0 -jOO g b.wt). Oral glucose tOiera1Ce tests i.OGTT) we~e conducted in five separate groups (n~e 
.r- '~~':'1 gr,·up) of male Wistar rats {2S0-30D g b. wtl . The animals were starved for 16 hours and 
adl'~i;l - ',f:'d with glucose (::1.86 g mg kg- i b wtj by gast~c gavage, followed by graded doses of APE 
(60 iL'J ar.'::: 240 mg. kg - ~ p. 0.). Blood ;f ucose concentrations were monitored aL 1'5 min intervals for 
c~'e ir,. ~oLlr. and hOl1r:y trereafter for t,e next 3 ~ours. A separate group of animals treated Wlth 
'TE't+o. mn (500 mg/kg p.o.) served as t'1e t~eated contro . Animals t rea ed with delonised water (3 
;- . xg 0 :). } served as the untreated co,'trol anima,s Stat i stical SIgnificance was determine d by using 
Ccaph Pad °ns." (version 2.OC) Softwa'~ The data were subjected to anal,{s !s of vanance using a one· 
w":!y cesign and Scheffe ' s rr.ultiple cerrparison test was used to assess any differences. A value of p "O.OS 
",as conSiul!red sigmficant. I-PE ,60 24,:) mg.kg-1 p.o.) decreased blood gil .. cose concentrations of the 
'at~ Jr a ·jose-dependent f'·a~..,er· wit~ ,;:)w to Mocerate ooses of APE exerting the1r maXImum 
hypogljcaernic effects aft2: 30 m,nutes. The med1an dose of A PE ( 120 mg. kg 1) decreased blood g ucose 
levels fro .. a peak of 69",0"2 mmoU- 1 to 5.9=0.2 mmoU- 1 by 30 ...,mutes. Metformin (500 mg.kg-1 p . 
o ) ir.ducea a sustained, h.ghly sigr,lflCant W<.O 001) reduction In the- blood gl cose levels of the animals 
FindlOgs from the present study indicate a short-tern' hypoglycemic effect of oral administration of A?E 
I" rats, presumably In a m echamst:c Tlanner s rrnla tc t,at of met ormm . 
£Jldoc: fne ADS tracts l2005) 10 P34 
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The effects of Sclerocarya b;rrea [(a. rich.) 
hochst.] [Anacardiaceae] stem-bark aqueous 
extract on blood glucose, kidney and 
cardiovascular function in rats 
" UniverSIty of KwaZulu-Natal. Durban. KwaZulu·Natal South Africa 
Available evidence suggests that Sderocorya birrea stem -bark extract (SSE) which possesses 
~ypoglycaernic activity ma ' be useful in the treatment and management of dIabetes meHltus. Since 
d1ab~tes is assocIated Wlth card iovasCLllar and kidney complications, we invest gated the influence of 
SSE 0,' blood glucose. blood pressure and renal function in some experimental animal paradigms. For 
OGTT tests, separate groups (n=6 in each group) of non-diabetic and streptozotocin-(STZ)-treated 
diabet;c rats fasted for 18 hours were gIVen glucose (0.86 g kg- 1 bocy weight , p.o ) !ollowed by SSE at 
various do~es (60. 120, 240 mg.kg- ; i. Anima s treated with deionised water (3 ml.kg ') or metformin 
(500 rng.kg ' ) served as untreated and positive controls. respectively. Blood glucose was monitored at 
15 ..... ,inute intervals for the first hour, and hourly thereafter for 3 hours. Acute rena ' effects were 
assessed by urine flow, Na· and K- excre-,on rates in anaesthetized rats chal:engec with hypotonic 
saline lOfus;on at 30-mm Intervals for 4 h of 1 h control, 1Yi h t reatment and n: h recovery penods 
following equilibration period (31/2 h). SSE was added to the infusate during the treatment period. Renal 
effects were also mOnitored in indivldually' caged rats administered daily with SSE for 5 weeks. The 
hypotensive effect of SSE was exanined in anaesthetized and consciolJs normotensive rats, while 
myocardial contractil periormance was evaluated on guinea-pig isolated atrial muscle strips. SSE dose--
dependently decreased blood glucose within the first 30 minutes in non-diabetic and STZ -dlabetic rats 
Similar effects were observed with metformin. t a· and K- excretion rates were not altered by acute or 
chroniC treatment WIth SSE. The extract caused significant reduction ,n blood pressure in anaesthetized 
and conscioL!s rats. SSE also produced concentratIOn-dependent. slgniflCant (P .. O.01) negative inotropic 
and chronotropic effects on guinea-pig Isolated, electrically·driven left-, and spontaneousty beating 
rlght-, atrial muscle preparations. respectively The current observations suggest t hat SSE has a 
cardioprotective role in managemert of dIabetes mellitus. 
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